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Atherosclerosis is a complex cardiovascular disease characterized by chronic progressive 
inflammation of the arteries. The progression of atherosclerosis from fatty streak to advance 
atherosclerotic plaque involves the development of a necrotic core region consists of 
cholesterol, lipids, calcium (Ca
2+
), dead cells and other cellular debris.  Macrophage 
infiltrations occurred in all stages of atherosclerotic progression and they are abundantly 
found in atherosclerotic plaques. Oxidised low density lipoprotein (oxLDL) plays a vital role 
in the initiation and development of atherosclerosis. OxLDL is present within atherosclerotic 
plaque and has been shown to be cytotoxic to various types of cells including macrophages.  
This research initially examined the cytotoxic effects of copper oxidised LDL on U937, 
human monocytes and HMDM cells. As expected oxLDL was cytotoxic; causing rapid, 
concentration and time dependent cell viability loss in all types of cells examined. 
Examination of the cell morphology showed that oxLDL caused a necrotic like cell death 
characterised by cell swelling and lysis. Flow cytometric assay coupled with propidium 
iodide (PI) staining of necrotic cells was compared to MTT reduction assays of cell viability. 
The flow cytometric technique had the advantage over the MTT reduction assay of being 
rapid and showing both the live and dead cell levels at an individual cell level. 
The progression of oxLDL-induced cell death correlated with the rapid increased in 
intracellular ROS production in the cytosol and the mitochondria. Immunoblotting results 
showed that oxLDL induced NADPH oxidase (NOX) activation and increased p47
phox
 
expression. This suggests NOX as the generator of reactive oxygen species (ROS) induced by 
oxLDL in these cells. However, apocynin and VAS2870, the two NOX inhibitors used in this 
study, were unable to inhibit the ROS generation caused by the oxLDL. This suggests that 
either these inhibitors are unable to inhibit the targeted NOX or other sources of ROS might 
exist and contributed to the overall increase in oxidative flux. 
OxLDL caused a rapid increase in cytosolic Ca
2+
 level. This was contributed by the 
extracellular Ca
2+
 source as well as Ca
2+
 mobilisation from the intracellular stores such as 
endoplasmic reticulum (ER). OxLDL-induced intracellular Ca
2+
 increase also correlated with 
the increase in intracellular ROS. Nevertheless, blocking of oxLDL-induced intracellular 
Ca
2+
 elevation by Ca
2+
 chelator, EGTA, did not reduce intracellular ROS generation. 
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Accordingly, this suggests that oxLDL-induced intracellular Ca
2+
 increase is not the cause for 
oxLDL-induced cell death. Additionally, oxLDL may also initiate a Ca
2+
-independent cell 
death pathway.  
The excess cytosolic Ca
2+
 taken up by the mitochondria may be detrimental and could result 
in mitochondrial Ca
2+
 overload. This will increase mitochondrial ROS production and initiate 
mitochondrial permeability transition (MPT) pores opening. Consequently, this could 
collapse the mitochondrial membrane potential (ΔΨm) due to the rupture of outer 
mitochondrial membrane (OMM) and resulted in cell death. Blocking of Ca
2+
 uptake into the 
mitochondria by ruthenium red protected cells from oxLDL-mediated cell death, possibly by 
reducing ROS production and preventing MPT activation.  
This study also demonstrated the protective effect of 7,8-dihydroneopterin (7,8-NP) on 
oxLDL-induced oxidative stress. 7,8-NP protected cells from oxLDL-induced intracellular 
ROS generation and cell viability loss. Intracellular Ca
2+
 increase was also reduced by 7,8-
NP in particular after 3 hours incubation with oxLDL. The action of 7,8-NP was better than 
that of apocynin in protecting U937 cells from oxLDL suggests its potential ability to 
scavenge ROS from various sources. 
Studies have implicated the involvement of H2S in various biological processes including 
atherosclerosis. Thus, the disruption of H2S homeostasis may contribute to the progression of 
atherosclerosis. Slow releasing H2S molecules (H2S donors) have been developed for a 
controlled and stable delivery of H2S to cells. In this study, specific H2S donors, including 
one which targets the mitochondria, were found to be protective against oxLDL-induced cell 
death in U937, human monocytes and HMDM cells. Although the exact mechanism is yet to 
be elucidated, these H2S donors were shown to block the elevation of intracellular Ca
2+
 and 
ROS production mediated by oxLDL. Therefore, these H2S donors could be the potential 





1.  Introduction 
 
 
Atherosclerosis and cardiovascular disease 
Atherosclerosis is a chronic inflammatory disease (Ross, 1999) that involves local thickening 
of the arterial vessel wall which is characterised by endothelial dysfunction, vascular 
inflammation and build-up of lipids, cholesterol, calcium and cellular debris within the intima 
layer (Libby, 2006). This will results in plaque formation, vascular remodelling, acute and 
chronic luminal obstruction, abnormalities of blood flow and diminished oxygen supply to 
target organs (Anderson, 1999). Most of the cardiovascular diseases developed are secondary 
to atherosclerosis (Bahorun et al., 2006). 
Accumulation of oxLDL within the plaques is a typical attribute of atherosclerosis (Yla-
Herttuala et al., 1989) which plays a vital role in the pathogenesis and contributes to the 
inflammatory state of atherosclerosis (Ross, 1999; Steinberg et al., 1989). Epidemiological 
studies have revealed a number of risk factors linked to atherosclerosis which could be 
divided into two categories i.e. modifiable and non-modifiable. Non-modifiable risk factors 
include age, gender and family history of heart disease whereas; cigarette smoking, obesity, 
physical inactivity, hypertension, diabetes and hyperlipidemia are amongst the modifiable 
risk factors (Frohlich & Al-Sarraf, 2013; Stocker & Keaney, 2004). 
Pathogenesis of atherosclerosis 
Atherosclerosis is rather asymptomatic and atherosclerotic plaque development is a 
progressive process that usually takes years, yet early changes in vessel walls which lead to 
atherosclerotic lesions are found even in healthy young people (Itabe, 2003). Three types of 
arteries are well known as the major sites of atherosclerosis i.e. coronary arteries, cerebral 
arteries and the aorta. Extensive atherosclerotic development narrows the lumen of the 




Figure ‎1.1: Atherosclerosis development in the arterial wall 
The progression of atherosclerosis at different stages depicted from the earliest intimal thickening, 
fatty streak, atheroma until advanced lesion associated with plaque rupture and thrombosis (Itabe, 
2003). 
The typical anatomy of normal arteries and atherosclerotic lesions are illustrated by Figure 
1.1. In normal arteries (A), the innermost layer of the artery i.e. intima is bounded by a 
monolayer of endothelial cells on the luminal side and a sheet of elastic fibres (the internal 
elastic lamina) on the peripheral side. The normal intima consists of extracellular connective 
tissue matrix made up primarily of proteoglycans and collagen. The middle layer i.e. media, 
consists of smooth mucle cells (SMCs) while the outer layer i.e. adventitia, consists of 
connective tissues with interspersed fibroblasts and SMCs. In the earliest stages of 
atherosclerotic lesions, there is accumulation of collagen fibers and lipids and invasion of 
various cells including macrophages between the endothelial cells and the elastic lamina (B).  
This is followed by the formation of lumps on the vessel walls which unite to form lesions 
which are called fatty streaks (Ross, 1986; Steinberg et al., 1989). Massive accumulation of 
lipids in the intimal areas and large numbers of macrophage-derived foam cells are found in 
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this stage (C). The next is the atheroma formation, characterised by the fibrous caps which 
contain smooth muscle cells and fibrous proteins such as collagens. Large accumulations of 
macrophages, smooth muscle cells and extracellular matrix proteins are found in the 
atheroma (D) (Ross, 1986; Steinberg et al., 1989). A thrombus is formed when the luminal 
surface of the atherosclerotic lesion is damaged, attracting platelets to adhere and aggregate at 
the damaged site (E). Thrombus formation can lead to complete occlusion of the blood vessel 
which is the primary cause of myocardial and cerebral infarction.  
 
Figure ‎1.2: Initiating events of early atherosclerosis development 
Native LDL entered into subendothelial space and subsequently oxidized by endothelial cells, 
macrophages or smooth muscle cells. OxLDL aids in recruiting circulating monocytes into the intima 
where they are differentiated into macrophages (1). OxLDL inhibits macrophage movement from the 
intima (2). OxLDL is then taken up by macrophages via scavenger receptors CD36 and SR-A to 
become lipid laden foam cells or fatty streak which is the early sign of atherosclerosis (3). This will 
cause injury and dysfunction of the endothelial (4) and enhances the proliferation of smooth muscle 
cells and other cells. Adapted from Lau (2001). 
Many hypotheses have emerged in order to explain the complex events associated with the 
development of atherosclerosis. At least three distinct hypotheses have been postulated, 
namely ‘response-to-injury’, ‘response-to-retention’ and ‘oxidative modification’ (reviewed 
in Stocker and Keaney (2004)). 
According to the ‘response to injury’ hypothesis, endothelial injury is a key event which 
initiates the inflammatory mechanisms associated with atherosclerosis (Ross, 1999). The 
endothelial damage precedes smooth muscle cell migration and proliferation, deposition of 
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the intracellular and extracellular lipid and accumulation of extracellular matrix. The 
‘response to retention’ hypothesis postulated that the central atherogenic process is the sub-
endothelial retention and accumulation of lipoproteins by extracellular matrix molecules such 
as proteoglycans (Williams & Tabas, 1995). The ‘oxidation modification’ hypothesis on the 
other hand suggested that the central component of the atherogenic process is the oxidative 
modification of LDL that acts as an immunogenic stimulus for monocyte recruitment to the 
vessel wall and phagocytic uptake of oxidized LDL by macrophages (Witztum, 1994). 
Much evidence has implicated the changes to the endothelial cells as the primary event in the 
complex atherosclerosis development which is progressively derived by inflammation (Libby 
et al., 2010). Ross (1993) hypothesised that when endothelial cells are injured or stressed, 
they will generate cytokines in response to the injury. These cytokines then, activate other 
cells in the vasculature such as macrophages, SMCs and neutrophils. Stimulated endothelial 
cells express surface molecules and chemokines which attract monocytes in the blood to 
attach to the endothelial cells. Subsequently, the monocytes transmigrate into vessel walls 
and differentiate into macrophages. LDL enters the intima soon after monocytes recruitment 
and undergoes modifications such as oxidation, proteolysis and aggregation, which may be 
partially caused by exposure to oxidants released by vascular wall (Lusis, 2000). OxLDL is 
then taken up by macrophages resulting in the formation of foam cells which is an early sign 
of atherosclerosis (Ross, 1993). Nevertheless, the details of these processes remain 
controversial especially on the exact initial events during the early stage of lesion formation.  
Oxidative modification hypothesis of atherosclerosis development suggests that LDL may 
accumulate within the intima.  The increased permeability of LDL at the arterial branch 
points allows the entry and accumulation of LDL in the intima (Lusis, 2000). Trapped LDL is 
susceptible to modification, particularly by oxidation resulting in the formation of oxLDL.  
OxLDL activates endothelial cells and up-regulates adhesion molecule expression and 
chemotactic chemokine secretion such as monocyte chemoattractant ptotein 1 (MCP-1), 
which will contribute to the recruitment of circulating monocytes into the intima. Brandes et 
al. (2001) has identified oxygen radicals as messengers for the expression of MCP-1 that 
attracts the migration of monocytes into the intima. The migrated monocytes will then 
proliferate and differentiate into macrophages. OxLDL and other forms of modified LDL are 
taken up rapidly by these macrophages via scavenger receptors, such as SR-A and CD36 
(Glass & Witztum, 2001; Steinberg et al., 1989). Internalization of oxLDL by macrophages 
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potentiates the inflammatory response, thus leads to the formation of foam cells which is a 
feature of the early stage atherosclerotic lesion (Figure 1.2). Continued formation and death 
of foam cells lead to the development of fatty streak followed by necrotic lipid core within 
the intima (Douglas & Channon, 2010).  
Role of monocytes/macrophages in atherosclerosis 
Monocytes are a heterogenous group of cells from the myeloid lineage constituting about 5 to 
10% of the total white blood cells that play important roles in health and diseases. Monocytes 
originate from the bone marrow and enter the circulation where they remain for up to 72 
hours after which they either enter the tissues or die (Martinez, 2009). In their study, Auffray 
et al. (2007) have found a group of resident monocytes patrolling for sites of inflammation in 
healthy arteries. In the tissues, they become activated and differentiate into tissue 
macrophages under the influence of macrophage- or granulocyte/macrophage colony 
stimulating factor (M-CSF or GM-CSF).  
Macrophages are also the most abundant cell type found in atherosclerotic plaques. 
Macrophage infiltration happened in all stages of atherosclerotic lesion development, from 
diffused intimal thickening (Nakashima et al., 2008) to the advanced plaque (Shaikh et al., 
2012). Macrophages play an important role in the early phase of atherosclerotic plaque 
development by ingesting oxLDL particles recognised via scavenger receptors on their cell 
surface (Peiser et al., 2002) whereby the inability to process these particles results in lipid-
filled foam cells formation (Libby, 2002). Macrophages in atherosclerotic lesions have been 
shown to comprise cellular features of both apoptosis and necrosis (Hegyi et al., 1996). The 
death of macrophages is believed to be one of the main events in the development of 
atherosclerosis that could be initiated in vitro by oxLDL (Marchant et al., 1995; Tertov et al., 
1989). Nevertheless, the mechanism of how oxLDL induced macrophages death is not fully 
understood. 
Oxidised low density lipoprotein (oxLDL) and 
atherogenesis 
OxLDL cytotoxicity 
Atherosclerosis is an inflammatory disease whereby oxLDL plays a vital role in the initiation 
and progression of the disease (Ross, 1999). OxLDL has been found in atherosclerotic lesions 
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of experimental animals and humans (Yla-Herttuala et al., 1989). An increased level of 
circulating oxLDL is associated with metabolic syndrome that may contribute to 
atherogenesis and heart disease (Holvoet et al., 2008).  





products (e.g. H2O2), radiation or prolonged incubation with cells (endothelial cells, smooth 
muscle cells and monocyte-macrophages) (Gieseg et al., 2008; Steinbrecher et al., 1984). 
OxLDL consists of various lipid peroxidation products including thiobarbituric reactive 
substances, conjugated dienes, lipid hydroperoxides and aldehydes (Steinberg, 1997).  
OxLDL induces various cellular activities and the production of pro-inflammatory cytokines 
and growth factors by almost all cell types of the arterial wall (Kume & Gimbrone, 1994) 
including up-regulation of monocyte chemoattractant protein-1 (MCP-1) and increased 
expression of vascular cell adhesion molecule-1 (VCAM-1) (Steinberg, 2009). OxLDL 
contributes to endothelial dysfunction and inflammation in vasculature by up-regulating the 
expression of inflammatory mediators (Maziere & Maziere, 2009). OxLDL was also capable 
in altering the balance of pro-coagulant and anti-coagulant activities in the vascular cell 
surface (Ishii et al., 1996). Studies in cultured endothelial cells suggest that oxLDL may 
enhance thrombogenecity through increased expression of plasminogen activator inhibitor-1 
(PAI-1) (Drake et al., 1991).  
OxLDL has been considered as a key risk factor in foam cell formation, endothelial 
dysfunction and inflammation whereby it manifests many deleterious effects including the 
transformation of macrophages and smooth muscle cells to foam cells (Rosenfeld & Ross, 
1990). Small dense LDL particles are taken up by macrophage scavenger receptor leading to 
foam cell formation (Chapman et al., 1998). Studies have shown that exposure to oxLDL for 
a prolonged period may cause cytotoxicity to the vascular cells (Cathcart et al., 1991; 
Steinberg, 1997). 
OxLDL-induced cell death  
OxLDL has been shown to be causing death in various types of cells involved in 
atherogenesis including endothelial cells (Hessler et al., 1979), lymphocytes (Alcouffe et al., 
1999), smooth muscle cells, macrophages, monocytes and monocyte-like U937 and THP-1 
cell lines (Baird et al., 2005; Gieseg et al., 2010; Marchant et al., 1995). The exact 
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mechanisms on how oxLDL causes cell death in vitro still remain unclear. Previous studies 
suggested that oxysterols, particularly 7-ketocholesterol (7-KC) as the main component of 
oxLDL that contributes to cell death. However, recent study from this laboratory has clearly 
indicated that 7-KC is not the one (Rutherford & Gieseg, 2012). Thus, it is more likely that 
oxidative stress induced by oxLDL is the main initiator of the death cascade.  
Depending on the cell type and extent of damaged, oxLDL-mediated cell death may occur via 
caspase-dependent or caspase–independent apoptosis or via necrosis (Asmis & Begley, 2003; 
Baird et al., 2004; Vicca et al., 2000). Previous studies done in this lab revealed that THP-1 
cells underwent a caspase-mediated apoptosis characterised by a relatively slow depletion of 
GSH compared to U937 cells which manifested necrotic cell death due to lack of caspase 
activation with rapid GSH loss and no phosphatidyl serine (PS) exposure (Baird et al., 2004). 
The difference in response to oxLDL between the two types of cell may be related to varying 
uptake mechanism of oxLDL (Baird et al., 2004) whereby U937 cells has been shown to 
express a 4-folds higher levels of CD36 scavenger receptors compared to THP-1 (Nguyen-
Khoa et al., 1999). Both caspase-dependent (Wintergerst et al., 2000) and -independent 
(Asmis & Begley, 2003; Yang et al., 2012b) cell death have been observed with HMDM 
cells. In our current setting, HMDM cells were observed to undergo a caspase-3 independent 
necrosis with a rapid GSH loss (Gieseg et al., 2010; Shchepetkina, 2013). Nevertheless, the 
exact cell death mechanism initiated by oxLDL may vary in the atherosclerotic plaque 
depending on the types of cells as well as the local environment (Baird et al., 2004) 
Types of cell death 
Necrosis and apoptosis 
Necrosis and apoptosis are the classical types of cellular death associated with oxLDL-
induced cell death which could be differentiated by their distinct morphological and 
biochemical changes (Salvayre et al., 2002). Necrosis is characterised by a complete loss of 
ion homeostasis resulting in cell swelling, degradation of internal organelle structure, nuclear 
membrane disruption and eventual rupture of plasma membrane (Syntichaki & Tavernarakis, 
2003). Mitochondrial integrity disruption prevents ATP production while loss of plasma 
membrane integrity caused the release of cellular contents including denatured proteins, DNA 
fragments and other debris into the extracellular compartment. Antioxidants such as GSH, 
pro-oxidants such as metal ions and damaging molecules such as activated calpains 
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(Halliwell, 2003) may also present in the discharged cellular contents that may affect 
neighbouring cells. Activated calpains or cathepsins could cause irreversible damage to the 
skeletal proteins that will eventually result in necrosis (Yang et al., 2012a). Additionally, 
abrupt loss of ATP could also lead to necrosis (Yang, 2009). 
Apoptosis is a highly regulated process (Kerr et al., 1972) that involves a series of 
intracellular signalling pathways for controlled shutdown of cells. Morphologically, apoptotic 
cells are characterised by cell shrinkage, plasma membrane blebbing and chromatin 
condensation while maintaining ion homeostasis and internal organelle integrity (Yuan & 
Yankner, 2000). Eventually, cells are broken down into apoptotic bodies without rupture of 
organelle membranes. Subsequently, the apoptotic bodies are recognised and engulfed by 
surrounding cells and phagocytes (Duprez et al., 2009) without causing an inflammatory 
response. Typical biochemical changes accompanying apoptosis include cytochrome c 
release from the mitochondria and redistribution of phosphatidylserine (PS) to the outer 
surface of plasma membrane which enables recognition of apoptotic bodies by phagocytes 
(van Engeland et al., 1998). A secondary necrosis causing the apoptotic bodies to lyse and 
release their contents will occur if they are not phagocytosed (Tabas, 2005) 
Endoplasmic reticulum (ER) stress-induced cell death 
The endoplasmic reticulum (ER) has emerged as a key player in various cellular responses 
including a variety of apoptotic signaling pathways (Heath-Engel et al., 2008) and cell stress. 
Studies have implicated a crucial role of ER stress in atherosclerosis and plaque rupture due 
to the presence of oxidized lipids, inflammation and metabolic stress (Muller et al., 2011a). 
Moreover, Yao et al. (2013) have showed that oxLDL was able to induce ER stress. ER is the 
primary site for intracellular Ca
2+
 storage and is the location for the folding and some post-
translational modification of transmembrane and secreted proteins. Disruption of ER 
functions could result in protein misfolding and activation of an adaptive stress response 
termed the unfolded protein response (UPR). The UPR attempts to increase the folding 
capacity of the ER through the induction of key proteins involved in chaperoning, protein 
folding and degradation pathways.  
Transduction of the UPR pathway occurs through three ER resident chaperone proteins that 
function as primary sensors of endoplasmic reticulum stress i.e. PKR-like endoplasmic 
reticulum kinase (PERK) (Harding et al., 1999), inositol requiring enzyme 1 (IRE1) (Shen et 
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al., 2001) and activating transcription factor 6 (ATF6) (Haze et al., 1999) that sense the 
accumulation of unfolded proteins within the ER lumen. Glucose-regulated protein 78 
(GRP78) is bound to these proteins, maintaining the sensors in an inactive configuration in 
the absence of stress induction (Bertolotti et al., 2000). Accumulation of unfolded proteins 
and the altered redox status within the ER lumen up-regulate the expression of GRP78 and 
trigger its dissociation leading to the initiation of UPR signal transduction pathways. OxLDL 
have also been shown to induce translocation of ATF6 from cytoplasm to the nucleus as well 
as up-regulating GRP78 (Yao et al., 2013). Sustained and unresolved ER stress can lead to 
apoptotic cell death via the induction of the proapoptotic transcriptional factor C/EBP 
homologous protein (CHOP), activation of c-jun amino-terminal kinase (JNK) and the Bcl-2 
proteins (Muller et al., 2011a). 
Autophagy 
Autophagy is another cellular response mainly regulated at the ER (Heath-Engel et al., 2008). 
It has been associated with oxLDL-induced ER and lysosomal oxLDL degradation (Muller et 
al., 2011b). During autophagy, cells form autophagosomes that sequester organelles, proteins 
or portions of the cytoplasm for delivery to the lysosome (He & Klionsky, 2009). The 
sequestered contents are degraded in the lysosome, allowing cells to eliminate damaged or 
harmful components through catabolism and recycling them to maintain nutrient and energy 
homeostasis. However, induction of autophagy may also lead to cell death (Kundu & 
Thompson, 2005). Unlike apoptosis, autophagic cell death is a caspase independent process 
characterized by the accumulation of autophagic vacuoles in the cytoplasm with extensive 
degradation of the Golgi complex and ER preceding destruction of the nucleus (Klionsky & 
Emr, 2000). This followed by the fusion of the autophagosome with lysosomes for 
catabolism by intralysosomal enzymes (Maiuri et al., 2007).   
Moreover, studies have suggested that there have been cross-talks between these cell death 
mechanisms which indicate that individual components of the cell death machinery do not 
operate in isolation whereby the activation of one cell death mechanism alone might not be 
sufficient to eliminate all damaged cells (Zhivotovsky & Orrenius, 2010).  
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Calcium and atherosclerosis 
General calcium homeostasis 
The balance between the influx of calcium (Ca
2+
) into the cytoplasm from extracellular 
compartment or intracellular organelles (sarco/endoplasmic reticulum) and the efflux of 
calcium from the cytoplasm regulates intracellular free Ca
2+ 
concentration. The cytosolic 
concentration of Ca
2+
 is tightly controlled by complex interactions between pumps, channels, 
exchangers and binding proteins. In resting condition, cytoplasmic Ca
2+
 is approximately 
10,000 times (100-200 nM) lower than extracellular Ca
2+
 (1-2 mM).  
This condition is maintained by the low permeability of the plasma membrane to ions and by 
the activity of the plasma membrane Ca
2+





(NCX) (Figure 1.3). The PMCA pumps Ca
2+
 out of the cytosol by actively transporting Ca
2+
 
against a large transmembrane Ca
2+
 electrochemical gradient whereby one molecule of ATP 
is hydrolysed for every Ca
2+
 ion that is expulsed. On the other hand, NCX is expressed only 
in excitable cells (e.g. muscle and neurons) that extensively use Ca
2+
 signals (Strehler, 1990). 
The energy stored in the Na
+





 ion is expelled in exchange of three Na
+
 ions. The net effect of these plasma 
membrane mechanisms is to maintain of low cytosolic Ca
2+
 environment relative to the 
extracellular space (Putney, 1997). 
The increase in intracellular Ca
2+
 can be induced through Ca
2+
 mobilisation from intracellular 
stores (mainly the sarco/endoplasmic reticulum (SR/ER)) and through the entry from the 
extracellular compartment. The main route inducing Ca
2+ 
release from intracellular stores 
involves the IP3 receptor (IP3R). When extracellular soluble agonists binds a G-coupled 
protein receptor, different isoforms of phospholipase C (PLC) are activated producing 
inositol-1,4,5-trisphosphate (IP3) and diacyl glycerol (DAG) (Berridge & Irvine, 1989) from 
the hydrolysis of phosphatidylinositol 4,5 bisphosphate (PIP2). DAG remained bound to the 
membrane while IP3 is released into the cytosol and binds to the IP3 receptor (IP3R) 
(Lemasters et al., 2009). The binding of IP3 to IP3R induces its opening and the release of 
Ca
2+
 from SR/ER into the cytosol.  
Ryanodine receptor (RyR) which is also located on the ER membrane is another mechanism 
for ER Ca
2+
 efflux whereby it is activated by Ca
2+
 itself (Zucchi & Ronca-Testoni, 1997). 
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Thus, a small amount of cytosolic Ca
2+
 near the receptor can stimulate the release of even 
more Ca
2+
 creating a positive feedback loop. RyR is considered as a calcium-induced calcium 
release (CICR) Ca
2+
 channel (Fabiato, 1983). IP3R are the predominant Ca
2+
 release channels 
in non-excitable (non-muscle) cells while RyR are predominant in excitable (muscle) cells 
(Iino, 1999). 
Intracellular store depletion of Ca
2+
 due to the opening of the IP3R and RyR triggers the 
activation of an inward rectifying Ca
2+
 current from the extracellular space termed as 
capacitative Ca
2+
 entry (CCE). Mechanism inducing intracellular Ca
2+
 increases involves the 
opening of the plasma membrane Ca
2+
 channels which include: Voltage Operated Ca
2+
 
channels (VOCCs), Receptor Operated Ca
2+
 channels (ROCCs) and Second Messenger 
Operated Channels (SMOCs). VOCCs open following a decrease of membrane potential 
(Bertolino & Llinas, 1992), ROCCs (also called ligand gated channels) open due to the 
binding of an external ligand (McFadzean & Gibson, 2002) and SMOCs open following the 
binding of a second messenger on the inner surface of the membrane (Meldolesi & Pozzan, 
1987). VOCCs are classified into high-voltage activated channels including the L, N, P/Q and 
R-type channels and low-voltage activated channels represented by T-type channels. VOCCs 
can be inhibitid by calcium channel blockers (CCBs). 
The mechanisms of Ca
2+
 clearance from the cytosol is of equal importance to the regulation 
of Ca
2+
 release from the ER/SR. The sarco/endoplasmic reticulum Ca
2+
 ATPase (SERCA) is 
a Ca
2+
 pump located in the membrane of the SR and ER whose function is to transport Ca
2+
 
from the cytosol to be stored into SR/ER using ATP as an energy source (MacLennan et al., 
1997). SERCA functions are regulated by both cytosolic and ER/SR conditions. Under 
resting conditions SERCA is relatively inactive but following an increase in cytosolic Ca
2+
, 
the activity of the pump is increased, resulting in re-sequestration of Ca
2+
 into the ER (Lytton 
et al., 1992). From the other side, the Ca
2+
 pumping activity of SERCA is regulated by the 
Ca
2+
 content of the ER. SERCA activity is maximal when the stored Ca
2+
 is depleted and 
decreases as the store approaches its maximal capacity (Mogami et al., 1998).  
The role of mitochondria in Ca
2+
 signalling pathways will be further elaborated in 




Figure ‎1.3: Regulation of intracellular calcium 
 (Orrenius et al., 2003) 
Calcium and oxidative stress association in cell death and atherosclerosis 
Dysregulation of Ca
2+
 homeostasis has been implicated to play a vital role in cell injury. 
Studies using various types of cells have showed that increased cytosolic Ca
2+
 levels after 
ROS or toxin treatment led to either caspase-3-dependent or –independent apoptosis 
(Escargueil-Blanc et al., 1994; Vindis et al., 2005; Yap et al., 2006) or necrosis (Aguilar et 




 may play an important role in the initiation and progression of the atherosclerotic lesion 
whereby many cellular processes that are involved in lesion formation being regulated by 
changes in intracellular Ca
2+
. These include the migration and proliferation of smooth muscle 
cells, release of growth factors, secretion of extracellular matrix protein, activation of 
platelets, cholesterol esterification, recruitment of monocytes and endothelial permeation 
(Orimo & Ouchi, 1990; Phair, 1988; Ross, 1986). Nicotera et al. (1992) has stated in their 
review the relation between oxidative stress and intracellular Ca
2+
 in cell injury leading to 
cell death. Geeraerts et al. (1991) have shown that in human endothelial cells challenged with 
oxidative stress, Ca
2+




The deleterious effects of ROS are mainly due to the ability of ROS to produce changes in 
subcellular organelles and induce intracellular Ca
2+ 
overload. Evidence shows that ROS can 
induce an increase in intracellular Ca
2+
 levels by releasing Ca
2+
 from internal stores and 
disturb Ca
2+
 clearance systems whereby intracellular Ca
2+
 increased is a hallmark of 
pathological states associated with oxidative stress (Camello-Almaraz et al., 2006). In 
addition, increased formation of ROS indicating the presence of oxidative stress has been 
observed in a wide variety of experimental and clinical conditions associated with 
cardiovascular disease including atherosclerosis (Dhalla et al., 2000).  
Oxidative stress and reactive oxygen species (ROS) 
Oxidative stress and atherosclerosis 
Oxidative stress is defined as an imbalance between ROS formation and antioxidant defense 
mechanisms in cell or tissue (Forbes et al., 2008) that leads to an altered redox status which 
can result in cell dysfunction and/or cell death (Madamanchi & Runge, 2007). Oxidative 
stress has been identified throughout the process of atherogenesis (Warnholtz et al., 1999) 
and as the process of atherogenesis proceeds, inflammatory cells and other constituents of the 
atherosclerotic plaque release large amounts of ROS, which further enhance this process. In 
general, increased production of ROS may affect fundamental mechanisms that contribute to 
atherogenesis i.e. oxidation of LDL, endothelial cell dysfunction, vascular smooth muscle 
growth and monocytes migration
 
(Berliner & Heinecke, 1996).  
Reactive oxygen species (ROS) 
Reactive oxygen species (ROS) are molecules or ions formed by the incomplete one-electron 
reduction of oxygen. ROS can be classified into two groups: 1) radicals – groups that contain 
an unpaired electron and are highly chemically reactive; 2) non-radicals – do not possess an 
unpaired electron but are prone to exchanging electrons with other molecules (Guzik & 
Harrison, 2006). Table ‎1.1 illustrates the common radicals and non-radicals of ROS. 
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Sources of ROS in the vasculature 
Various potential enzymatic sources of vascular ROS have been identified including NADPH 
oxidases (NOX), xanthine oxidase, lipoxygenase, cycloygenase, P450 monoxygenase, 
uncoupling of nitric oxide synthase (NOS) and mitochondrial respiration as illustrated in 
Figure 1.4 (Kyaw et al., 2004). However, NOX are thought to be the predominant source of 
ROS in the vasculature (Griendling et al., 2000). As opposed to the other sources of ROS, 
NOX seem to be the only dedicated ROS producing enzyme. Since the sole purpose of NOX 
is the formation of ROS, this makes them as potential therapeutic targets for oxidative stress. 
Detail information on NOX is further elaborated in NADPH oxidase (NOX) section. 
 
Figure ‎1.4: Sources of reactive oxygen species in the vasculature 
Potential sources for O2
.-
 generation in the vasculature include NADPH oxidase (NOX), xanthine 
oxidase, lipooxygenases, cyclooxygenases and mitochondria. O2
•- 
can be rapidly dismutated to H2O2 
by superoxide dismutases (SODs) followed by OH
.
 formation via Fenton reaction. O2
•- 
may also react 
with NO to form ONOO
-
, a much more potent oxidant. H2O2 can be broken down by catalase to form 
H2O and O2. (Kyaw et al., 2004) 
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Mitochondria – an overview 
The mitochondrion is defined by two structurally and functionally different membranes i.e. 
the plain outer membrane (OMM) and the highly selective inner membrane (IMM) with an 
intermembrane space (IMS) in between. Mitochondria are the major source of ATP via 
oxidative phosphorylation. The process of oxidative phosphorylation takes place in the IMM 
(Madamanchi et al., 2005) which consists of the electron transport chain (ETC) complex. 
ETC is composed of 5 multiple subunit complexes namely, Complex I (NADH-ubiquinone 
dehydrogenase), Complex II (succinate cytochrome c reductase), Complex III (ubiquinone 
cytochrome c reductase), Complex IV (cytochrome c oxidase) and Complex V (ATP 
synthase).    
 
 
Figure ‎1.5: A schematic illustration of mitochondria showing mitochondrial electron 
transport chain (ETC) complexes. 
 (Mehta & Li, 2009) 
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NADH and FADH2 are final products generated by the citric acid cycle from multiple chains 
of reactions. Electrons are transferred from NADH to Complex I or FADH2 to Complex II 
and passed on to ubiquinol via coenzyme Q which will then get transferred to Complex III. 
Cytochrome c transfers electrons from Complex III to Complex IV and in this process water 
is formed from reduced molecular oxygen. The transfer of electrons in ETC creates trans-
membrane electrochemical gradient through constant pumping of electrons across IMM at 
Complexes I, III and IV. The proton-motive force (Δp) initiates protons re-entry into the 
matrix which is then used by Complex V to synthesise ATP from inorganic phosphate and 
ADP. Additionally, Δp also mediates ATP-ADP exchange by the adenine nucleotide 
translocase (ANT). Approximately 0.2 – 2.0% of the molecular oxygen leaks through ETC to 
form ROS (Madamanchi & Runge, 2007)(Figure 1.5).  
Mitochondria play an important role in the development of atherosclerosis. As the key 
intracellular organelles determining the survival and death of the cells, mitochondria are the 
key source and primary target for intracellular detrimental ROS production (Murphy, 2009).  
Complex I and III are considered as the primary sites for ROS production (Turrens, 2003). In 
the absence of ATP, reverse electron transport could occur whereby electrons derived from 
FADH2 via Complex II are transferred into Complex I, (D. Han et al., 2003; Y. Liu et al., 
2002) thus generating more ROS. Thereby, Complex I is considered as a 
pathophysiologically relevant source of ROS production in the ETC.  
Moreover, various factors are involved in the regulation of ROS in mitochondria such as 
ETC, oxygen concentration, availability of NADH and FADH2, uncoupling proteins, 
antioxidant defences and the modulation of nuclear factors (Ballinger, 2005). Superoxide 
formed in the matrix is rapidly converted to H2O2 by superoxide dismutase (SOD) which is 
then converted to water by glutathione peroxidase (GPx). Nevertheless, transition metals may 
also reduce H2O2 into hydroxyl radical (Madamanchi & Runge, 2007). Superoxide can also 
reacts with NO to generate peroxynitrite, which is capable in causing the inactivation of 
enzymes, DNA damage and mitochondrial dysfunction (Ballinger et al., 2000). Studies also 
indicate that cellular ROS generated by NOX might act as a positive feedback, leading to 
increased production of ROS from mitochondria, which is termed as ROS-induced ROS 
release (Brandes, 2005). In addition, increased superoxide generation by NOX also induces 
mitochondrial oxidative damage via structural changes to the IMM and disturbs flow in the 
ETC which enhances ROS production (Doughan et al., 2008; Ray & Shah, 2005). 
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Calcium and mitochondria 
Mitochondria are closely involved in many Ca
2+
 signalling roles (Rizzuto et al., 2000). 
Mitochondria sequester Ca
2+
 through the mitochondrial uniporter (MCU) which uses the 
mitochondrial membrane potential (MMP) to trigger the uptake of positively charged Ca
2+
 
(Kirichok et al., 2004). When cytoplasmic Ca
2+
 level rises, Ca
2+
 can diffuse through the 
OMM into the IMS via the voltage-dependent anion channel (VDAC), which will then get 
transported into the mitochondria via MCU located in the IMM (Gunter et al., 2000; Rizzuto 
et al., 2000) (Figure 1.6). While resting cytoplasmic Ca
2+
 levels are below the MCU affinity 
values for Ca
2+
, there are a number of mitochondria which are strategically located near Ca
2+
 
release site of the ER (Rizzuto et al., 1998). This will then cause local Ca
2+
 concentration to 
exceed MCU affinity values and are above the threshold for uptake (Rizzuto et al., 1992). In 
addition, MCU appears to be gated by local adenine nucleotide concentrations 
(ATP>ADP>AMP) located at the outer surface of the IMM (Bianchi et al., 2004). 
Mitochondrial Ca
2+









 exchanger (mHCX) located on 
the IMM whereby Ca
2+
 gradient across the IMM provides energy for the counter-transport. 
The mNCX imports 3 Na
+
 ions for every Ca
2+
 ion exported (Baysal et al., 1994) whereas the 
mHCX imports 2 H
+
 for each Ca
2+
 ion (Gunter et al., 2000). However, rapid mitochondrial 
Ca
2+
 influx can saturate these efflux pathways (Bernardi, 1999), thus increasing 
mitochondrial Ca
2+





 overload which has been taken up by mitochondria can subsequently stimulate the 
opening of the mitochondrial permeability transition pore (MPTP) connecting the cytosol 
with the mitochondrial matrix (Bianchi et al., 2004; Crompton, 1999; Kroemer et al., 2007) ) 
thus causes mitochondrial permeability transition (MPT). MPT is followed by IMM 
depolarization, uncoupling of oxidative phosphorylation, matrix swelling and OMM rupture 
(Kroemer et al., 2007). Therefore, if majority of mitochondria in the cell are disrupted, it may 
lead to inadequate glycolytic sources of ATP. These ATP-depleted cells may then undergo 




Figure ‎1.6: Mitochondrial Ca2+ transporters 
 (Celsi et al., 2009) 
NADPH oxidases (NOX) 
NOX structure, homologs and distribution 
NOX are a group of membrane associated enzymes expressed in vascular cells. The structure 
and functions of NOX are well characterized in phagocytic cells such as neutrophils and 
macrophages. Under pathological conditions, NOX is one of the enzymes that can be 
activated in many cell systems to generate large amounts of superoxide (Griendling et al., 
2000). In the majority of vascular disease models, NOX have been shown to be the main 
source of superoxide (Guzik & Harrison, 2006).   
NOX family consists of several homologs (or isoforms) which differ in their expression, 
structure and function. Seven homologs of NOX are NOX1, NOX2, NOX3, NOX4, NOX5, 
DUOX1 and DUOX2 (Figure 1.8). NOX homologs contain an FAD and NADPH binding 
site, two heme molecules and six transmembrane domains (Figure 1.7). DUOX1 and 
DUOX2 are very similar to NOX5 but they possessed an additional peroxidase domain. 
NOX1 and NOX4 share approximately 60% and 39% amino acid identity with NOX2 
respectively (Bedard & Krause, 2007). With regards to NOX4, Poldip2 has been identified by 




Figure ‎1.7: Common gp91phox/NOX2 structure 
Each NOX family members contain this common components which consits of six transmembrane 




Figure ‎1.8: Models of NOX homologs 
Each of the seven members of the NOX family requires a different set of conditions and protein 
association. Upper lane from left to right: NOX1, NOX2, NOX3; lower lane from left to right: NOX4, 




NOX complex consists of two membrane components, p22
phox
 (a small α-subunit) and 
gp91
phox
 (a larger β-subunit which is termed as NOX2). NOX2 associates with p22
phox
 in a 
1:1 complex that contributes to its stabilization. NOX2 and p22
phox
 formed the cytochrome 
b558 complex (Groemping & Rittinger, 2005). In addition, NOX complex contains four 






 and guanine nucleotide binding protein 
Rac1 or Rac2. Upon stimulation, these cytoplasmic subunits translocate to cytochrome b558 
whereby this assembly is mandatory for NOX activation and facilitates electron transfer from 
NADPH to oxygen (Figure 1.9).   
SH3 binding domain on p22
phox







(Groemping & Rittinger, 2005). NOX1-4 are associated with p22
phox
 as a 
docking subunit (Guzik & Harrison, 2006), which is important for their activity whereas 
NOX5, DUOX1 and DUOX2 do not require p22
phox
 (Al Ghouleh et al., 2011). NOX4 is 
constitutively active and do not need any regulatory subunits (Dworakowski et al., 2008). 
Expression and distribution of NOX in various types of cells/tissues/organs is summarized by 
Table 1.2. Cellular distributions and localization of NOX homologs play a vital role as to 
how individual NOX regulate signaling (Al Ghouleh et al., 2011). Nevertheless, it should be 
noted that different species may have different profiles of NOX protein expression. For 
example, NOX5 is not expressed in the vasculature of rodents (Maru et al., 2005) whereas 
DUOX1/2 are not expressed in mouse airway epithelial cells. 
Table ‎1.2: Distribution and localization of NOX 






Mechanism of NOX activation 
NOX activation process has been well characterized in leukocytes. In resting state, 
cytoplasmic subunits interact with each other in a trimeric (1:1:1) complex (Vignais, 2002). 
At this stage, p47
phox
 is in an auto-inhibited form where two SH3 domains bind to a polybasic 
region (Groemping et al., 2003) and upon activation, p47
phox
 becomes highly phosphorylated. 
This is mandatory to abolish the auto-inhibited state and thereby enables its translocation to 
cytochrome b558 (Ago et al., 2003). Subsequently, this results in the assembly of p47-p67-
p40
phox
 to the membrane and docks via its SH3 domain to p22
phox
 (Groemping et al., 2003). 
In addition, docking of p47
phox
 to cytochrome b558 also facilitates the interaction between 
p67
phox
 and NOX2 which is needed for the activation of catalytic subunit (Han et al., 1998). 
DeLeo et al. (1995) have reported three interaction sites between p47
phox
 and NOX2 whereas 
more than a dozen sites of p47
phox
 have been shown to undergo phosphorylation when cells 
are activated (Huang & Kleinberg, 1999). Next critical step is the translocation of the 
activated GTPase Rac to cytochrome b558 that occurs independent of p47
phox
 since Rac-GTP 
anchors itself in the membrane through its prenylated tail (Brandes & Kreuzer, 2005). NOX 
activation is illustrated in Figure 1.9. 
However, the exact composition and assemble of vascular (non-phogocytes) NOX is not fully 
understood. Vascular cells demonstrate a constitutively active NOX that generates 
significantly low levels of ROS compared to leukocytes (Lassègue & Clempus, 2003). 
Additionally, Li and Shah (2002) have found a pre-assembled NOX in endothelial cells 






. Moreover, NOX4 was shown to generate 






 cytosolic subunits and also novel 
subunits NOXO1 and NOXA1 provide no further increase in its activity (Ago et al., 2004; 
Kawahara et al., 2005). The difference between phagocytic and non-phagocytic NOX is 




Figure ‎1.9: Activation of the NADPH oxidase (NOX) complex 












 and the small G-protein Rac. Upon activation (by various inflammatory 




 and the 
GDP/GTP exchange on Rac. The cytosolic components then translocate to the membrane where they 
form a complex with cytochrome b558. The oxidase complex then initiates electron flow and 
generation of O2
-
 through the NADPH-derived electron reduction by the flavocytochrome (adapted 
from (Wilkinson & Landreth, 2006)). 
 
Figure ‎1.10: Differences of NADPH oxidase components between phagocytic and non-
phagocytic cells 
(Novo & Parola, 2008) 
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Studies have revealed that various stimuli may lead to the activation of NOX and ROS 
production. OxLDL has been suggested to activate NOX through CD36 binding in smooth 
muscle cells (Sukhanov et al., 2006) whereby ROS production after oxLDL treatment caused 
the loss of the glycolytic enzyme, GAPDH. Subsequently, this halted cellular ATP stores and 
led to necrosis. The loss of GAPDH can be prevented by NOX inhibitors and various 
antioxidants (Sukhanov et al., 2006). Additionally, in smooth muscle cells, ROS production 
and GAPDH loss was also prevented by anti-CD36 antibodies, suggesting that NOX 
activation could be triggered by oxLDL binding to CD36 (Sukhanov et al., 2006). 
NOX-derived ROS and atherosclerosis 
The importance and involvement of NOX in inflammatory diseases including atherosclerosis 
has been extensively studied (Aviram et al., 1996; Harrison et al., 2003; Singh & Jialal, 
2006). Generally, all processes related to the development of atherosclerotic plaque are 
associated with NOX (Amanso & Griendling, 2012). As an example, NOX-derived 
superoxide from macrophages might contribute to the oxidation of lipids in atherosclerosis 
(Cathcart, 2004). In human atherosclerotic plaque, Sorescu et al. (2002) has demonstrated the 
increase of NOX2 parallel with the atherosclerotic plaque development whereas NOX4 
mRNA remained unchanged throughout the stages of atherosclerosis. However, NOX4 
expression was much lower in advanced lesions. Another study by Barry-Lane et al. (2001) 







double-knock out mice where a marked reduction of atherosclerotic lesions was observed. 
NOX inhibitors 
Currently, there are a number of NOX inhibitors being used mostly in experimental works, 
classified as peptide and non-peptide based inhibitors. Among the peptide based inhibitors 
are PR-39 antibiotic peptide (Shi et al., 1996) and gp91-ds-tat (Rey et al., 2001) while the 
non-peptide inhibitors include DPI (diphenyl iodonium) (Majander et al., 1994), phenylarsine 
oxide (PAO) (Vignais, 2002), gliotoxin (Nishida et al., 2005), 4-(2-aminoethyl)-
benzenesulfonyl fluoride (AEBSF) (Diatchuk et al., 1997), neopterin (Kojima et al., 1993), 
plumbagin (Ding et al., 2005), S17834 (Cayatte et al., 2001), apocynin (Basu et al., 1971) 
and VAS2870 (ten Freyhaus et al., 2006). GKT is another compound emerging as a 
promising and clinically relevant NOX inhibitor (Altenhofer et al., 2014). Although there are 
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many possible NOX inhibitors available, most of them are either non-specific (Bedard & 
Krause, 2007) or are having unclear mechanism of action. 
Apocynin 
 
Figure ‎1.11: Chemical structure of apocynin 
(Petronio et al., 2013) 
Apocynin (4-hydroxy-3-methoxy-acetophenone) (Figure 1.11), isolated from the roots of a 
Picrorizha kurroa plant (Basu et al., 1971) is a naturally occurring NOX inhibitor used in 
Ayurvedic medicine for the treatment of asthma. Apocynin has been studied as a possible 
remedy for many inflammation related diseases including cardiovascular disease (Williams & 
Griendling, 2007). It inhibits NOX activity in neutrophils (Simons et al., 1990) and non-
phagocytic cells (Meyer et al., 1999). Even though its exact mechanism of action is unknown, 




 to the membrane 
thus blocking NOX assembly (Meyer et al., 1999; Stolk et al., 1994a). Its inhibitory action is 
believed not to be NOX specific but also involves myeloperoxidase (MPO) (Van den Worm 
et al., 2001). Nevertheless, it has been suggested that apocynin requires H2O2 and 
peroxidases (e.g. MPO) to be activated into an active dimer of diapocynin (Stolk et al., 
1994a; Vejrazka et al., 2005) that reacts with thiol groups in the NOX subunit which prevents 
NOX assembly upon activation.  
Apocynin has been described as a promising candidate for therapeutic and research uses 
because of good oral bioavailability and not toxic in vivo. Apocynin is known to be a potent 
intracellular inhibitor of superoxide generation by activated neutrophils and eosinophils 
(Stolk et al., 1994a; Stolk et al., 1994b). However, studies have shown that apocynin can also 
stimulate ROS generation in non-phagocytic cells (Riganti et al., 2006; Vejrazka et al., 2005) 
thus raised the issue of specificity of this compound in exerting its effects. Moreover, 
apocynin has been shown to act more as an antioxidant by increasing GSH synthesis and 
activates the AP-1 transcription factor (Lapperre et al., 1999). Apocynin also affects cell 
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processes in the vasculature other than NOX activity including arachidonic acid metabolism 
(Engels et al., 1992), nitric oxide synthesis and cyclooxygenase pathway (Aldieri et al., 2008; 
Heumuller et al., 2008). Besides, apocynin has also been shown to be a direct ROS scavenger 
in certain experimental conditions (Heumuller et al., 2008). 
VAS2870 
 
Figure ‎1.12: Chemical structure of VAS2870 
(Stielow et al., 2006) 
VAS2870 (3-benzyl-7-(2-benzoxazolyl)thio-1,2,3-triazolo(4,5-d)pyrimidine) (Figure 1.12) is 
the prototype of the triazolo pyrimidine compounds reported to act as a rapid and reversible 
inhibitor of NOX activity (Schramm et al., 2012). VAS2870 has been shown to inhibit NOX 
activity in oxLDL-exposed human umbilical vein endothelial cells (HUVEC), which mainly 
expressed NOX4 (Stielow et al., 2006) and platelet-derived growth factor (PDGF)-stimulated 
rat smooth muscle cells (ten Freyhaus et al., 2006). In addition, VAS2870 does not have 
direct ROS scavenging properties and does not interfere with xanthine oxidase-mediated 
ROS generation (ten Freyhaus et al., 2006). Despite its ability to inhibit NOX, its mechanism 
of action remains elusive. In human leukocytes, ten Freyhaus et al. (2006) have shown that 
VAS2870 does not block the translocation of p47
phox
 to the membrane, instead it may 
interfere with NOX assembly once the translocation occurred. This is supported by 
experiments in a cell free system that showed inhibition of VAS2870 on NOX2 activity when 
added before but not after NOX has been stimulated (Wingler et al., 2011).  
VAS2870 has been regarded as not selective for any NOX isoforms since it also inhibited 
NOX2-induced oxidative stress in HL-60 cells and in a cell free system of human neutrophils 
(ten Freyhaus et al., 2006). Therefore, studies are required to determine the characteristics of 
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VAS2870 and its derivatives in terms of their specific mechanism of action, 
pharmacokinetics and efficacy (Wingler et al., 2011). In addition, VAS2870 has been shown 
to modify T regulatory cell function (Efimova et al., 2011) and increases TGF-β-induced 
apoptosis of liver tumour cells (Sancho & Fabregat, 2011). VAS2870 also inhibits the 
stimulation of vasculogenesis of mouse embryonic stem cells upon treatment with PDGF-BB 
(Lange et al., 2009). 
7,8-dihydroneopterin (7,8-NP) 
 
Figure 13: Chemical structure of 7,8-NP 
 
In macrophages, γ-interferon (IFN-γ) which is released by activated T cells stimulates the 
synthesis and secretion of 7,8-NP (Figure 1.13). Gieseg et al. (2009a) suggests that in 
atherosclerotic plaque, 7,8-NP may exert its effects within inflammatory sites to protect 
macrophages from the possible oxidants.  In vitro studies have shown that 7,8-NP is a potent 
antioxidant that can prevent oxidative damage on cells, cellular membranes, cellular proteins 
and protein thiols (Duggan et al., 2002; Gieseg et al., 2000; Gieseg et al., 2001b).  
The protective effects of 7,8-NP appears to be attributed to its radical scavenging capability. 
7,8-NP has been shown to scavenge oxidants, including superoxide and hydrogen peroxide 
(Shen, 1994), hydroxyl radicals (Heales et al., 1988), peroxyl radicals (Oettl et al., 2004), 
lipid peroxyl radicals (Gieseg et al., 1993) and HOCl (Yang, 2009). 7,8-NP can also prevent 
copper-, peroxyl radical- and cell-mediated LDL oxidation by scavenging the lipid-derived 
radicals which promote the protein peroxidation (Gieseg et al., 2003; Gieseg et al., 1995).  
Moreover, 7,8-NP has also been shown to prevent oxLDL-induced intracellular GSH loss in 
U937 cells by scavenging oxLDL-mediated ROS, which in turn maintained the intracellular 
redox environment, thus prevented cell death (Baird, 2003). 7,8-NP may also protect 
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HMDMs from oxLDL-mediated cell death via down-regulation of scavenger receptor CD36, 
therefore decreasing CD36-mediated uptake of oxLDL (Gieseg et al., 2010). Much evidence 
in the literature have also recorded the anti-inflammatory and antioxidant properties of 7,8-
NP. Thus, with known antioxidant capacity and the ability of protecting cells from oxLDL-
induced cell death from previous investigations, 7,8-NP  is of relevant to this research.  
Hydrogen sulfide (H2S) 
Hydrogen sulfide (H2S) is a colourless, flammable and poisonous gas with a characteristic 
rotten egg odour. It is present in the effluent of hydrothermal vents and sulphur springs (di 
Masi & Ascenzi, 2013; Smith & Gosselin, 1979) and has long been known as a toxic 
pollutant (Mancardi et al., 2009). Interestingly, H2S has been recognized as an important 
signalling molecule of the cardiovascular, inflammatory and immune systems (Wagner et al., 
2009). It plays a vital role as a novel biologically active gas alongside with nitric oxide (NO) 
and carbon monoxide (CO) which involves in intracellular signalling processes (Song et al., 
2014). 
Biosynthesis and metabolism 
H2S is enzymatically synthesised from amino acid cysteine, homocysteine and cystathionine 
by pyridoxal-5’-phosphate (PLP)-dependent enzymes such as cystathionine-β-synthase (CBS; 
E.C. 4.2.1.22) and cystathionine-γ-lyase (CSE; E.C. 4.4.1.1) (Vandiver & Snyder, 2012; 
Wang, 2002; Whiteman et al., 2011a). CBS and CSE are expressed in various locations 
including the brain, peripheral nervous system, liver, joint cells, intrauterine tissue, placenta 
and kidney (Whiteman et al., 2011a).  However, CBS is predominantly expressed in the brain 
and nervous system (Abe & Kimura, 1996; Kimura, 2000) while CSE is mainly observed in 
vascular smooth muscle cells and in the heart (Geng et al., 2004; Zhao et al., 2001). It has 
also been proposed that 3-mercaptopyruvate sulfurtransferase (3-MST) which is an α-
ketoglutarate and cysteine-dependent enzyme located in mitochondria (Shibuya et al., 2009) 
generates H2S within the mitochondria (Modis et al., 2013a). 3-MST is also expressed in the 
brain and most of the H2S produced by this enzyme is bound to the form of sulfane sulphur. 
In vivo, H2S is metabolised by oxidation in mitochondria or by methylation in cytosol and 
can be scavenged by methemoglobin or by metallo- or disulfide-containing molecules such as 
oxidised glutathione (Beauchamp et al., 1984; Wang, 2003). H2S is mainly excreted in the 
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kidney as free or conjugated sulfate and as thiosulfate (Wang, 2003) and is also exhaled from 
the lungs. Biosynthesis and metabolism of H2S are simplified in Figure 1.14. 
 
Figure ‎1.14: H2S metabolism pathways 
 (Mani et al., 2014) 
Physiological and pathophysiological roles of H2S 
Various physiological effects of H2S include as a major endothelium-derived hyperpolarizing 
factor (EDHF) which causes hyperpolarization and vasorelaxation of vascular endothelium 
and smooth muscle cells (Mustafa et al., 2011; Yang et al., 2008). As an antioxidant, H2S can 
also prevent cytokine or oxidant-induced oxidative damage (Taniguchi et al., 2011). 
Moreover, H2S can also down-regulate NF-κB activation or up-regulate heme oxygenase 1 
expression, thus inhibiting the expression of pro-inflammatory factors (Hu et al., 2007; Oh et 
al., 2006; Pan et al., 2011). Additionally, H2S may help in regulating various bodily functions 
with its cytoprotective (Calvert et al., 2010), antifibrotic (Tan et al., 2011) and antiapoptotic 
properties (Sen et al., 2012).  
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Pathophysiological role of H2S has been implicated in many inflammatory and cardiovascular 
diseases (Bhatia, 2012).  H2S has been demonstrated to protect against oxidative injury in in 
vivo and in vitro models of myocardial ischemia-reperfusion models (Chen et al., 2007; Chen 
et al., 2006). Moreover, the inhibition of H2S synthesis has been shown to accelerate the 
recovery of mean arterial pressure in a haemorrhagic shock model (Mok et al., 2004). Other 
beneficial effects of lowering H2S levels was demonstrated in carrageenan-induced hindpaw 
edema (Bhatia et al., 2005b), acute pancreatitis (Bhatia et al., 2005a) and septic shock (Li et 
al., 2005). Table 1.3 summarizes various H2S roles in physiological and pathological 
conditions. 
Table ‎1.3: H2S roles in physiological and pathophysiological conditions 
(adapted from di Masi & Ascenzi (2013)) 
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During atherosclerotic lesion formation, oxLDL has been shown to play a vital role in 
causing cell death to the macrophages. Since the pathogenesis of atherosclerosis is complex, 
extensive studies have been done by researchers around the world to develop understanding 
of this disease. The major aim of this PhD project is to investigate the mechanism of cell 
death induced by oxLDL focusing on intracellular oxidants (ROS) production, particularly 
superoxide. The current research will study and compare these effects in three different types 
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of cells i.e. U937 cells, human monocytes and human monocytes derived macrophages 
(HMDM cells). U937 cell line has been used extensively in various health and disease studies 
whereas human monocytes and HMDM cells are the best type of cells for in vitro study since 
those cells are involve in the development of atherosclerosis in vivo. Although the exact 
mechanism and the real processes that occurred in vivo are never known, these cells will be 
the best to mimic the actual phenomena happening in the human body. 
The initial part of Chapter Three will examine the cytotoxic effects of oxLDL on cell 
viability of U937, human monocytes and HMDM cells. Effects of oxLDL on cell 
morphology and cell viability will be determined to establish the LC50 concentration for each 
batch of oxLDL prepared for further experimentation throughout the research programme. 
The analysis was to confirm and extend the studies done by previous researchers in this 
group. Comparison between MTT and PI-flow cytometry assays for the determination of cell 
viability will also be studied to validate the agreement between the two methods and to 
determine the benefits and drawbacks of one assay over another. 
Previous studies have shown that oxLDL had caused oxidative stress by inducing 
intracellular production of ROS through the activation of NADPH oxidase (NOX) enzymes 
on the plasma membrane of the cells. Accordingly, Chapter Four will study the effects of 
oxLDL-induced oxidative stress, ROS generation and NOX activation mechanism. The 
effects of NOX inhibitors i.e. apocynin and VAS2870 as well as 7,8-dihydroneopterin on 
intracellular ROS production and cell viability will also be studied. 
Study by our previous researcher in this laboratory has showed the importance of calcium 
(Ca
2+
) in HOCl-mediated cell death in HMDM cells. Our hypothesis is that Ca
2+
 is essential 
and is the main cause of oxLDL-mediated cell death. Hence, Chapter Five will investigate 
the role of Ca
2+
 in oxLDL-mediated cell death. The study will examine the effects of 
intracellular and extracellular Ca
2+
 on cell death induced by oxLDL. Different types of Ca
2+
 
channel inhibitors and Ca
2+ 
chelators will be tested to determine their ability in preventing 
intracellular Ca
2+
 rise when induced with oxLDL as well as preserving cell viability from the 
toxicity of oxLDL.  
Hydrogen sulfide (H2S) involvement in biological processes has proved to be promising, 
particularly with atherosclerosis. Therefore, Chapter Six will study for the first time the 
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effects of different types of slow releasing H2S donor compounds on oxLDL-mediated cell 
death. If these compounds are able to protect cell death caused by oxLDL, their mechanism 
of action will also be investigated with regards to Ca
2+









Throughout this research, experiments were carried out using reagents of analytical grade or 
better. Water was deionized and ultrafiltered using a Milli-Q filtration water system and, 
unless otherwise stated, all solutions were prepared using this nanopure water. 
 
-mercaptoethanol Sigma Chemical Co., Missouri, USA 
2-aminoethoxydiphenyl borate (2-APB) Sigma Chemical Co., Missouri, USA 
3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyl-
tetrazolium bromide (MTT) 
Sigma-Aldrich Co., LLC, New Zealand 
4-bromo-calcium ionophore A23187 (Br-A) Sigma Chemical Co., Missouri, USA 
4-Morpholine-propanesulfonic acid (MOPS)  Sigma Chemical Co., Missouri, USA 
7,8-Dihydroneopterin (7,8-NP) Schirck Laboratories, Switzerland 
Acetic acid (glacial) Scharlau Chemie S.A., Barcelona, Spain 
Acetone Merck Ltd, Poole, England 
Anchor non fat milk powder Fonterra New Zealand, Ltd, New Zealand 
4’-hydroxy-3-methoxyacetophenone (apocynin) Sigma Chemical Co., Missouri, USA 
Argon gas BOC Gases, Auckland, New Zealand 
BAPTA-AM Invitrogen, Life Technologies, New Zealand 
Bicinchoninic acid (BCA) protein determination kit Pierce, Illinois, USA 
Bovine serum albumin (BSA) Gibco Invitrogen Corporation, Auckland, New 
Zealand 
Bromophenol blue Sigma Chemical Co., Missouri, USA 
Calcium ionophore A23187 Sigma Chemical Co., Missouri, USA 
Chelex 100 resin Bio-Rad Laboratories, California, USA 
Cholesterol reagent Roche Diagnostics, USA 
Copper chloride (CuCl2) Sigma Chemical Co., Missouri, USA 
Coumassie blue Bio-Rad Laboratories, California, USA 
Cyclosporin Sigma Chemical Co., Missouri, USA 
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2′,7′-dichlorodihydrofluorescein diacetate  
(H2DCF-DA) 
Invitrogen,, Oregon, USA 
Dantrolene Sigma Chemical Co., Missouri, USA 
Dihydroethidium (DHE) Invitrogen,, Oregon, USA 
Dimethyl sulphoxide (DMSO) BDH Laboratory Supplies Ltd., Poole, England 
Dipotassium phosphate (K2HPO4) Scharlau Chemie, Italy 
Ethanol Merck, Darmstadt, Germany 
Ethylenediaminetetraacetic acid (EDTA) Sigma Chemical Co., Missouri, USA 
Ethyleneglycoltetraacetic acid (EGTA) Sigma Chemical Co., Missouri, USA 
Ferrous ammonium sulphate Sigma Chemical Co., Missouri, USA 
Flunarizine Sigma Chemical Co., Missouri, USA 
Fluo 3 AM Invitrogen,, Oregon, USA 
Glycerol Sigma Chemical Co., Missouri, USA 
Glycine Bio-Rad Laboratories, California, USA 
Granulocytes-macrophage colony-stimulating factor 
(GM-CSF) as Leukine® sargamostim 
Seattle, USA 
Hydrochloric acid, fuming 37 % (HCl) Merck, Darmstadt, Germany 
Isopropanol Mallinckrodt Chemicals, New Jersey, USA 
Methanol Merck, Darmstadt, Germany 
MitoSox red Invitrogen,, Oregon, USA 
Molecular Weight Marker Bio-Rad 
Nifedipine Sigma Chemical Co., Missouri, USA 
Nitrogen gas BOC Gases, Auckland, New Zealand 
NuPAGE 4-12% Bis-Tris Gel, 1.0 mm x 10 well Invitrogen, California, USA 
Phorbol 12-myristate 13-acetate (PMA) Sigma Chemical Co., Missouri, USA 
Ponceau S Sigma Chemical Co., Missouri, USA 
Potassium bromide (KBr) Merck, Darmstadt, Germany 
Potassium chloride (KCl) Merck Darmstadt, Germany 
Potassium dihydrogen phosphate (KH2PO4) Scharlau Chemie, Italy 
Potassium hydroxide (KOH) Merck, Darmstadt, Germany 
Ruthenium Red Sigma Chemical Co., Missouri, USA 
Sodium chloride (NaCl) Merck, Darmstadt, Germany 
Sodium dihydrogen orthophosphate monohydrate 
(NaH2PO4.H20) 
Merck, Darmstadt, Germany 
Sodium dodecyl sulphate (SDS) Sigma-Aldrich Co., LLC, New Zealand 
Sodium hydrogen carbonate (NaHCO3) Merck, Darmstadt, Germany 
Sodium hydroxide (NaOH) Scharlau Chemie, Italy 
Supersignal West Dura chemiluminescence Pierce Biotechnology Inc., Illinois, USA 
Thapsigargin Sigma-Aldrich Co., LLC, New Zealand 
Thimerosal Sigma Chemical Co., Missouri, USA 
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Trichloroacetic acid (TCA) Sigma Chemical Co., Missouri, USA 
Tris buffer Roche Diagnostics GmbH, Mannheim, Germany 
Trypan blue solution (0.4%) Sigma Chemical Co., Missouri, USA 
Tween-20 Sigma Chemical Co., Missouri, USA 
VAS2870 Sigma Chemical Co., Missouri, USA 
Verapamil hydrochloride Sigma Chemical Co., Missouri, USA 
 
Media 
Foetal bovine serum (FBS) Invitrogen, Life Technologies, New Zealand 
Penicillin/Streptomycin (10000 units/ml penicillin G 
and 10000 µg/ml streptomycin) 
Invitrogen, Life Technologies, New Zealand 
Roswell Park Memorial Institute (RPMI) -1640 media, 
with phenol red 
Sigma-Aldrich Co., LLC, New Zealand 
Roswell Park Memorial Institute (RPMI) -1640 media, 
without phenol red  
Sigma-Aldrich Co., LLC, New Zealand 
Earle’s Balanced Salt Solution (EBSS) Gibco
®
 , Life Technologies, New Zealand 
 
Antibodies 
Mouse monoclonal against -Actin Sigma-Aldrich Chemical Co., USA 
Mouse monoclonal IgG1 p47-phox Santa Cruz Biotechnology Inc., USA 





General solutions and buffers 
Phosphate buffered saline (PBS)  
Phosphate buffered saline (PBS) contained 150 mM sodium chloride (NaCl, MW= 58.44 
g/mol) to 10 mM sodium dihydrogen orthophosphate (pH 7.4) (NaH2PO4.H2O, MW= 
137.99g/mol).  A litre of PBS was prepared by adding 50 mL of 3M NaCl, 40 mL of 
NaH2PO4.H2O (pH 7.4) and 910 mL of nano-pure water. PBS solution for cell culture work 
was vacuum filtered using a 0.45um membrane (Phenomenex) and sterilized by autoclaving 
(15 minutes, 121ºC and 15 psi). Prior to use with cells, it was warmed up to 37ºC in a water 
bath. 
7,8-dihydroneopterin (7,8-NP) solution 
A 2 mM stock of 7,8-dihydroneopterin (7,8-NP) (MW= 255.2 g/mol) was prepared fresh 
every time, immediately before each experiment. 7,8-NP powder (Schircks Laboratories, 
Switzerland) was dissolved in the appropriate medium (depending on experiment to be done) 
followed by 10-15 minutes ultrasonication. The 7,8-NP solution was then filter-sterilised 
using a 0.22 µm MS
®
 PES syringe filter (Membrane Solutions, USA) and diluted to working 
concentrations before added to cells. The solution was kept on ice at all times.  
Apocynin solution 
A 2 mM stock solution of apocynin (MW= 166.17 g/mol) was prepared by dissolving 
apocynin powder (Sigma-Aldrich) in PBS or RPMI-1640 media. After being filter-sterilised 
through a 0.22 µm MS
® 
PES syringe filter, the solution was stored at -4
o
C and used within a 
month.  
Phorbol 12-myristate 13-acetate (PMA) 
A 5 mM stock solution of PMA (MW= 616.83 g/mol) was made by dissolving PMA in 
DMSO, stored at -20 ºC and diluted to 5 µM in PBS or RPMI1640 with no phenol red before 
addition to the cells. 
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MTT assay solution 
MTT (3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide) stock solution was 
prepared by dissolving MTT powder  (Sigma-Aldrich Co., St. Louis, USA) in RPMI 1640 
without phenol red to give a final concentration of 5 mg/mL. This solution was filter-
sterilised using a 0.22 μm MS
®
 PES syringe filter and stored at -20 ºC in the dark until use. 
For viability assay, the stock solution was diluted in pre-warmed RPMI-1640 without phenol 
red to give a final concentration 0.5 mg/mL MTT. 
A 0.01 M HCl solution was made up from 11.44 M HCl and nano pure water. Sodium 
dodecyl sulphate (SDS) powder was added to this solution and stirred up slowly to give a 




Cell culture  
All cell culture work and experiments were conducted under aseptic conditions in a class II 
biological safety cabinet (Clyde-Apex BH 200). All equipment and plastic wares were 
supplied sterile, ready to use and disposable (Falcon, Terumo, Unomedical, Greiner Bio-one) 
or had been sterilised by autoclaving (15 min, 121
o
C, 15 psi). All media and solutions were 
sterilised either by autoclaving or by filtration through a sterile 0.22 μm membrane filter 
(Membrane Solutions, USA). All equipment and tissue culture items were sprayed 
thoroughly with 70% (
v
/v) ethanol (diluted in distilled water) before being placed into the 
class II biological safety cabinet. Cells were incubated in an incubator at 37ºC in a humidified 
atmosphere containing 5% CO2 (Sanyo Electric Co. Ltd., Japan).  
Cell culture media 
Cell culture media with different chemical compositions were used for cell culture depending 
on the suitability of the cells and experimental conditions. In the present study, Roswell Park 
Memorial Institute 1640 medium (RPMI-1640) was used in the culture of U937 cell line, 
human monocytes and human monocyte derived macrophages (HMDM). 
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Roswell Park Memorial Institute (RPMI)-1640 media (with or without phenol red) 
The media was prepared according to the manufacturer’s instructions. Powdered RPMI (with 
or without phenol red) was first dissolved in nano-pure water. Whenever necessary, 11.4 M 
hydrochloric acid (HCl) was added to completely dissolve the powder. It was then followed 
by the addition of sodium bicarbonate (NaHCO3) and pH adjustment to 7.4 with 1 M NaOH. 
The media was filter-sterilised through a 0.22 um MillexR-GP filter/a 0.20 µm Sartolab
®
-P20 
filter (Sartorius AG, Goettingen, Germany) using a peristaltic pump (CP-600, Life 
Technologies) into sterile 500 mL bottles. The prepared media was stored at 4ºC and warmed 
to 37ºC in a water bath before use.  
Earle’s Balanced Salt Solution (EBSS) (without calcium, magnesium and phenol red) 
EBSS (Gibco
®
, Life Technologies) was used for experiments that involved determination of 
intracellular and extracellular calcium. This solution was supplied as ready to use. CaCl2 was 
added to the solution to give a concentration of 0.423 nM of calcium when needed for 
experiments. 
Standard RPMI-1640 media 
RPMI-1640 medium (with phenol red) supplemented with 100 U/mL penicillin G, 100 
µg/mL streptomycin and 5% (v/v) foetal bovine serum (FBS) was used for normal U937 cell 
maintenance. As for human monocytes and HMDM, 10% (v/v) human serum was used to 
substitute FBS for normal cell maintenance.  
Cell culture experimental conditions and procedures 
Experiments were performed using 24-well suspension culture plates (Cellstar®, Greiner 
Bio-one) for both U937 cells and human monocytes. For experiments with U937 cells, wells 
of the plates were coated with 8 µL of 50 mg/mL bovine serum albumin (Sigma-Aldrich) 
whereas 5% human serum was added for human monocytes. Total experimental volume was 
1 mL for each well. Cells were counted using a haemocytometer and a light microscope after 
staining with trypan blue at a ratio of 1:1 for U937 cells whereas for human monocytes a ten 
times dilution with trypan blue was normally perform prior to cell counting. The required 
quantity of cells for the experiment was centrifuged at 500 g for 5 minutes at room 
temperature and re-suspended in the appropriate experimental medium at 37ºC. The cell 
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suspension was then aliquoted into wells containing the medium at a final concentration of 
0.5 x 10
6
 cells/mL for U937 cells and 1 x 10
6
 cells/mL for human monocytes.  
Unless stated otherwise, experiments for HMDM were performed in the original plates where 
they were seeded into at a concentration of 1 x 10
6
 cells/mL in a 48 well plates. The total 
volume of incubation medium during experiments was 500 µL and 5% human serum was 
also added into each well during treatment. 
Preparation of human serum for cell culture 
Human serum used for cell culture of human monocytes and HMDM in the present study was 
from haemochromatosis blood donors obtained under ethics approval CTY/98/07/069 
approved by the Upper South (B) Regional Ethics Committee. Unlinked blood from 
consenting donors was collected into 450 mL dry blood bags (no anticoagulant added, 
Fresenius Kabi, Homburg, Germany) by the New Zealand Blood Service (Riccarton branch, 
Christchurch).  The blood bags were left in a vertical position in the poplypropylene 
container at room temperature for 2 hours to allow blood clot. Subsequently, the blood bags 
were transferred to 4
o
C fridge and stored overnight to grant adequate time for the separation 
of serum from the clot.  
Next, the blood bags were cut opened under aseptic conditions in the CII cabinet and the 
serum was collected into 50 mL centrifuge tubes using a 25 mL sterile plastic pipette. The 
tubes were centrifuged for 15 minutes at 1000 g (Heraeus Multifuge-SR, BioStrategy,New 
Zealand) to pellet the remaining red blood cells. If the resulting serum appeared to contain 
any red blood cells, the centrifugation was repeated. The clear serum obtained after 
centrifugation was transferred to new 50 mL tubes and stored in a – 20
o
C freezer until frozen 
followed by a – 80
o
C freezer for long term storage of up to 6 months.  
Preparation and culture of U937 cell line 
The U937 cell line is a type of immortal cell line and was originally isolated from the pleural 
fluid of a 37 year old male patient with histiocytic lymphoma (Sundstrom & Nilsson, 1976). 
U937 cells resemble many monocyte/macrophage-like morphology and characteristics and 
they are widely used as an in vitro model for various biomedical research. U937 cells used in 
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this laboratory were a gift from the Haematology Research Laboratory at the Christchurch 
School of Medicine, University of Otago and stored in 1 mL vials in liquid nitrogen storage. 
Before the cells are being used for experiments, a frozen 1 ml vial containing 20 x 10
6
 
cells/mL in DMSO was removed from liquid nitrogen storage and defrosted in a water bath at 
37ºC until almost completely thawed. The concentrated cell suspension was poured into 30 
ml of RPMI-1640 medium in a 50 ml centrifuge tube and centrifuged at 500 g for 5 minutes 
to separate the DMSO freezing medium and the cells. The cell pellet was resuspended in 10 
ml of RPMI-1640 medium in a 25 cm
2 
tissue culture flask (Falcon, BD, USA).  
Once the cells achieved an appropriate density i.e. approximately 1.0 x 10
6
 cells/mL and are 
having a normalised division rate followed by 20-48 hours in the subsequent subculturing, 
they were considered fit for experimental purpose. Microscopically, U937 cells are round in 
shape with short microvilli (Pagliara et al., 2005). Cell density was maintained at 0.3-1.5 x 
10
6
 cells/mL by subculturing in Cellstar® 150 cm
2
 tissue culture flasks (Greiner Bio-one, 
Germany) every 2-4 days. A new stock of the concentrated U937 cells was brought up after 
six month of usage of the existing cells in order to avoid any contaminations or possible 
problems associated with prolonged cell culture.  
Preparation and culture of human monocytes and human monocytes 
derived macrophages (HMDM) 
Isolation of monocytes from whole blood 
Blood with no donor identification (unlinked) from healthy consenting haemochromatosis 
individuals were collected into 500 mL autologous blood bag containing citrate phosphate 
dextrose adenine anticoagulant (CPDA-1, Compoflex
®
) by the New Zealand Blood Service 
(NZBS). The cells were normally prepared immediately after blood collection or kept for up 
to 18 hours at 4
o
C if processing cannot be carried out on the same day.  
The technique described by Amit (2008) and Yang (2009) has been used to separate the 
monocytes from other types of blood cells. Firstly, a bag of whole blood was inverted gently 
for 10-12 times to ensure even distribution of the cells before placing it into the CII cabinet 
aseptically. Next, one of the blood bag tube was cut opened and the blood was transferred 
into sterile 50 mL centrifuge tubes and centrifuged at 1000 g (slow deceleration) for 30 
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minutes at room temperature. After centrifugation, the cells were separated into a few layers 
consisting of erythrocytes at the bottom, topped with white layer of leukocytes (buffy coat) 
and overlaid with plasma layer. The plasma layer was aspirated leaving the leukocytes layer 
(approximately 17.5 mL) which was removed using a mixing cannula attached to a 10 mL 
plastic syringe, pooled and mixed with equal volume of PBS by inverting thoroughly. The 
mixture was then under laid with 15 mL of Lymphoprep
®
 (lymphoprep) using a mixing 
cannula attached to a 20 mL plastic syringe before being centrifuged again at 1000 g (slow 
acceleration/deceleration) for 30 minutes at room temperature. The resulting white layer of 
monocytes/lymphocytes was visible about halfway down the 50 mL tube encircled by clear 
plasma and lymphoprep layers. The top layer solution was aspirated leaving approximately 2 
cm above the leukocytes layer. 
The cells in solution were transferred into a new 50 mL centrifuge tubes using a mixing 
cannula attached to plastic syringe and thoroughly resuspended and evenly divided between a 
designated numbers of tubes with each containing 15 mL of solution. A volume of 30 mL of 
PBS was topped up into each tube and mixed by inverting before being centrifuged at 500 g 
for 15 minutes. Once centrifuged, the supernatant was aspirated, cell pellets were 
resuspended with 45mL of PBS and tubes were inverted to mix and centrifuged at 500 g for 
another 10 minutes. This washing step was repeated once more before the cells were 
resuspended in the RPMI-1640 media containing Pen/Strep but no serum. The cells were then 
plated into 6 well suspension plates (Cellstar) and incubated in the CO2 incubator for 40 
hours (37
o
C, 5% CO2). 
Seeding, culture and monitoring of HMDM cells 
After approximately 40 hours of incubation in the absence of serum, the T-cells died due to 
lack of serum, the platelets attached to the bottom surface of the plate while the monocytes 
stayed viable in the suspension (Yang, 2009). At this stage, experiments with human 
monocytes were able to commence and the cells were acceptable for experimental purpose 
for another 3 to 4 days. The cell suspension was aspirated, pooled into 50 mL tubes and 
centrifuged at 500 g for 15 minutes at room temperature and the supernatant was removed. 
The cells were resuspended in RPMI-1640 media supplemented with 10% (v/v) human 
serum. Granulocytes macrophage colony stimulating factor (GM-CSF) administered as 
Leukine
®
 (Bayer, USA) was added to the cell suspension to enhance the differentiation of 
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monocytes into macrophages. The final concentration of GM-CSF was 50 ng/mL of cell 
suspension.  
The cells were seeded (plated) into 48 well plates (adherent, Cellstar) at a concentration of 
1x10
6
 cells/mL. Media change using RPMI-1640 with 10% human serum was carried out 
every 3 to 4 days. Experiments using HMDM were conducted once the majority of the 
monocytes had matured into macrophages, normally between days 11 and 16 after seeding of 
the monocytes. Every 3 to 4 days, HMDM differentiation and morphology were monitored 
and examined using Leica DM IL (Leica Microsystems, Wetzlar, Germany) inverted 
microscope equipped with a camera and connected to the computer with Leica Application 
Suite Version 2.8.1 software which enabled images of the cells to be taken and recorded. 
Approximately 7 days after seeding, a good or satisfactory cell preparation will end up with 
majority of the well surface dominated by round poached-egg like cells. 
Blood collection from donors and plasma preparation for LDL purification 
Blood collection was done under ethics approval granted from Upper South (B) Regional 
Ethics Committee - CTY/98/07/069. All healthy blood donors (male and female) were 
required to fast overnight plus a written consent was obtained from each donor before blood 
collection. Blood was collected by venipuncture using a 21G x 
3
/4 inch or 19 G needle 
attached to a 30 mL syringe (Terumo, USA). The blood was then collected directly into 50 
mL centrifuge tubes (Greiner Bio-one) containing 500 µL of 100 mg/mL EDTA (pH 7.4), to 
give a final concentration of 0.1% EDTA. A total of 200 mL of blood was collected from 
each donor.  
The blood was then centrifuged for 20 minutes at 4ºC in a swing-out rotor at 4,100 g with the 
brake off to separate red blood cells and plasma. The plasma was subsequently transferred to 
50 mL round bottomed centrifuge tubes and centrifuged at 11,000 g for 30 minutes at 4ºC, 
with slow acceleration/deceleration in a fixed angle rotor to remove any remaining cellular 
debris. Plasma from all donors was then pooled together into a single measuring cylinder to 
minimise inter-individual variation (Gieseg & Esterbauer, 1994). The plasma was stored at -
80ºC in 30 mL aliquots for up to 6 months.  
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LDL purification from pooled plasma 
Isolation of LDL from plasma using gradient centrifugation 
The method of Chung et al. (1980) with modifications of a single vertical spin described by 
Gieseg and Esterbauer (1994) was used for LDL isolation in the present study. This method 
involves preparing one step gradient that redistributes to form a continuous gradient that 
separates the lipoproteins during ultracentrifugation. 
Frozen human plasma in a 30 mL tube was thawed under cold running water and centrifuged 
at 4,700 rpm for 10 minutes at 4ºC to remove any precipitated fibrinogen. The supernatant 
was decanted into a glass beaker and placed on ice. The plasma density was adjusted to 1.24 
g/mL by gradually adding 11.4 g of solid potassium bromide (KBr). The solution was capped 
with parafilm and gentle stirring was applied while dissolving KBr in order to prevent the 
formation of foam. 
Approximately, 8 mL of 1 mg/mL EDTA (pH 7.4) was added to each of the 8 polyallomer 
ultracentrifugation tubes (OptiSeal™, Beckman Coulter, USA). This was followed by under-
layering with around 4 mL of KBr-plasma using a long luer-fitting needle attached to a 5 ml 
syringe. The tubes were transferred to the Beckman Near Vertical (NVTi-65) rotor (Figure 
2.1) and centrifuged at 60,000 rpm for 2 hours at 10ºC using slow acceleration/deceleration in 
Optima™ L-90K Preparative Ultracentrifuge (Beckman Coulter Inc., Fullerton, California) 
(Figure 2.1). After centrifugation, a yellow/orange coloured band of LDL (Figure 2.2) in the 
density range of 1.019 to 1.063 g/mL was collected into a 15 mL centrifuge tube using a 90
o
-
bent needle attached to a 10 mL syringe. Freshly prepared LDL was then flushed with argon 




Figure ‎2.1: Beckman Optima™ L-90K Preparative Ultracentrifuge and Beckman Near 
Vertical (NVTi65) rotor 
The plasma was centrifuged at 60,000 rpm for 2 hours at 10
o
C using slow acceleration/deceleration 
for LDL isolation.  
 
Figure ‎2.2: LDL purification 
LDL isolated from pooled plasma using density centrifugation. LDL band as indicated by the arrow. 
LDL concentration determination 
LDL concentration was determined as a function of total cholesterol content by an enzymatic 
reaction using a cholesterol kit supplied by Roche Diagnostic. The assay involves incubating 
10 µL of LDL with 1 mL of cholesterol reagent at room temperature for 10 minutes. 
Absorbance was then read at 500 nm against a blank containing only cholesterol reagent. 
LDL concentration was then calculated from this absorbance, based on the estimate of 
cholesterol accounting for 31.69% of the whole LDL particle by weight and LDL having a 
molecular weight of 2500 kDa (Gieseg & Esterbauer, 1994). The value used for LDL 





the mass of apolipoprotein B (protein component of the LDL molecule) as 5:1 (Gieseg & 
Esterbauer, 1994) 
Calculation of LDL concentration:  
Absorbance x 14.9 = [cholesterol] (mM) 
[cholesterol] (M) x 386.64 g/mol = [cholesterol] (g/L) 
[cholesterol] (g/L) x 100/31.69 = [LDL] (g/L or mg/mL) 
LDL washing and concentration 
LDL was concentrated using Amicon® Ultra-15 filter tubes (Millipore, USA). Before usage, 
the filter tubes were rinse with nano pure water followed by centrifugation with PBS for 2 
minutes to wash. LDL was placed into the filter tubes, topped up with PBS and centrifuged at 
3,000 g for 30 minutes at 4ºC (fast acceleration/deceleration). This step was then repeated 
thrice to ensure elimination of EDTA from the LDL. The duration of the last centrifugation 
varied depending on the desired final volume/concentration of LDL.  The final concentration 
of the concentrated LDL was adjusted to approximately 10 mg of LDL per mL of solution 
(total mass) (see LDL concentration determination). After use, the filter tubes were rinsed 
with nano pure water. It was then followed by 2 minutes centrifugation with nano pure water 
and 1 minute centrifugation with 95% ethanol before storage in a fridge at 4
o
C with 5 mL of 
50% ethanol at the bottom of the tubes.  
LDL oxidation 
Preparation of dialysis tubing 
The dry dialysis membrane tubes (Medicell International Ltd., London, England) with 14.4 
mm flat width and 14,000 Daltons molecular weight cut off were pre-treated before use. The 
dialysis tube was cut into approximately 25 cm length sections and boiled in a glass beaker 
containing solution of 5% 
w
/v NaHCO3 and 1 mM EDTA for 20 minutes on a heating block. 
The tubes were then washed with distilled water and re-boiled in a glass beaker containing 
nano pure water for 20 minutes. Finally, the tubes were washed thoroughly with nano pure 
water and stored in 50% ethanol at 4ºC. The tubes were rinsed thoroughly with nano pure 
water followed by PBS before being used for LDL oxidation. 
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Copper oxidation of LDL 
LDL oxidation method used in this study was adapted from (Gerry et al., 2008). 
Concentrated LDL at approximately 10 mg/mL (total mass) was mixed with 0.5 mM copper 
chloride (CuCl2) and placed into a double-knotted dialysis tube secured at both ends with 1.7 
mL micro tubes. The LDL-containing dialysis tubing was placed in a large glass bottle 
containing 1 L of PBS per 10 mg of LDL protein and CuCl2 at a final concentration of 0.5 
mM CuCl2. LDL in the dialysis tube was dialysed for 24 hours at 37ºC in an orbital shaker 
(Bioline, Edwards Instrument Company, Australia). Complete oxidation of LDL occurred 
when the yellow LDL colour turned colourless with a tinge of cloudy white (Figure 2.3). 
The dialysis tube containing oxLDL was then transferred to a fresh bottle containing 1 L of 
PBS, a quarter teaspoon of washed Chelex-100 and a magnetic flea and stirred at 4ºC for two 
hours in order to remove the excessive copper ion. This step was repeated twice with the third 
change of PBS-Chelex taking place overnight. OxLDL was then taken out from the dialysis 
tube, filter-sterilised through a 0.22 µm MS
®
 PES syringe filter in the CII cabinet and stored 
at 4ºC. The oxLDL was used within a month after oxidation. 
 
Figure ‎2.3:LDL in dialysis tube after oxidation 
LDL turned colourless which indicates complete oxidation. 
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Cell viability analysis 
MTT reduction assay  
The MTT reduction assay is a widely used and accepted method for measuring cell viability. 
It has been shown previously in this laboratory that results obtained by this method correlate 
with the results produced by the trypan blue exclusion assay (Baird, 2003). Viable cells with 
active metabolism reduce the yellow tetrazolium MTT compound via the action of NADH 
and NADPH dehydrogenase enzymes into an insoluble purple formazan product with a 
maximum absorbance near 570 nm (Figure 2.4). The resulting formazan crystals can be 
solubilised and quantified spectrophotometrically (Mosmann, 1983) so that the colour 
intensity indicates both the number of cells and their metabolic activity..  
 
Figure ‎2.4: The structures of MTT and coloured formazan product 
The dehydrogenase enzymes of metabolising cells generate reducing agents, NADH and NADPH 
which reduce yellow tetrazolium salt to purple formazan. 
HMDM cells were washed with warm PBS and incubated with 600 µL of MTT solution at 
37
o
C in the dark for 30 minutes to 1 hour. The incubation time with MTT varied depending 
on the cell density and overall metabolic activity of the control cells. For experiment with 
U937 cells or human monocytes, the cells (in culture plates) were incubated in RPMI-1640 
without phenol red and the MTT reagent of 5 mg/mL was added directly to the wells to give a 
final concentration of 0.5 mg/ml MTT for 2 hours. The cells were incubated in the dark at 
37
o
C for 1 to 2 hours to allow sufficient formazan crystals to develop. The purple formazan 
crystals were then dissolved by the addition of an equal volume of 10% (
w
/v) SDS in 0.01 M 
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HCl into each well with thorough mixing. Absorbance was read at 570 nm against a blank 
that contained the reagents only. 
Trypan Blue Exclusion Staining 
The number of viable cells in the culture can be measured using trypan blue exclusion 
staining method. This is done by mixing the dye with the suspension cells at the appropriate 
ratio (normally 1:1 for U937 cells and 1:10 for human monocytes) prior to counting the 
number of live cells in the defined regions of a haemocytometer (Marienfeld, Germany). 
Viable cells have intact membranes that are impermeable to the dye rendering them to appear 
opaque when viewed under the light microscope. In contrast, dead cells which have 
compromised membrane integrity developed a deep blue stained due to trypan blue uptake. 
However, this stain is unable to distinguish between healthy cells and cells that are still alive 
but losing cell function. 
Propidium Iodide (PI) Staining 
Another method used in this research for the determination of cell viability is propidium 
iodide (PI) stain done via flow cytometer (see Flow cytometry analysis – Propidium 
Iodide). Since this technique is rapid with more advantages compared to MTT and trypan 
blue, it has been used as the major method in assessing cell viability throughout the whole 
course of this study. 
Determination of protein concentration 
Protein concentration was determined using the bicinchoninic acid (BCA) protein 





 by protein in an alkaline medium with the colorimetric detection Cu
+
 using a unique 
reagent containing bicinchoninic acid (Smith et al., 1985). This reaction product of this assay 
exhibits a strong absorbance at 562 nm with increasing protein concentrations ranging from 
20 to 2000 µg/mL (Pierce™ Instruction Manual). 
The working reagent was freshly prepared by mixing Reagent A (sodium carbonate, sodium 
bicarbonate, BCA and sodium tartrate in 0.1 M sodium hydroxide) and Reagent B (4% 
CuSO4.5H2O) at a 50:1 ratio (1 mL Reagent A to 20 µL Reagent B).  
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The assay was done by mixing 50 µL of sample with 1 mL of working reagent and incubated 
at 60°C for 30 minutes with gentle shaking in a heated shaking block. The reaction was 
stopped by placing samples on ice before absorbance reading was performed at 562 nm 
against water blank.   
Protein concentration was determined from a standard curve prepared by the incubation of 
known concentrations of BSA (0-250 µg/mL) in 1 mL of working reagent (Figure 2.5). 
 
Figure ‎2.5: Example of standard curve for protein concentration determination using 
BCA reagent kit 
 
SDS-PAGE and Western blot analysis 
Solutions for SDS-PAGE and Western blot analysis 
Cracker buffer was prepared by dissolving 1% (
w
/v) SDS (MW= 288.38 g/mol), 20% (
w
/v) 
glycerol (MW= 92.10 g/mol), 0.1% (
w
/v) bromophenol blue (MW= 670.02 g/mol) and 125 
mM Tris-HCl, pH 6.8 (adjusted with concentrated HCl) in nano pure water. Prior to use, 1 
mL of the above solution was mixed with 2% (
v
/v) of β-mercaptoethanol and 0.5 mM EDTA. 
Lysis buffer consisted of 40 mM of HEPES (MW= 238.31 g/mol), 50 mM of NaCl (MW= 
58.44 g/mol) and 1 mM EGTA (MW = 380.4 g/mol) in nano pure water, pH adjusted to 7.4 
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using 10 M NaOH and stored at 4°C. Prior to use, Complete Mini (Roche Diagnostics, 
Germany)) protease inhibitor stock (7x) was added to lysis buffer.. One Complete Mini 
protease inhibitor cocktail tablet was dissolved in 1.5 mL of nanopure water to give a 7× 
stock solution. The complete lysis buffer was stored on ice until use. 
A 10x stock solution of MOPS (4-morpholine-propanesulfonic acid) buffer was prepared 
with 500 mM MOPS, 500 mM Tris base, 1% (
w
/v) SDS and 10 mM EDTA in nano pure 
water with the pH adjusted to 7.7 by adding concentrated HCl. The stock solution was diluted 
to 1x concentration before use. 
Transfer buffer for Western blot analysis contained 25 mM Tris, 200 mM glycine (MW= 
75.07 g/mol) and 20% (
v
/v) methanol in nano pure water, stored at 4°C.  
Ponceau S stain for staining of nitrocellulose membrane contained 0.01% (
w
/v) Ponceau S and 
5% (
v
/v) acetic acid. 
Tris-buffered saline (TBS) for washing of nitrocellulose membrane consisted of 40 mM Tris-
HCl (pH 7.5), 150 mM NaCl, 0.05% (
w
/v) Tween-20, and 0.01% (
w
/v) thimerosal (contains 
Hg) in nano pure water.  
The 5% (
w
/v) blocking solution (TBS-milk, TBSM) was prepared by dissolving 10 g of non-
fat milk powder (Anchor, New Zealand) in 200 mL of TBS and was stored at 4°C while the 2% 
TBSM were made up by diluting the 5% TBSM with TBS accordingly. 
Sample preparation for U937cells, human monocytes and HMDM cells – Western Blot 
analysis 
Cell samples for U937 were collected and washed twice with cold PBS by centrifuging at 500 
g for 5 minutes at room temperature whilst for HMDM cells, the attached cells were washed 
twice with cold PBS. A volume of 150 µL of ice cold complete lysis buffer was used to lyse 
U937 cell pellets and HMDM cell in the culture plates. The cell lysate was then transferred 
into a 1.7 mL eppendorf tube and incubated on ice for 30 minutes to lyse the cells fully. The 
cell lysate was then vortexed briefly and was stored at -80°C until use. Protein assay was 




Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) protein 
electrophoresis 
A required amount of cell lysate (based on the protein concentration) was aliqouted into 1.7 
mL micro tubes. Ice cold acetone was added to each tube (the volume of acetone was 10x of 
cell lysate) and centrifuged at 15,000 g for 10 minutes at 0
o
C to precipitate the proteins. The 
supernatant was discarded and the protein pellets in the tubes were left in the fume cabinet to 
dry off the remaining acetone. The pellets were dissolved in the cracker buffer with 2% β-
mercaptoethanol to the final protein concentration of 0.5 – 2 µg protein per µL. The samples 
were then heated in a heating block at 95ºC for 3 minutes to denature the protein followed by 
centrifugation for 5 minutes at 20,800 g at room temperature to remove cell debris. 
Gel electrophoresis was performed on the samples using a gradient polyacrylamide gel, 4-12% 
(Bis-Tris Gel, Invitrogen, Carslband, CA, USA) which was run in the XCell SureLock™ 
Mini-Cell system (Invitrogen, US) containing 1x MOPS running buffer. Five microliters of 
pre-stained molecular weight marker mix (BioRad, USA) and 5-25 µL of samples (depending 
on required protein content) were loaded into the wells of the gel. The gel was run at 200 V 
until the dye front reached the bottom of the gel. 
Western blot – membrane transfer and immunoblotting 
The proteins on the SDS-PAGE gel were transferred onto a nitrocellulose membrane (NC) 
(0.45 µm pore size, Invitrogen, USA) using a tank transfer electrophoresis unit (HoeferTM 
TE22, USA) filled with cold transfer buffer. The transfer duration was 10 hours with voltage 
set at 70 V using the PowerPac 300 (BioRad, USA) power supply. After completion of the 
transfer, the NC was rinsed with nano pure water and stained with Ponceau S stain for 1 
minute to check the result of the transfer. 
The washing and incubation of the NC membrane were performed on a rocking platform 
mixer (Ratex Instruments, Australia). After brief rinsing with nano pure water, the membrane 
was blocked using 5% TBSM for 1.5 hours (changed at each 30 minutes during incubation). 
This was followed by three times of 5-minute wash in TBS. The membrane was then probed 
with the primary mouse monoclonal IgG1 antibodies against p47
phox
 (Santa Cruz 
Biotechnology Inc, USA) in 1:250 dilution using 2% TBSM for 1.5 hours. The NC 
membrane was then washed for 5 times with TBS (5 minutes each). An incubation of the NC 
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membrane with the secondary antibody goat anti-mouse IgG-HRP (Santa Cruz 
Biotechnology Inc, USA) diluted to 1:750 with 2% TBSM was then performed. The 
membrane was then washed as mentioned above and was followed by quick rinsing in nano 
pure water twice to remove any residual TBS. Tween-20 in TBS inhibits peroxidase from 
reacting with the chemiluminescence substrates and this may interfere with the detection (see 
Detection).   
Detection  
The secondary HRP-coupled antibody chemiluminescene signal on the NC membrane was 
detected using Supersignal West Dura Chemiluminescence (TerumoScientific, USA) kit 
which consists of the luminal/enhancer solution and the substrate peroxide solution. The 
working solution was made up of the two solutions at 1:1 ratio immediately before being 
applied onto the NC membrane. The luminal/enhancer reacts with the horseradish peroxidase 
(HRP) of the secondary antibody on the NC membrane and hydrogen peroxide in the solution 
to generate 3- aminophthalate plus the emission of light at 425 nm.  
The working solution was applied evenly onto the NC membrane and incubated in the dark 
for 10 minutes. The images on the NC were obtained on high resolution, without filter and in 
the absence of light using time-lapse auto-exposure setting on Syngene Chemigenius-2 
bioimaging system (Syngene, USA). The images were analysed for band intensity using 
GeneSnap software (Syngene, USA). The NC membrane was then stored in TBS at 4ºC for 
β-actin detection (see β-actin detection). 
β-actin detection 
The NC membrane was re-probed for β-actin as control for checking equal loading of 
proteins. The membrane was incubated for 1.5 hours with the primary mouse monoclonal 
antibodies against β-actin (Sigma-Aldrich Chemical Co., USA) diluted to 1:10,000 in 1% 
TBSM. The procedures and detection were the same as those mentioned in the two sections 
above. The only two exceptions in the procedure were that the secondary antibody goat anti-
mouse IgG-HRP (Santa Cruz Biotechnology Inc, USA) was diluted to 1:1,000 in 2 % TBSM 
and the exposure time for chemiluminescence signal detection was 2 minutes. 
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Flow cytometry analysis  
Flow cytometry is powerful method that is used for huge number of quantitative biomedical 
applications and it provides rapid, reliable and accurate quantitative analysis of cells of 
interest. Flow cytometry also gives high-throughput automated quantification of fluorescence 
compared to fluorescent microscopy. It allows the analysis of various properties of single 
cells suspended in a fluid and can be used for the analysis of cell cycle, viability, apoptosis, 
calcium influx, membrane potential or amounts of surface receptors or intracellular proteins 
and many more. 
Principles of flow cytometry  
 
Figure ‎2.6: A cross section showing the flow chamber. 
 
The principle called hydrodynamic focusing is used in flow cytometry. In the flow chamber 
(Figure 2.6), sample containing single cells suspension emerges from the sample needle into 
a surrounding sheath fluid which is moving at a greater speed. Consequently, acceleration 
resulting at the orifice forces the cells to travel separately in the central part of the fluid jet 
that emerges from the flow chamber. The cells are illuminated by a focused laser beam when 
they flow past the detector point and the illuminating light gets scattered. The relative size 
and granularity of a cell influenced the way in which light is scattered.  Low angle scattered 
light depends on cell size and is detected as forward scatter (FSC). On the other hand, cell 
granularity and surface convolutions scatter light at higher angles and the signal is measured 
orthogonal to the stream as side scatter (SSC). At the same time, fluorescence emission will 
also occur if the cells have been previously probed with a fluorescent dye capable of 
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absorbing the illuminating light. Both the scattered light and emitted fluorescence are 
collected and sent to different detectors using optical filters. Fluorescence (FL) measurements 
are also made in the orthogonal direction with detectors appropriate to the specific emission 
spectrum of the fluorescent probes used. 
All of the research work involving intracellular processes in this study was carried out using 
Accuri C6 flow cytometer
® 
(BD Biosciences, USA) (Figure 2.7). Cytosolic calcium ion 
(Ca
2+
) level, intracellular superoxide (ROS) production, mitochondrial membrane potential 
and cell viability in U937 cells, human monocytes and HMDMs were studied by probing the 
cells with the appropriate fluorescent dyes followed by flow cytometry analysis. Depending 
on the purpose of the experiments, different sets of settings including flow rate, core size and 
number of events were applied. The laser settings used were 488 nm excitation wavelength 
plus a range of emission fluorescence detectors/filters including FL1 for Fluo-3AM, FL2 for 
DHE and TMRM and FL3 for PI (shown in Figure 2.8). Data were recorded and analysed 
using the cFlow Plus software (BD Biosciences).  
 








 flow cytometer is calibrated weekly using 8 peak beads and 6 peak beads 
solutions before running samples for analysis. Examples of the calibration histograms are 
shown in Figure 2.9. 
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A) 8 peak beads 
   
  
 
B) 6 peak beads 
   
  
 
Figure ‎2.9: Calibration histrograms of Accuri C6® flow cytometer 
Example of histograms showing the A) 8 peak beads and B) 6 peak beads calibration of SSC/FSC and 
each filter channels. 
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Fluo-3-acetoxymethyl ester (Fluo-3 AM)  
 
Figure ‎2.10: Chemical structure of Fluo-3 AM. 
Fluo-3-acetoxymethyl (AM) ester (Figure 2.10) is a fluorochrome used to measure 
intracellular (cytosolic) free calcium. This AM form can easily penetrate the plasma 
membrane and is entrapped within the cells after cleavage of the ester group by intracellular 
(cytoplasmic) esterase enzymes to form Fluo-3 and AM. Upon excitation at 488 nm, Fluo-3 
emits a green fluorescence at 530 nm wavelength when bound to free calcium ions in the 
cytosol (Minta et al., 1989).  
Fluo-3AM (1 mM in DMSO; MW = 1129.9 g/mol) (Life Technologies, NZ) was purchased 
as ready to be used and stored at -20ºC. Final concentration of the dye used was 1.5 uM. Cells 
were incubated with Fluo-3AM for 30 to 40 minutes in the dark before treatment with various 
calcium channel blockers and oxLDL. Levels of intracellular free calcium were measured 
from 10,000 live cells gated area via flow cytometer (FL1 filter). 
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Propidium iodide (PI) 
 
Figure ‎2.11: Chemical structure of PI 
Propidium iodide (PI) (Figure 2.11) is a highly fluorescent red dye which is generally 
impermeable to viable cells. It binds to double stranded DNA of the cells by intercalating 
between base pairs. The cell membrane integrity excludes PI in viable and apoptotic cells 
whereas necrotic cells are permeable to PI (Moller et al., 2005) resulting in non-viable cells 
having bright red fluorescent while viable cells are non-fluorescent (Ross et al., 1989). PI is 
excited at 488 nm and emits at a maximum wavelength of 617 nm. PI can be used in 
combination with other dyes such as fluorescein isothiocyanate (FITC) and phycoerythrin 
(PE) that are also exited at 488 nm due to its spectral properties.  
Stock solution of 1 mg/mL PI was prepared by dissolving 10 mg PI in 10 mL nano pure water 
and stored at 4
o
C, final concentration used was 1.5 µg/mL. U937 cells and human monocytes 
were incubated with PI (in RPMI-1640 or PBS) for 10 to 15 minutes in the dark before 
measurement using flow cytometer. As for HMDM cells, PI was added directly to 
Accutase™ and incubated for 15 minutes to allow detachment of the adherent cells before 
subjected to flow cytometry analysis (FL3 filter).  
A same volume of cell samples (10 to 15 µL) were run through the flow cytometer. On the 
FSC vs FL3 (PI) plot, a rectangle was drawn from 0 to approximately 1,000,000 on the FSC 
scale and from 0 to approximately 10
6
 on the FL3 scale (Figure 2.12 A). This is the area 
where cellular debris usually located and will be excluded from the analysis. Next, on the 
Count vs FL3 (PI) plot, two horizontal bars (sections) were drawn i.e. one from 
approximately 10
6
 to the far left of the plot (percentage of PI negative cells) and one from 
approximately 10
6
 to the far right of the plot (percentage of PI positive cells) (Figure 2.12 B). 
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The total number of cells from each bar (section) will be automatically calculated and 
displayed by the Accuri C6
®
 flow cytometer. Result is reported as a percentage of total 
number of cells in the control samples excluding the debris (assuming that same volume of 
samples should contain similar number of cells). PI positive cells are cells that stained with PI 






Figure ‎2.12: Flow cytometry measurement and analysis of cell viability 
Example of dot plot/histogram of U937 cells. A) shows FSC vs FL3: a rectangle drawn to exclude 
cellular debris; B) shows Count vs FL3: M3 is the percentage of PI positive cells and M4 is the 
percentage of PI negative cells (M3 + M4 = 100%). 
Dihydroethidium (DHE) 
 




Dihydroethidium (DHE) (Figure 2.13) is a fluorescent probe widely used for detecting 
intracellular superoxide anions (Zhao et al., 2005). This  dye reacts with superoxide resulting 
in the formation of a two-electron oxidised product, ethidium (E
+
), which binds to DNA and 
leads to enhancement of red fluorescence (Zhao et al., 2003). 
Stock solution of 1 mM DHE (MW = 315.4 g/mol) was prepared in DMSO and stored at -
20
o
C. Final concentration of DHE used was 10 µM in cell preparation. After an experimental 
treatment and PBS washing, U937 cells and human monocytes were incubated with 200 µL 
of 10 µM DHE in sterile PBS for 20 minutes in the dark before measurement using flow 
cytometer. For HMDM cells, DHE was added directly to Accutase™ and incubated for 20 
minutes to allow detachment of the adherent cells before subjected to flow cytometry 
analysis. Intracellular superoxide was measured by flow cytometer using FL2 filter from 
10,000 viable cells gated area. 
Tetramethylrhodamine methyl ester (TMRM)  
 
Figure ‎2.14: Chemical structure of TMRM 
Tetramethylrhodamine methyl ester (TMRM) (Figure 2.14) is a fluorescent probe used to 
monitor mitochondrial membrane potential. It is a lipophilic cation, which accumulates in 
mitochondria proportionate to the mitochondrial membrane potential. The cationic nature of 
TMRM will cause intense fluorescence at more negative membrane potentials and losing its 
fluorescence as the membrane potential becomes more positive (Scaduto & Grotyohann, 
1999).  
TMRM (MW 500.9) stock was prepared in methanol and stored at -20ºC. Final concentration 
of TMRM used was 10 nM. After experimental treatments and PBS washing, U937 cells and 
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human monocytes were incubated with 150 µL of 10 nM TMRM in sterile PBS for 20 
minutes in the dark before measurement using flow cytometer. For HMDM cells, TMRM 
was added directly to Accutase™ and incubated for 20 minutes to allow detachment of the 
adherent cells before subjected to flow cytometry analysis (FL2 filter).  
MitoSOX Red (MitoSOX) - mitochondrial superoxide probe 
 
Figure ‎2.15: Chemical structure of MitoSOX 
MitoSOX Red (MitoSOX) (Figure 2.15) is a novel fluorochrome for highly selective 
detection of superoxide in the mitochondria of live cells (Robinson et al., 2006). The probing 
principle of this cell permeable probe is very similar to that of DHE but it is more selectively 
targeted to the mitochondria. It uses the steep electrochemical gradient across the 
mitochondrial inner membrane to enrich the triphenylphosphonium cation (TPP+)-tag 
fluorescence over a 100-fold within the mitochondria compared with the cytosol (Smith et 
al., 2011). Once in the mitochondria, MitoSOX is readily oxidized by superoxide but not 
other ROS and exhibits red fluorescence (excitation/emission = 510/580 nm) (Janes et al., 
2004). The oxidation product becomes highly fluorescent upon binding to nucleic acid.  
MitoSOX (MW = 759 g/mol) of 5 mM stock solution was prepared by dissolving one vial 
(50 μg) of MitoSOX in 13 μL DMSO immediately before use. 
After an experimental treatment and PBS washing, HMDM cells were incubated with 130 µL 
of Accutase™ plus 5 μM MitoSOX for 15 minutes at 37 °C in the dark. After detachment of 
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the cells, flow cytometry analysis was carried out to measure the level of mitochondrial 
superoxide from 10,000 live cells gated area (FL2 filter). 
Special methods 
Preparation of hydrogen sulfide (H2S) donors for experiments 
Hydrogen sulfide (H2S) donors in powder form were prepared fresh before experiments were 
carried out. Stock solutions were prepared by reconstituting H2S donors in PBS except for 
AP39 which was reconstituted in DMSO. H2S stock solutions were further diluted to the final 
concentrations when added to the cells (Table ‎2.1). 
Table ‎2.1: Preparation of H2S donors solutions. 








GYY4137 376.4 White powder 2 mM (in PBS) 200 µM 
AP39 721.7 Orange-brownish 
powder 
100 µM (in 
DMSO) 
100 nM 
AP67 273.3 Whitish powder 2 mM (in PBS) 200 µM 
AP72 287.3 Whitish powder 2 mM (in PBS) 200 µM 
AP105 372.5 Yellowish powder 2 mM (in PBS) 200 µM 
AP106 402.5 Yellowish powder 2 mM (in PBS) 200 µM 
Statistical analysis 
Statistical analysis was performed on all graphed data using GraphPad Prism version 6.0 for 
Windows (GraphPad Software, San Diego, California, USA). Significance was confirmed via 
analysis of variance (ANOVA) followed by multiple comparison post tests (Dunnet, Sidak, 
Bonferroni or Tukey) where appropriate for the quantitative indication of significance 
between treatments and/or time points. Significant levels are indicated in the following 
manner: (*) p ≤ 0.05, (**) p ≤ 0.01 and (***) p ≤ 0.001.  
The results revealed in this thesis were obtained from triplicates of one experiment which is 
representative of at least three separate experiments unless stated otherwise. The mean and 
standard errors of the mean (SEM) shown within each experiment were calculated from 




3.  OxLDL cytotoxicity and flow 
cytometry analysis of cell viability 
 
Introduction 
This chapter aims to examine the toxic effects of oxLDL on U937 cells, human monocytes 
and HMDM cells which includes cell viability analysis and cell morphology determination. 
LC50 for each batch of oxLDL preparations will be determined for further experiments. 
Comparison of MTT and PI-flow cytometry assays for cell viability determination will also 
be done to establish a major technique to be used in subsequent studies. 
OxLDL is associated with the initiation and development of atherosclerosis (Ross, 1999; 
Smook et al., 2008).  One of the characteristics that might mediate this process is its 
cytotoxic effect. Studies have shown that oxLDL is toxic and caused death in variety of cells 
including macrophages (Hardwick et al., 1996), endothelial cells (Porn-Ares et al., 2003; 
Quinn et al., 1985), smooth muscle cells (Guyton et al., 1995; Hessler et al., 1979; Nishio et 
al., 1996) and lymphocytes (Meilhac et al., 1999). This laboratory has previously shown 
oxLDL cytotoxicity on U937 and THP-1 cell lines (Baird et al., 2004; Chen, 2012) and 
HMDM cells (Gieseg et al., 2010; Katouah, 2012; Shchepetkina, 2013). In vitro, oxLDL has 
also been shown to cause both apoptotic and necrotic cell death (Asmis & Wintergest, 1998; 
Gieseg et al., 2010; Hardwick et al., 1996) depending on the dose and duration of exposure to 
oxLDL (Han & Pak, 1999). 
The research describe in this thesis is focused on the mechanisms of oxLDL-mediated cell 
death in U937 cells, human monocytes and HMDM cells. Therefore, cytotoxicity of oxLDL 
to these cells needed to be characterised before further studies on the mechanism of oxLDL-
mediated cell death were carried out in chapter 4, 5 and 6. This analysis also allowed 
previous findings by this laboratory on the effects of oxLDL toxicity on cell viability to be 
verified. In this study, cells were exposed to the acute toxicity of oxLDL by treating with 
oxLDL for 24 hours whereby previous studies in this laboratory normally measured cell 
viability after a standard 24 hours incubation with oxLDL (Amit, 2008; Baird, 2003). 
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Experiments were carried out with different concentrations of oxLDL for 24 hours that 
enabled the determination of LC50 concentration of a particular batch of oxLDL. This LC50 
concentration will then be used as a guide for subsequent experiments using a same oxLDL 
batch. LC50 is the concentration of oxLDL that caused 50% cell death within 24 hours (Zhang 
et al., 2006).  Additionally, time-course studies were also performed to investigate the 
kinetics of oxLDL toxicity in all three types of cells by incubating with LC50 concentration of 
oxLDL for up to 24 hours. 
Cell viability assays: MTT versus PI 
In this chapter, cell viability measurements using MTT reduction and PI-flow cytometry 
assays were compared. MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolinum 
bromide) reduction assay is a widely used method in analysing cell activities such as cell 
viability and proliferation rates in cell cultures (Denizot & Lang, 1986; Mosmann, 1983). It is 
one of the metabolic assays that based on the reduction of MTT to water-insoluble purple 
formazan complex inside the viable cells through mitochondrial dehydrogenases as well as 
non mitochondrial, cytosolic and microsomal enzymes (Gonzalez & Tarloff, 2001; Liu et al., 
1997). Nevertheless, intracellular MTT reduction rate is assumed to be closely related to the 
number of actively metabolising cells in the cell culture (Gonzalez & Tarloff, 2001; 
Mosmann, 1983).  
In contrast, propidium iodide (PI) assay is based on the ability of this highly fluorescent dye 
to penetrate cells that lack membrane integrity. Early apoptotic cells exclude PI but not 
necrotic and late apoptotic cells. Integrating PI and flow cytometry analysis therefore, enables 
the detection of viable cells from dead cells whereby the latter emitted bright red fluorescence 
compared to the former which do not fluoresced (Ross et al., 1989). The most prominent 
working principle of flow cytometry assay is that is allows direct counting of cells without 





OxLDL-induced cytotoxicity in U937 cells, human monocytes and HMDM 
cells: effects of different oxLDL concentrations 
The acute toxicity of oxLDL to U937 cells, human monocytes and HMDM cells was 
investigated by exposing cells to the increasing concentrations of oxLDL for 24 hours. Cell 
viability was measured using PI via flow cytometry assay (data analysis using PI stain and 
flow cytometry is detailed in Chapter Two). A concentration-dependent decrease in the cell 
viability (PI negative cells) with the increasing amount of oxLDL was observed for all types 
of cells (Figure 3.1 B, 3.2 B and 3.3 B). Morphological changes of the cells occurred after 
oxLDL treatment were also examined under the inverted light microscope (Figure 3.1 A, 3.2 
A and 3.3 A). Flow cytometry histograms also illustrate the loss of viable cells with 
increasing oxLDL concentrations whereby more cells being stained with PI (PI positive cells) 
which shifted to right of the histograms (increased in fluorescence) and a decrease in viable 
cells (PI negative cells) (Figure 3.1 C, 3.2 C and 3.3 C).  
Final oxLDL concentrations of 0.10, 0.25, 0.50 and 0.75 mg/mL reduced U937 cell viability 
(PI negative cells) by 10%, 30%, 50% and 75% respectively (compared to control) (Figure 
3.1 B). Approximately 15% and less viable cells were seen with the treatment of 1.00, 1.25 
and 1.50 mg/mL oxLDL. Therefore, LC50 concentration obtained was between 0.25 to 0.50 
mg/mL oxLDL. On the other hand, percentage of cell death was also increased with 
increasing concentrations of oxLDL (PI positive cells). However, the sum of PI negative cells 
and PI positive cells was always lower than 100% due to a number of cells which had 
completely lysed and became debris, thus not counted either as PI negative or PI positive 
cells (Figure 3.1 B). Morphologically, control cells (no oxLDL added) were round in shape, 
which is the classic feature of U937 cells. Cells treated with 0.10 and 0.25 mg/mL oxLDL 
showed swelling appearance whilst cells treated with 0.50 mg/mL oxLDL had more distorted 
cell membranes and cell debris. OxLDL at 0.75 mg/mL and above had caused significant cell 
damages with disruption of cell membranes and loss of cellular contents (Figure 3.1 A). 
These are characteristics of necrotic cell death. This finding is in-line with Chen (2012) who 
obtained the LC50 concentrations of oxLDL between 0.2 to 0.5 mg/mL with U937 cells 
throughout her studies. 
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Histograms of PI-flow cytometry for U937 cells showed that with increasing concentrations 
of oxLDL, the number of cells shifted to the right of the histograms also increased (M3 - PI 
positive cells) while there were lesser cells with low PI stained (M4 – PI negative) . This 
indicates that more cells were taking up PI stain (PI positive) which reflects higher 
percentage of cell death with higher concentrations of oxLDL (Figure 3.1 C). 
A) 
 
    
Control 0.10 mg/mL oxLDL 0.25 mg/mL oxLDL 0.50 mg/mL oxLDL 
    
0.75 mg/mL oxLDL 1.00 mg/mL oxLDL 1.25 mg/mL oxLDL 1.50 mg/mL oxLDL 
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Figure ‎3.1: Effect of oxLDL on U937 cell viability. 
U937 cells (0.5×10
6
 cells/mL) were incubated at 37
o
C in non-phenol red RPMI-1640 with increasing 
concentrations of oxLDL for 24 hours. A) Cells were viewed in situ in tissue culture wells using an 
inverted microscope (400x magnification) after 24 hours incubation with oxLDL. Images were taken 
using a Leica C-Mount camera and processed using Leica Application Suite software. B) Cell 
viability was determined using PI-flow cytometry assay. Data are expressed as percentage of the total 
cells in cell only control samples. Results shown are mean ± SEM of triplicates from a representative 
experiment. Statistical significance (two-way ANOVA, Sidak’s multiple test) is indicated from: PI 
negative cell only control vs PI negative oxLDL treatments, ***, p<0.001; PI positive cell only 
control vs PI negative oxLDL treatments, ^^^,p<0.001. C) Flow cytometry histograms of U937 cells 
treated with different concentrations of oxLDL (counts vs PI), M3 indicates PI positive stained cells 
and M4 indicates PI negative stained cells. 
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Human monocytes are relatively smaller compared to U937 cells with average cell size 
ranging from 7 to 10 µm. Average cell viability reduction of 10 and 30% compared to control 
(PI negative) has been observed with final oxLDL concentrations of 0.25 and 0.50 mg/mL, 
respectively.  Approximately 50%, 35% and 25% of cells were still viable (PI negative) after 
24 hours treatment with 0.75, 1.00 and 1.50 mg/mL oxLDL, respectively. Thus, for human 
monocytes, LC50 concentration of oxLDL was determined between 0.75 to 1.00 mg/mL. 
Likewise, concentration-dependent cell death (PI positive) occurred with increasing 
concentrations of oxLDL (Figure 3.2 B). Moreover, some of the cells might have undergone 
cell lysis and became debris. 
Morphologically, control cells (no oxLDL added) were small, round in shape and appeared 
bright yellow under light microscope. Cells treated with 0.25 mg/mL oxLDL showed 
swelling appearance whilst cells treated with 0.50 mg/mL oxLDL had more distorted cell 
membranes and cell debris. OxLDL at 0.75 mg/mL and above had caused cell damages with 
disruption of cell membranes and loss of cellular contents (Figure 3.2 A). The morphological 
changes in human monocytes caused by oxLDL also suggest the necrotic type of cell death. 
Additionally, flow cytometry histograms (Figure 3.2 C) showed a small population of cells 
have shifted to the right of the histogram with 0.25 mg/mL oxLDL treatment (PI positive) 
while more obvious shifting of the cells to the right (taking up more PI stain) when treated 
with 0.5 mg/mL oxLDL, indicating more dead cells in the population. Live cells (M8 - PI 
negative) were greatly reduced while dead cells (M7 - PI positive) were significantly 
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Figure ‎3.2: Effect of oxLDL on human monocytes cell viability. 
Human monocytes (1×10
6
 cells/mL) were incubated at 37
o
C in non-phenol red RPMI-1640 with 
increasing concentration of oxLDL for 24 hours. A) Cells were viewed in situ in tissue culture wells 
using an inverted microscope (400x magnification) after 24 hours incubation with oxLDL. Images 
were taken using a Leica C-Mount camera and processed using Leica Application Suite software. B) 
Cell viability was determined using PI-flow cytometry assay. Data are expressed as percentage of the 
total cells in cell only control samples. Results shown are mean ± SEM of triplicates from a 
representative experiment. Statistical significance (two-way ANOVA, Sidak’s multiple test) is 
indicated from: PI negative cell only control vs PI negative oxLDL treatments, **, p<0.01, ***, 
p<0.001; PI positive cell only control vs PI negative oxLDL treatments, ^^, p< 0.01, ^^^, p<0.001. C) 
Flow cytometry histograms of U937 cells treated with different concentrations of oxLDL (counts vs 




HMDM cells were cultured and differentiated from human monocytes using GM-CSF. 
HMDM cells are relatively large compared to human monocytes with an average cell 
diameter of 20 µm. At oxLDL concentration of 0.75 mg/mL, cell viability (PI negative) was 
reduced by 15% (compared to control). Treatment with 1.00, 1.50 and 2.00 mg/mL oxLDL 
had resulted in decreased viable cells (PI negative) by approximately 40, 50 and 70% 
respectively compared to control cells. Thus, LC50 concentration achieved was between 1.0 to 
1.5 mg/mL oxLDL (Figure 3.3 B). This finding agreed with Amit (2008) whereby 1.0 
mg/mL oxLDL was able to cause approximately 50% of cell viability loss (determined using 
MTT reduction assay) but a lower oxLDL concentration was reported by Gieseg et al. (2010). 
Increased in cell death (PI positive cells) was also been observed with increasing oxLDL 
concentrations. 
Control cells (with no oxLDL added) resembled poached egg-like appearance which is the 
classic morphology of HMDM cells. Cells treated with oxLDL appeared swollen, enlarged 
and distorted compared to control cells especially with higher oxLDL concentrations. Loss of 
cellular contents resulted in the presence of cell debris while a number of cells were also seen 
detached and were floating in the culture media (Figure 3.3 A). These characteristics of cell 
death were similar to those observed with U937 cells and human monocytes, thus suggesting 
that oxLDL had caused necrotic cell death for all three types of cells. 
Flow cytometry histograms (Figure 3.3 C) indicated shifting of HMDM cell population to 
the right when treated with increasing oxLDL concentrations. This clearly showed that 
oxLDL is toxic to HMDM cells, thus causing a decrease in viable cells (M6 - PI negative 
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Figure ‎3.3: Effect of oxLDL on HMDM cell viability. 
HMDM cells (1x10
6
 cells/mL) were incubated at 37
o
C in non-phenol red RPMI-1640 with increasing 
concentration of oxLDL for 24 hours. A) Cells were viewed in situ in tissue culture wells using an 
inverted microscope (400x magnification) after 24 hours incubation with oxLDL. Images were taken 
using a Leica C-Mount camera and processed using Leica Application Suite software. B) Cell 
viability was determined using PI-flow cytometry assay. Data are expressed as percentage of the total 
cells in cell only control samples. Results shown are mean ± SEM of triplicates from a representative 
experiment. Statistical significance (two-way ANOVA, Sidak’s multiple test) is indicated from: PI 
negative cell only control vs PI negative oxLDL treatments, ***, p<0.001; PI positive cell only 
control vs PI negative oxLDL treatments, ^^, p< 0.01, ^^^, p<0.001. C) Flow cytometry histograms of 
U937 cells treated with different concentrations of oxLDL (counts vs PI), M5 indicates PI positive 




OxLDL-induced cytotoxicity in U937 cells, human monocytes and HMDM 
cells: examination over time 
A time course study was performed to observe the progression of oxLDL-mediated cell death 
in all three types of cells by incubating with LC50 concentration of oxLDL for up to 24 hours 
(incubated with oxLDL for 0, 3, 6, 9, 12 and 24 hours). Figures 3.4 A, 3.5 A and 3.6 A 
illustrated the morphological changes in U937, human monocytes and HMDM cells observed 
under the inverted microscope during their incubation with oxLDL respectively. At the end of 
the respective incubation time, samples were collected and cell viability (PI negative/PI 
positive) was determined using PI-flow cytometry assay (Figure 3.4 B, 3.5 B and 3.6 B).  
For U937 cells, there were no clear changes in cell appearance after 3 hours incubation with 
oxLDL. After 6 hours of incubation with oxLDL, cells had swelling appearance with 
distorted cell membranes and bleb formation. Obvious changes of cell morphology were seen 
at 9 and 12 hours incubation whereby large number of cells had undergone severe cell 
damage with cell membrane disruption and loss of cellular contents. After 24 hours, majority 
of cells appeared lysed and cellular debris was release into the culture media (Figure 3.4 A). 
Likewise, morphological changes manifested by these cells resembled the characteristics of 
necrotic cell death.  
Viable cells (PI negative cells) were about 10%, 15% and 20% less compared to control after 
incubation of 3, 6, and 9 hours with oxLDL, respectively. Further drop to 60% of viable cells 
(PI negative) was observed after 12 hours incubation with oxLDL and this was significantly 
reduced to about 30% at the end of 24 hours incubation (Figure 3.4 B). Similarly, the 
decreased in viable cells (PI negative) resulted in the increased of dead cells (PI positive) but 
cells have also lysed, became debris (especially at longer incubation time) and not measured 
as PI positive cells. This is the reason accounting for only 25% of cells were measured as PI 
positive (dead cells) after 24 hours incubation with oxLDL. 
Flow cytometry histograms showed the cell dynamics over the incubation period with oxLDL 
(Figure 3.4 C). Number of viable cells (M1 – PI negative) has reduced while the dead cells 
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Figure ‎3.4: Time course effects of oxLDL-induced cell viability loss in U937 cells 
U937 cells (0.5×10
6
 cells/mL) were incubated at 37
o
C in non-phenol red RPMI-1640 with the LC50 
concentration of oxLDL for the indicated time. A) Cells were viewed in situ in tissue culture wells 
using an inverted microscope (400x magnification) after 0, 3, 6, 9, 12 and 24 hours incubation with 
oxLDL. Images were taken using a Leica C-Mount camera and processed using Leica Application 
Suite software. B) Cell viability was determined using PI-flow cytometry assay. Data are expressed as 
percentage of the total cells in 0 hour control samples. Results shown are mean ± SEM of triplicates 
from a representative experiment. Statistical significance (two-way ANOVA, Sidak’s multiple test) is 
indicated from: PI negative 0 hour control vs PI negative oxLDL treatments, ***, p<0.001; PI positive 
0 hour control vs PI negative oxLDL treatments, ^^, p< 0.01, ^^^, p<0.001. C) Flow cytometry 
histograms of U937 cells treated with different concentrations of oxLDL (counts vs PI), M2 indicates 




With human monocytes, there were no obvious morphological changes after 3 hours 
incubation with oxLDL. Cells started to swell and became distorted after 6 hours incubation 
with more noticeable damage happened after 9 and 12 hours. After 24 hours, there were 
massive dead cells with cellular debris present (Figure 3.5 A). Proved by the morphological 
characteristics, necrotic cell death also occurred in human monocytes caused by acute oxLDL 
toxicity. 
Cell viability loss (decreased in PI negative cells) was approximately 10, 20 and 25% after 3, 
6, and 9 hours of incubation with oxLDL, compared to 0 hour control. After 12 and 24 hours 
incubation with oxLDL, viable cells (PI negative) were about 60 and 45% compared to 0 
hour control cells. In addition, cell death has also increased over the incubation period with 
oxLDL whereby 25% of the cells were dead (PI positive) after 24 hours (Figure 3.5 B).  
Flow cytometry histograms showed the shifting of the cells to the right with longer 
incubation time with oxLDL. Number of viable cells (M4 - PI negative) has reduced 
significantly while the number of dead cells (M3 – PI positive) has gained (Figure 3.5 C). 
At 24 hours, the rise in PI positive cells was not significant compared to the 12 hour time 
measurement. But the number of PI negative cells had significantly reduced suggesting 
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 cells/mL) were incubated at 37
o
C in non-phenol red RPMI-1640 with the 
LC50 concentration of oxLDL for the indicated time. A) Cells were viewed in situ in tissue culture 
wells using an inverted microscope (400x magnification) after 0, 3, 6, 9, 12 and 24 hours incubation 
with oxLDL. Images were taken using a Leica C-Mount camera and processed using Leica 
Application Suite software. B) Cell viability was determined using PI-flow cytometry assay. Data are 
expressed as percentage of the total cells in 0 hour control samples. Results shown are mean ± SEM 
of triplicates from a representative experiment. Statistical significance (two-way ANOVA, Sidak’s 
multiple test) is indicated from: PI negative 0 hour control vs PI negative oxLDL treatments, ***, 
p<0.001; PI positive 0 hour control vs PI negative oxLDL treatments, ^^, p< 0.01, ^^^, p<0.001. C) 
Flow cytometry histograms of U937 cells treated with different concentrations of oxLDL (counts vs 




HMDM cells incubated with LC50 concentration of oxLDL did not show significant 
morphological changes in the first 3 hours of incubation. After 6 hours, the cells appeared to 
be enlarged and swollen compared to the 0 hour control cells. Cell membranes became 
distorted and disrupted with the presence of cellular debris after 9, 12 and 24 hours 
incubation with oxLDL. A number of cells were also detached from the bottom of the culture 
plate and were floating in the culture media (Figure 3.6 A). These morphological changes 
showed that oxLDL-induced HMDM cell death also resulted in necrotic type of cell death as 
been observed in U937 cells and human monocytes.  
Figure 3.6 B showed that after 12 hours incubation with oxLDL, viable cells (PI negative) 
left were approximately 60%. A further reduction of 20% of viable cells occurred within 12 
to 24 hours of incubation and this finding agreed with the previous work of Katouah (2012) 
and Shchepetkina (2013). Nevertheless, percentage of dead cells (PI positive) at 12 hours and 
24 hours treatment with oxLDL remained approximately the same, suggesting that most of 
the cells have also lysed and became debris, thus was not counted as PI positive stained cells. 
Flow cytometry histograms illustrated the shifting of cells from viable cells (M1 – PI 
negative) to become dead cells (M2 – PI positive) over the designated incubation time with 
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Figure ‎3.6: Time course effects of oxLDL-induced cell viability loss in HMDM cells. 
HMDM cells (1×10
6
 cells/mL) were incubated at 37
o
C in non-phenol red RPMI-1640 with the LC50 
concentration of oxLDL for the indicated time. A) Cells were viewed in situ in tissue culture wells 
using an inverted microscope (400x magnification) after 0, 3, 6, 9, 12 and 24 hours incubation with 
oxLDL. Images were taken using a Leica C-Mount camera and processed using Leica Application 
Suite software. B) Cell viability was determined using PI-flow cytometry assay. Data are expressed as 
percentage of the total cells in 0 hour control samples. Results shown are mean ± SEM of triplicates 
from a representative experiment. Statistical significance (two-way ANOVA, Sidak’s multiple test) is 
indicated from: PI negative 0 hour control vs PI negative oxLDL treatments, ***, p<0.001; PI positive 
0 hour control vs PI negative oxLDL treatments, ^^^, p<0.001. C) Flow cytometry histograms of 
U937 cells treated with different concentrations of oxLDL (counts vs PI), M2 indicates PI positive 




Comparison of cell viability measurements: MTT and PI-flow cytometry 
assays 
Cell viability assays can be classified into assays that measure metabolic activity, metabolic 
markers or loss of membrane integrity. Previous work for cell viability determination in our 
laboratory has been carried out using MTT reduction assay which measures intracellular 
metabolic activity. Cell viability assay using PI exploits the loss of membrane integrity in 
dead cells whereby DNA of the compromised cells will be stained by PI as opposed to the 
viable cells. Integrating PI with flow cytometry method creates a new dimension for the 
analysis of cell viability in this laboratory. Therefore, another focus of this chapter is to study 
and compare both types of assay in various aspects. 
Example of an experiment and the results obtained from MTT reduction assay and PI-flow 
cytometry assay are shown in Figure 3.7. The end result of MTT reaction with U937 cells 
after solubilisation of MTT formazan with 10% SDS in a cell culture plate is showed in 
Figure 3.7 A. Depending on the reaction between MTT reagent and the cells, this then 
resulted in different colour (intensities) being formed which is the basis of measuring cell 
viability using MTT reduction assay.  
Flow cytometry histograms (count vs PI) for U937 cells treated with different concentrations 
of oxLDL after 24 hours that has been stained with PI are showed in Figure 3.7 B. With 
increasing concentrations of oxLDL, more cells have shifted from viable cells region (M1 – 
PI negative) to the right of the histogram. This shifting showed that more cells are being 
stained with PI (M2 – PI positive) which depicts decreasing cell viability with increasing 
oxLDL concentrations. From the histograms, almost none of the cells were viable when 
treated with higher oxLDL concentrations of 0.8 and 1.2 mg/mL. Although both assays (MTT 
and PI) are not in the same of category for cell viability measurements, results obtained by 
each method were comparable (R
2
= 0.9721) (Figure 3.7 C and 3.7 D). This will be explained 
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Figure ‎3.7: Example of cell viability determination experiment using MTT reduction 
and PI-flow cytometry assays and results obtained for U937 cells. 
U937 cells (0.5×10
6
 cells/mL) were incubated with increasing concentrations of oxLDL at 37
o
C in 
non-phenol red RPMI-1640 for 24 hours. A) Cell viability was measured using MTT reduction assay 
and B) PI-flow cytometry assay (M1 – PI negative stained cells; M2 – PI positive stained cells). The 
results are analysed as percentage of the cell only control for MTT reduction assay and percentage of 
PI negative cells compared to total number of cells in cell only control for PI-flow cytometry assay 
Results are displayed as mean ± SEM of triplicates and data from both assays were compared for C) 
correlation between percentages of viable cells and D) effects of different oxLDL concentrations, 
significance is indicated between both methods at LDL concentration of 0.4 mg/mL, **, p<0.01 (two-
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Figure ‎3.8: LC50 of oxLDL of different batches to U937, human monocytes and HMDM 
cells. 
Dot plots presenting a range of LC50 determined for oxLDL from various oxLDL batches (LC50 of 
oxLDL vs percentage of PI negative cells compared to control) for A) U937 cells, B) Human 
monocytes and C) HMDM cells, respectively. Different toxicities with different percentages of PI 




Effects of oxLDL on cell viability and morphology 
Results in this chapter confirmed previous data that low mg/mL concentrations of oxLDL 
levels are toxic to U937 cells, human monocytes and HMDM cells. OxLDL toxicity was 
concentration- and time-dependent where higher cell viability loss was observed with 
increased oxLDL concentrations and this is in agreement with the previous findings from our 
laboratory (Baird, 2003; Rutherford & Gieseg, 2012). It is noticeable from this study that the 
toxicity of oxLDL to the cells appeared to be variable between different oxLDL batches 
(Figure 3.8). LC50 concentrations of between 0.25 and 0.50 mg/mL oxLDL was observed for 
U937 cells while LC50 for human monocytes and HMDM cells appeared to be higher i.e. 
between 0.75 and 1.00 mg/mL and between 1.00 to 1.50 mg/mL, respectively. This finding is 
in-line with the previous studies (Gieseg et al., 2009b; Katouah, 2012) in this laboratory even 
though the exact cause of cytotoxicity difference is still unknown (Gieseg et al., 2009b). The 
differences in oxLDL cytotoxicity between U937 cells, human monocytes and HMDM cells 
could be due to differences in cell type, cell size, mechanism of oxLDL uptake and cell 
metabolism. Therefore, the toxicity of each batch of oxLDL was tested to determine the LC50 
concentration before the particular oxLDL was used in subsequent experiments.  
Glutathione (GSH) is the main component of intracellular antioxidant defence mechanism 
whereby its loss is an excellent biomarker of oxidative damage (Valko et al., 2007). Various 
levels of GSH within the cells have been found to change the LC50 for HOCl toxicity towards 
HMDM cells. Previous studies from this lab have demonstrated that prior to cell death, rapid 
loss in intracellular GSH was one of the earliest cellular events in U937 and HMDM cells in 
response to oxLDL or HOCl insult (Baird et al., 2004; Chen, 2012; Rutherford & Gieseg, 
2012; Yang, 2009). GSH loss was faster than cell viability loss at each time point, with a 20% 
and 60% reduction after 3 and 6 hours, respectively (Amit, 2008). This might indicate that the 
gradual loss of GSH mediated by oxLDL preceded HMDM cell death and might also suggest 
that the depletion of GSH was required for oxLDL-mediated macrophage toxicity (Amit, 
2008; Gieseg et al., 2009b). These findings are in-line with various researchers who have 
showed that depletion in reduced GSH levels enhances oxLDL toxicity in human monocytes 
and macrophages (Darley-Usmar et al., 1991; Gotoh et al., 1993; Wang et al., 2006). 
Shchepetkina (2013) also showed that oxLDL caused a concentration-dependent GSH loss in 
HMDM cells. Additionally, the timing of initial ROS generation and the drop in GSH level 
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was parallel, suggesting a connection between them (Gieseg et al., 2010; Shchepetkina, 
2013). 
OxLDL-induced toxicity could either be of necrosis or apoptosis type of death depending on 
the types of cells (Baird et al., 2004; Gieseg et al., 2009b). Biochemical assays are normally 
used to determine cell viability e.g. MTT, PI and trypan blue. However, in order to support 
cell viability results, changes in cell morphology had also been captured using inverted light 
microscope parallel to the incubation period with oxLDL. Results from this study clearly 
showed that acute toxicity of oxLDL had caused the necrotic type of cell death in U937 cells, 
human monocytes and HMDM cells. Morphological appearance of these cells showed 
features of cell swelling, cell membrane disruption and loss of cellular contents which 
corresponded with necrotic cell death. 
Previous studies in our lab showed that oxLDL caused necrotic death in U937 and HMDM 
cells with a rapid loss of intracellular GSH without caspase-3 activation (Gieseg et al., 
2009b). In U937 cells, this resulted in the oxidation of essential free thiol groups in the active 
site with no phosphatidylserine (PS) exposure on the cell membrane (Baird et al., 2004). 
Nonetheless, it has been shown that oxLDL caused caspase-3 dependant apoptosis (Baird et 
al., 2004; Vicca et al., 2000) in THP-1 cells with a small reduction in cellular GSH level, cell 
shrinkage and PS exposure to the outer space of the cell membrane which stained Annexin V 
positive. This phenomenon could be the result of varying mechanism of oxLDL intake by the 
different types of cells whereby one of the possibilities could be due to the scavenger 
receptors presence on the cell surface. Scavenger receptors (SR) are highly implicated as the 
key players in the initiation and development of atherosclerosis (Goldstein et al., 1979). Of 
these SR, scavenger receptor A (SR-A) and CD36 are known to be involved in oxLDL-
induced cell death as well as foam cell formation (Gieseg et al., 2009b). CD36 expression 
levels in U937 cells has been shown to be significantly higher compared to THP-1 which 
may result in an initial burst of oxLDL uptake during oxidative stress (Nguyen-Khoa et al., 
1999).  
In this study, a delay in oxLDL causing damage to the cells have been observed as there were 
no significant difference in cell morphology and viability decrease within 3 hours incubation 
of oxLDL. Different oxLDL preparations have contributed to this observation by previous 
researchers in this lab. This delay suggests that oxLDL does not cause instant damage to the 
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cells but triggers cellular events such as GSH loss and metabolic dysfunction (Baird et al., 
2005; Shchepetkina, 2013) that will initiate cell death cascade. It has also been shown by 
Shchepetkina (2013) that HMDM cells committed to death after 6 hours of incubation with 
oxLDL whereby removing oxLDL from the media at this time did not help to recover cell 
viability. 
Results obtained in this chapter confirmed that oxLDL is toxic to cells in the culture but the 
exact molecular mechanisms involved in oxLDL-induced cell death remain unclear. Previous 
findings in our laboratory strongly suggested that oxidative damage could be triggering the 
rapid cell viability loss (Chen, 2012; Gieseg et al., 2010; Shchepetkina, 2013). This was 
further explored in the following chapters of this thesis. 
Cell viability assays: comparison between PI-flow cytometry and MTT 
assays 
The study of cell death mechanism is the main objective of this whole research. Therefore, it 
is essential to determine and choose the appropriate type of analysis or assay with the best 
features for the determination of cell viability throughout the study. MTT reduction and PI-
flow cytometry are among the cell-based viability assays used to distinguish viable cells from 
dead cells. The percentage of viable cells measured using MTT assay is proportional to the 
amount of purple formazan being generated by cellular NADPH-converting enzymes, thus 
depending on the intracellular metabolism that reflects the mitochondrial activity of the cells 
(Mosmann, 1983). Since the measurement of formazan is based on the optical density value 
(absorbance) measured by spectrophotometer, therefore, MTT assay can represent the cell 
number and can be compared among the samples, only when cells in the particular sample are 
in the same metabolic rate. In contrast, flow cytomety assay directly counts the number of 
cells that flow through the laser beam of the flow cytometer (detailed in Chapter 2 – 
Principles of flow cytometry). Hence, the number of cells counted is proportional to the cell 
concentration and not the metabolic state of the cells (Wang & Zheng, 2002).  
In this study, there was agreement between MTT and PI-flow cytometry assays for cell 
viability (Figure 3.7 C). The reasons are that the cells used for the two assays were of the 
same type, being treated with the same concentrations of oxLDL and were in the same 
metabolic state (Wang & Zheng, 2002) when measurements were done. The percentage of 
cytotoxicity obtained using both MTT and PI-flow cytometry assays also showed an 
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increasing trend with increasing oxLDL concentrations (Figure 3.7 D). Nevertheless, cell 
viability measurement using MTT assay yielded higher percentage of viable cells compared 
to PI-flow cytometry. The contributing factor might be due to the specificity of the assays i.e. 
MTT assay is measuring the metabolic activity of the cells. This means that some cells that 
are dying might still be able to metabolise MTT and contribute to the higher percentage of 
live cells as compared to PI which only binds to the DNA of the dead cells. Since the plasma 
membrane is the first to be exposed to oxLDL, it may be more readily and easily affected 
compared to the mitochondria thus explains why PI-flow cytometry assay is more sensitive 
(Liao et al., 2011). Cell viability data obtained by MTT assay is therefore impacted by the 
changes in intracellular metabolic activity that indirectly reflect overall cell viability (Wang 
& Zheng, 2002).  
Since the MTT assay only depends on colour reactions, colour intensities of the controls 
would affect the interpretation of results. Additionally, the percentage of cells in control 
samples measured by MTT will always be regarded as 100% but in real condition there will 
always be some dead cells in the control samples. Thus, this could contribute to the higher 
percentage of the control cells measured by MTT reduction assay compared to PI-flow 
cytometry analysis. 
However, there are distinct characteristics of PI-flow cytometry assay that may provide added 
advantages over MTT reduction assay. First, it requires only a few treatment steps (Wang & 
Zheng, 2002) before measurement of cell viability is carried out. A required volume of cells 
need to be transferred into a vial before PI is added and incubated in the dark before analysis. 
It requires only a short incubation time period of 15 minutes compared to MTT assay which 
needs approximately 1 to 2 hours incubation time with MTT reagent. MTT assay requires an 
extra step of dissolving the purple formazan complex with SDS before absorbance can be 
measured using a spectrophotometer. PI-flow cytometry assay also has added advantage of 
quantitative analysis of the cells whereby it allows the counting of the cells. 
In addition, PI-flow cytometry assay has fast turnaround time with only few seconds to less 
than a minute to run a sample. Notably, a relatively small volume of sample is required for 
analysis (approximately 150-200 µL) compared to MTT assay. Another feature exclusive to 
PI-flow cytometry assay is that the cell profile as well as dynamic changes of the cells can be 
obtained and distinguished through dot plots and histograms. This is useful as we are able to 
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see the changing in the size of the cells (forward scatter) and fluorescence intensities when 
the cells move from ‘live phase’ (PI negative) to ‘dead phase’ (PI positive) as shown in 
Figure 3.1 C, 3.2 C, 3.3 C, 3.4 C, 3.5 C, 3.6 C and 3.7 B. The number of viable cells (PI 
negative) and dead cells (PI positive) in each sample are able to be quantitated as opposed to 
MTT assay. Another advantage of using PI-flow cytometry is that it allows repeated 
measurements of the same sample. For MTT assay, this is a limitation because the cells 
become non-viable with the chemical treatment used in the assay, thus repeating or 
complementary assays cannot be carried out on the same plate of cells. 
Flow cytometry assay also enable more than one dye (dyes that are not using the same filter 
for measurement) to stain the cells at the same time and measurement can be carried out 
simultaneously (e.g. PI and Annexin V for the measurement of necrotic and apoptotic cells). 
Another advantage of PI-flow cytometry is the use of very small volume of reagent compared 
to MTT assay. In this study, approximately 4 uL of 100 µg/mL PI was added to a 250 µL 
sample and this volume is significantly less than the volume needed for MTT assay.  
Summary 
Results in this chapter have clearly demonstrated that oxLDL is toxic to U937 cells, human 
monocytes and HMDM cells. The toxicity caused by oxLDL is concentration and time 
dependent i.e. increased toxicity with higher oxLDL concentrations and longer incubation 
time. These findings were in agreement with the previous studies done by other researchers in 
this lab and also in other labs using oxLDL. LC50 concentrations of oxLDL varied for 
different types of cells and falls within certain ranges of concentrations. Morphological 
changes of the cells viewed under the light microscope serve as an additional tool in 
confirming the results obtained by biochemical analysis (MTT, PI and trypan blue). Flow 
cytometry assay of cell viability using PI dye has more advantages over the conventional 
MTT reduction assay. PI-flow cytometry assay is rapid, reliable, accurate, easy and cheap to 
run, thus making it favourable for usage throughout the study. In this study, MTT reduction 
assay was used mainly to compare and to check the results obtained by PI-flow cytometry 





4.  OxLDL induces oxidative stress and 
NADPH oxidase (NOX) activation 
 
Introduction 
This chapter aims to investigate whether oxLDL caused toxicity through oxidative stress. 
Effects of oxLDL on intracellular ROS production and NOX activation will be studied. Two 
NOX inhibitors namely, apocynin and VAS2870 as well as 7,8-dihydroneopterin will be used 
to determine their effects on ROS generation, NOX activation and cell viability. 
Results from Chapter Three have revealed that oxLDL caused toxicity to different types of 
cells but the exact mechanism on how oxLDL exerts its toxicity is still unclear. Thus, the aim 
of this chapter is to investigate the most prominent mechanism proposed to govern oxLDL 
cytotoxicity which is oxidative stress. Atherosclerosis is one of the diseases associated with 
oxidative stress whereby it is highly related with the mechanism of action of oxLDL 
cytotoxicity (Galle et al., 2006; Gieseg et al., 2009b; Salvayre et al., 2002). 
OxLDL-induced oxidative stress 
OxLDL-induced ROS generation has been studied in various types of vascular cells including 
neutrophils (Maeba et al., 1995), endothelial cells (Zmijewski et al., 2005), smooth muscle 
cells (Higashi et al., 2005; Hsieh et al., 2001; Jimenez-Corona et al., 2012) and macrophages 
(Asmis & Begley, 2003; Lee et al., 2010). Our laboratory has previously showed that oxLDL 
caused a significant increase in ROS (superoxide) levels in U937 cells (Chen, 2012) and 
HMDM cells (Shchepetkina, 2013).  
Increased intracellular ROS generation plays a vital role in oxLDL-mediated macrophage cell 
death (Asmis & Begley, 2003; Ball et al., 1995; Seimon & Tabas, 2009). Moreover, studies 
have addressed the involvement of oxidative stress in the development of atherosclerosis via 
over-production of ROS or failure of antioxidant defence system (Harrison et al., 2003; 
Stocker & Keaney, 2004). Previous findings showed that oxLDL triggered an increased 
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oxidative stress in HMDM, resulting in the excessive production of intracellular superoxide, 
rapid loss of cellular GSH and eventual loss of cell viability (Gieseg et al., 2010). Superoxide 
has been proposed as the primary ROS generated after exposure to oxLDL (Gieseg et al., 
2010), yet it is the precursor of other ROS that are more active and toxic such as H2O2, 
peroxyl, peroxynitrite and HOCl (Chapter One - Figure 1.4) (Stocker & Keaney, 2004). It 
has been shown that the main contributors of macrophage lysis were peroxide and the 
resulting peroxyl radical rather than superoxide (Asmis & Begley, 2003) but the particular 
oxidant(s) triggered by oxLDL signalling is/are difficult to distinguish due to lack of 
specificity of the existing molecular probes (Mukhopadhyay et al., 2007). 
In this section, oxLDL-induced oxidative stress in U937 cells, human monocytes and HMDM 
cells was investigated by studying the effect of oxLDL on intracellular ROS (superoxide) and 
mitochondrial ROS (superoxide) production using the fluorogenic dyes, dihydroethidium 
(DHE) and MitoSOX Red, respectively. 
NADPH oxidase (NOX)  
NADPH oxidases (NOXs) potentially play a major role in the development and progression 
of cardiovascular diseases (Williams & Griendling, 2007) whereby the only known function 
of NOX is to generate ROS. This feature makes NOX different from other sources of ROS 
such as xanthine oxidase (XOD) or uncoupled NOS since these enzymes generate ROS only 
when they are in a dysfunctional state. Therefore, it might be beneficial to target NOXs and 
develop therapeutics against them. To date, a handful of compounds (mentioned in Chapter 
One – NOX inhibitors) have been developed and tested against NOX inhibition but data are 
still lacking, particularly on their mechanism of action.  
NOX inhibitors – apocynin and VAS2870 
The ability of apocynin to inhibit NOX has been studied extensively in in vivo and in vitro 
experimental models. In human cellular studies using neutrophils, Van den Worm et al. (2001) 
has determined an IC50 (half maximal inhibitory concentration) of 10 µM for apocynin when 
stimulated with opsonised zymosan A (OPZ) or PMA. Moreover, apocynin does not interfere 
with the killing capacity of polymorphonuclear cells (PMNs) and it exhibits a very low 
toxicity with a LD50 of 9 g/kg when orally given to mice (Van den Worm et al., 2001). 
Although its exact mechanism of action is unknown, many studies have proposed that 
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apocynin prevents the translocation of p47
phox
 cytosolic subunit of NOX, therefore preventing 
NOX activation. Ximenes et al. (2007) have suggested that MPO catalyses apocynin 
oxidation into an active dimer radical form. This radical form of apocynin is thought to react 
with the essential thiol groups of p47
phox
, thus inhibits the activation of NOX (Figure 4.1).  
 
Figure ‎4.1: NADPH oxidase inhibition mechanism by apocynin in phagocytic and non-
phagocytic cells  
The inhibition by apocynin is effective only in the presence of apocynin dimers which is catalyses by 
MPO (Rabelo et al., 2010). 
With regards to atherosclerosis, Aviram et al. (1996) have showed that inhibition of J-774 
A.1 murine macrophage NOX with 600 µM apocynin inhibited macrophage-induced 
oxidation of LDL by 89% compared to control cells. Additionally, Holland et al. (1998) have 
demonstrated that when stimulated with thrombin (phospholipase A2 activator), endothelial 
cells incubated 600 µM apocynin inhibited NOX resulting in reduced ROS generation. 
Likewise, apocynin was also seen to significantly reduce cellular H2O2 levels mediated by 
high LDL in endothelial cells (Holland et al., 1997).  
However, the use of apocynin has been controversial and may have potential downsides. 
Studies in various types of cells have shown that apocynin may caused oxidative stress and 
could be pro-oxidant because of MPO-mediated apocynin radical generation. Apocynin was 
found to stimulated ROS production in rat vascular fibroblast and inhibited respiratory burst 
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in rat monocytes induced by zymosan. This indicated that it might act as an NOX inhibitor in 
phagocytes and as a stimulator in non-phagocytes (Vejrazka et al., 2005). Apocynin has been 
shown to induce an increase in H2O2 formation and a reduction in GSH/GSSG ratio, followed 
by an enhanced efflux of GSH in N11 glial cells (Riganti et al., 2006). Riganti et al. (2006) 
have also observed reduced GSH levels in alveolar epithelial cells treated with apocynin. 
Meanwhile, Castor et al. (2010) proposed that GSH oxidation was due to the pro-oxidant 
activity of apocynin radicals. Thus, apocynin itself could be inducing oxidative stress 
followed by cytotoxic effects depending on cell types and conditions. 
The compound, VAS2870 was discovered via a high-throughput screening assay specific for 
NOX activity and further characterised by NMR and spectrometry. VAS2870 has been 
shown to inhibit superoxide generation with an IC50 of 10.6 µM in cell free system containing 
membranes and cytosolic fractions of human neutrophil and 2 µM in whole-cell assay of HL-
60 cells, respectively (ten Freyhaus et al., 2006). At 10 µM, VAS2870 inhibits NOX activity 
in oxLDL-treated human umbilical vein endothelial cells (HUVEC) (Stielow et al., 2006) and 
platelet-derived growth factor (PDGF)-induced primary rat aortic vascular smooth muscle 
cells (VSMC) (ten Freyhaus et al., 2006). At 50 µM, upon exposure to PDGF-BB, VAS2870 
inhibits the stimulation of vasculogenesis of mouse embryonic stem cells (Lange et al., 2009). 
In zebrafish larvae, VAS2870 inhibits wound margin H2O2 production without obvious 
toxicity (Niethammer et al., 2009). 
VAS3947, which is a derivative of VAS2870 has been shown to inhibit NOX activity in 
various types of cells (Wind et al., 2010). Comparative analysis of VAS3947 and other 
common molecules used to inhibit NOX activity such as apocynin, AEBSF and DPI 
demonstrate a more effective and specific inhibition of this compound. However, the IC50 
values of VAS3947 varied depending on the cell models. Established IC50 of 12 µM for 
CaCo-2 cells (mainly NOX1 and NOX2 and some NOX4 and NOX5), 2 µM for HL-60 cells 
(NOX2 and NOX5) and 13 µM for A7r5 cells (mainly NOX4 and some NOX1 and NOX3) 
indicates that this compound is not an isoform-specific NOX inhibitor although it is specific 
for NOX class of enzymes (Cifuentes-Pagano et al., 2012). 
In this study, the ability of oxLDL to activate NOX will be investigated by examining p47
phox
 
phosphorylation via western blotting. Despite not knowing their exact mechanism of action, 
apocynin and VAS2870 have been shown by many studies to inhibit ROS flux in various 
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types of cells. However, there was no information on how these NOX inhibitors affect cell 
survival of oxLDL-exposed cells (particularly on U937, human monocytes and HMDM 
cells). Since ROS-mediated oxidative stress is reported to play a vital role in oxLDL-induced 






OxLDL induces intracellular ROS production in U937 cells, human 
monocytes and HMDM cells. 
OxLDL-induced intracellular ROS generation was studied in U937 cells, human monocytes 
and HMDM cells. The intracellular ROS were detected using fluorescence detection of 
dihydroethidium (DHE) measured using flow cytometry (see Chapter Two – 
Dihydroethidium (DHE)). DHE is a widely used probe for detecting intracellular superoxide 
(Zhao et al., 2005).  
The initial experiments were to confirm that oxLDL induces the generation of intracellular 
ROS (superoxide) in the cells. U937 cells were incubated with increasing concentrations of 
oxLDL for 3 hours, followed by DHE fluorescence measurement using flow cytometer. 
Results showed that the intracellular fluorescence intensity was significantly increased in 
cells treated with oxLDL compared to control. An increase of 30%, 100% and 130% in DHE 
fluorescence (compared to control) were observed when the cells were treated with 0.25, 0.50 
and 1.00 mg/mL oxLDL respectively (Figure 4.2). This clearly shows that oxLDL induced 
intracellular ROS production, in particular – superoxide which then may contribute to 
oxidative stress. 
Effects of oxLDL on ROS production induced by oxLDL between different cell lines were 
also compared between U937 and THP-1. Results showed that with increasing oxLDL 
concentrations, DHE levels also increase in both types of cells. Though, the increased in 
DHE fluorescence was relatively low for THP-1 cells compared to U937 cells. This might 
indicate different responses of the cells to oxLDL (Figure 4.3). Previous studies had shown 
that only a small loss in GSH was observed in oxLDL treated THP-1 cells while almost all of 
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Figure ‎4.2: Effect of different concentrations of oxLDL on intracellular ROS production 
in U937 cells. 
U937 cells (0.5×10
6
 cells/mL) were incubated in RPMI-1640 containing the increasing concentrations 
of oxLDL for 3 hours at 37
o
C. A cell only control with 0 mg/mL oxLDL added was included. At the 
end of treatment, the cells were washed with PBS and probed with 10 μM DHE for 20 minutes in the 
dark before measuring the DHE fluorescence by flow cytometry for intracellular ROS. Results are 
presented as mean fluorescence intensity (MFI) ± SEM of triplicates from a representative experiment. 
Significance is indicated from the cell only control (one-factor ANOVA, Sidak’s post test): *, p<0.05; 
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Figure ‎4.3: Effects of different concentrations of oxLDL on intracellular ROS 
production in U937 and THP-1 cells. 
U937 and THP-1 cells (0.5×10
6
 cells/mL) were incubated in RPMI-1640 containing the increasing 
concentrations of oxLDL for 3 hours at 37
o
C. A cell only control with 0 mg/mL oxLDL added was 
included. At the end of treatment, the cells were washed with PBS and probed with 10 μM DHE for 
20 minutes in the dark before measuring the DHE fluorescence by flow cytometry for intracellular 
ROS. Results are presented as mean fluorescence intensity (MFI) ± SEM of triplicates from a 
representative experiment. Significance is indicated between U937 and THP-1 cells for each oxLDL 
concentration (two-factor ANOVA, Sidak’s post test): **, p<0.01; ***, p<0.001. 
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A time course study was also performed to examine the kinetics of the oxLDL induction. 
Cells were incubated with LC50 concentration of oxLDL (0.5, 1.0 and 1.5 mg/mL for U937, 
human monocytes and HMDM cells, respectively) for a designated period of time followed 
by probing with DHE. Flow cytometer was used to measure the DHE fluorescence levels at 
various times which reflect the production of superoxide anion (Rodrigues et al., 2013) over 
time. A time-dependent increased in the DHE levels occurred in U937 cells, human 
monocytes and HMDM cells treated with oxLDL. For U937 cells, an average increased in 
DHE fluorescence of 30%, 50%, 85% and 130% compared to 0 hour control was observed 
after 1, 3, 6 and 9 hour incubation with oxLDL respectively. The DHE level dropped after 9 
hours with a decreased of 15% fluorescence intensity after 12 hours incubation with oxLDL 
(Figure 4.4 A). This is supported by the flow cytometry histogram which showed a shift to 
the right of the histogram over time which indicates increased fluorescence levels (Figure 4.4 
B).  
This was different to the trend observed by Chen (2012) whereby marked increased in DHE 
fluorescence reached maximum at 3 hours and dropped severely to the 0 hour control level 
after 6 hours. The abrupt decrease in fluorescence may be due to cell lysis occurred after 3 
hours incubation with oxLDL which caused the leakage of oxidants from the cells. In 
addition, the measurement of DHE fluorescence was then performed using fluorescent 
microscopy. Fluorescent microscopy technique has a few disadvantages including only 
allowing a semi-quantitative measurement of a relatively limited numbers of cells at the same 
time. Furthermore, cells loaded with fluorescent dyes tend to increase ROS generation by 


































































 cells/mL) were incubated in RPMI-1640 containing the LC50 concentration (0.5 
mg/mL) of oxLDL at 37
o
C. At various times, cells were collected, washed with PBS and probed with 
10 μM DHE for 20 minutes in the dark before measuring the DHE fluorescence by flow cytometry for 
intracellular ROS. A) shows the mean fluorescence intensities presented as a percentage of 0 hour 
control. Results are presented as mean fluorescence intensity (MFI) ± SEM of triplicates from a 
representative experiment. B) shows the flow cytometry histogram plot of cell count against DHE 
fluorescence. Significance is indicated from the 0 hour control. (one-factor ANOVA, Dunnett’s post 
test): *, p<0.05; **, p<0.01; ***, p<0.001. 
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A time course effects of oxLDL-induced ROS production were also studied in human 
monocytes and HMDM cells. For human monocytes, an increase of 10% (compared to 0 hour 
control) in DHE fluorescence was seen as fast as 1 hour incubation with oxLDL. A further 
increase of 20% occurred at 3 hours (compared to 1 hour) while greater increase of 
fluorescence were measured after 6 and 9 hours of oxLDL incubation (70 % increase 
compared to 0 hour control). The DHE fluorescence increase peaked at 9 hour before 
declining by 30% after 12 hours (Figure 4.5). Similarly, this shows that oxLDL was able to 
cause ROS generation in human monocytes and the similar pattern of increasing intracellular 
oxidative flux occurred over time, reached maximum level before gradual declined from peak 
value.  
Time-course effect of oxLDL on intracellular ROS production in HMDM cells is showed in 
Figure 4.6. An early increase in DHE fluorescence occurred after 1 hour and continuously 
increased after 3 and 6 hours incubation with oxLDL. Mean fluorescence intensity reached 
maximum after 9 hour with 40% increased above 0 hour control before a sharp decline after 
12 hours to almost the same level obtained at 6 hour. This finding confirmed the ability of 
oxLDL to initiate oxidative stress in HMDM cells that caused intracellular ROS generation. 
In this study, the trend of increasing ROS generation overtime and gradual decline after 































































 cells/mL) were incubated in RPMI-1640 containing the LC50 concentration 
(1 mg/mL) of oxLDL at 37
o
C. At various times, cells were collected, washed with PBS and probed 
with 10 μM DHE for 20 minutes in the dark before measuring the DHE fluorescence by flow 
cytometry for intracellular ROS. A) shows the mean fluorescence intensities presented as a percentage 
of 0 hour control. Results are presented as mean fluorescence intensity (MFI) ± SEM of triplicates 
from a representative experiment. B) shows the flow cytometry histogram plot of cell count against 
DHE fluorescence. Significance is indicated from the 0 hour control (one-factor ANOVA, Dunnett’s 
































































 cells/mL) were incubated in RPMI-1640 containing the LC50 concentration (1.5 
mg/mL) of oxLDL at 37
o
C. At various times, cells were collected, washed with PBS and probed with 
10 μM DHE for 20 minutes in the dark before measuring the DHE fluorescence by flow cytometry for 
intracellular ROS. A) shows the mean fluorescence intensities presented as a percentage of 0 hour 
control. Results are presented as mean fluorescence intensity (MFI) ± SEM of triplicates from a 
representative experiment. B) shows the flow cytometry histogram plot of cell count against DHE 
fluorescence. Significance is indicated from the 0 hour control. (one-factor ANOVA, Dunnett’s post 
test): *, p<0.05; **, p<0.01. 
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Mitochondrial ROS detection 
Mitochondria have been known as the potential source of superoxide production and undergo 
oxidative damage upon exposure to oxLDL (Zmijewski et al., 2005). MitoSOX, which 
contains a triphenylphosphonium cation (TPP+) conjugated to DHE via a linker carbon-
carbon alkyl chain has been used effectively to directly measure mitochondrial superoxide 
(Robinson et al., 2006; Mukhopadhyay et al., 2007). The effect of oxLDL on mitochondrial 
superoxide production in HMDM cells was studied by treating cells with LC50 concentration 
of oxLDL, followed by probing with MitoSOX Red (MitoSOX) which is specifically targeted 
to mitochondrial ROS (see Chapter 2 – MitoSOX Red) before detection via flow cytometry. 
Data collected at FSC/SSC of 585/542 nm in the FL2 channel. In this part of the study, a time 
course experiment has been performed to detect and quantify the production of mitochondrial 
ROS in HMDM cells. Mitochondrial ROS detection using MitoSOX in U937 cells has been 
done by Chen (2012) in this lab. 
Results obtained from this experiment showed that oxLDL caused an increase in 
mitochondrial ROS production over time. Approximately 20% increase in fluorescence was 
observed after 1 hour incubation with oxLDL followed by an increase of 30%, 50% and 70% 
after 3, 6 and 9 hours respectively compared to 0 hour control. After12 hours of incubation 
with oxLDL, more than 15% reduction in MitoSOX fluorescence was observed (Figure 4.7). 
Previous study in this laboratory has utilised MitoSOX for the detection of mitochondrial 
ROS in U937 cells after stimulation by increasing concentrations of oxLDL using fluorescent 
microscope (Chen, 2012). It has been shown by Chen (2012) that the increase in 
mitochondrial ROS production in U937 cells was concentration dependent and appeared to be 
more linear compared to the increase in overall oxLDL-induced intracellular ROS production. 
Chen (2012) suggested that the oxidative damage caused by oxLDL on mitochondria could 
be a later event whereby the increased in oxidative stress was primarily from an extra-
mitochondrial origin in U937 cells. This may also imply that mitochondrial dysfunction could 
be a secondary event initiated by oxLDL-induced ROS overproduction and other cellular 































































Figure ‎4.7: Time course effect of oxLDL-induced ROS production in the mitochondria 
of HMDM cells. 
HMDM cells (1×10
6
 cells/mL) were incubated in RPMI-1640 containing the LC50 concentration (1.5 
mg/mL) of oxLDL at 37
o
C. At various times, cells were collected, washed with PBS and probed with 
5 μM MitoSOX red for 10 minutes in the dark before measuring the fluorescence by flow cytometry 
for mitochondrial superoxide. Results are presented as mean fluorescence intensity (MFI) ± SEM of 
triplicates from a representative of experiment. Significance is indicated from the 0 hour control. 
(one-factor ANOVA, Dunnett’s post test): *, p<0.05; **, p<0.01. 
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NADPH oxidases (NOX) involvement in oxLDL-induced oxidative stress: 
effects of NOX inhibitors – apocynin and VAS2870 on cell death 
It has been shown that oxLDL had caused the increase in ROS production that resulted in 
oxidative stress in all three types of cells in the earlier experiments. Studies suggest that 
excessive generation of ROS is a key player that contributes to the progression of 
atherosclerosis. This is supported by the presence of oxidation products of lipids and proteins 
in atherosclerotic plaques (Stocker & Keaney, 2004). However, the source of the ROS and 
the mechanism of oxLDL triggering ROS production are still unclear. NOX has been 
implicated as the major superoxide generating enzyme complex and thus it was hypothesised 
that NOX may be the predominant source of ROS leading to oxidative stress in the 
progression of atherosclerotic plaque (Aviram et al., 1996; Singh & Jialal, 2006). 
The following studies were aimed to examine the ability of oxLDL to activate NOX and the 
role of NOX in oxLDL-induced oxidative stress. The effects of NOX inhibitors, apocynin 
and VAS2870 on oxLDL-induced cell death and superoxide production will be studied. 
Initial experiments in this section were performed to examine the effects of apocynin and 
VAS2870 on U937 cells, human monocytes and HMDM cells. This is important to ensure 
that the resulting cell death was caused by oxLDL but not by apocynin or VAS2870 being 
toxic to the cells.  
Cells were incubated with different concentrations of apocynin for 3 hours before addition of 
oxLDL and cell viability (PI positive and PI negative stained cells) was measured using PI-
flow cytometry assay. The same experiments in the absence of oxLDL were also carried out 
to examine the effects of apocynin alone on U937 cells, human monocytes and HMDM cells. 
For U937 cells, there was no cell viability loss compared to the cell only control after 
treatment with 10, 20, 50, 100 and 200 µM apocynin for 27 hours (Figure 4.8) implicating 
that apocynin had no cytotoxic effect in these range of doses. With the presence of oxLDL 
for 24 hours, cell viability (PI negative cells) has been reduced by 65% compared to cell only 
control. Pre-treatment with of apocynin of different concentrations has seen significant 
protection from oxLDL-induced cell death by 15-20% (PI negative cells) (Figure 4.9). In the 
previous study by Chen (2012), significant protection of 10-20% from oxLDL-induced cell 
loss has been observed with pre-incubation of 10 – 100 µM of apocynin (using MTT 
reduction assay for cell viability determination). 
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For human monocytes, there was also no cell viability loss in cells incubated with different 
ranges of apocynin as compared to cell only control (Figure 4.10) indicating that apocynin 
itself is not cytotoxic. However, following a 24-hour incubation with LC50 concentration of 
oxLDL, no significant protection of apocynin was seen as there was no difference in cell 
viability loss (PI negative cells) compared to oxLDL treated cells (Figure 4.11). This shows 
that, despite not being toxic, apocynin was not able to provide protection to human 
monocytes against oxLDL-induced cytotoxicity. 
Likewise, apocynin of different concentrations were not toxic to HMDM cells as no 
significant cell viability loss (PI negative cells) was observed compared to cell only control 
(Figure 4.12). However, there was also no significant protection of apocynin on oxLDL-
induced cell loss (PI negative cells) was observed with pre-incubation of apocynin ranging 
from 10 to 200 µM (Figure 4.13). This finding agrees with Shchepetkina (2013) who had 
also showed no protection of apocynin (50, 100 and 200 µM) to oxLDL-induced toxicity on 
HMDM cells despite its ability to reduce 7,8-NP oxidation. Extended study by Shchepetkina 
(2013) had the incubation period with apocynin shortened to 15 hours and found that the 
distribution of apoptotic, necrotic and live cells after oxLDL treatment was unaffected by the 
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Figure ‎4.8: Effect of different concentrations of apocynin on U937 cells. 
U937 cells (0.5×10
6
 cells/mL) were incubated at 37
o
C in non-phenol red RPMI-1640 with increasing 
concentrations of apocynin for 27 hours. A cell only control was added. A) Cells were viewed in situ 
in tissue culture wells using an inverted microscope (400x magnification) after 27 hours incubation 
with oxLDL. Images were taken using a Leica C-Mount camera and processed using Leica 
Application Suite software. B) Cell viability was determined using PI-flow cytometry. Data are 
expressed as percentage of the total number of cells in control samples. Results shown are mean ± 
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Figure ‎4.9: Effect of different concentrations of apocynin and oxLDL on U937 cells. 
U937 cells (0.5×10
6
 cells/mL) were incubated at 37
o
C in non-phenol red RPMI-1640 with increasing 
concentrations of apocynin for 3 hours followed by treatment of LC50 concentration (0.4 mg/mL) of 
oxLDL for 24 hours. A cell only control was included. A) Cells were viewed in situ in tissue culture 
wells using an inverted microscope (400x magnification) after 27 hours incubation with oxLDL. 
Images were taken using a Leica C-Mount camera and processed using Leica Application Suite 
software. B) Cell viability was determined using PI-flow cytometry. Data are expressed as percentage 
of the total number of cells in control samples. Results shown are mean ± SEM of triplicates from a 
representative experiment. Statistical significance (two-factor ANOVA, Sidak’s post test) is indicated 
from: PI negative cells - control vs oxLDL and oxLDL vs apocynin + oxLDL, ***, p<0.001; PI 
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Figure ‎4.10: Effect of different concentrations of apocynin on human monocytes. 
Human monocytes (1×10
6
 cells/mL) were incubated at 37
o
C in non-phenol red RPMI-1640 with 
increasing concentrations of apocynin for 27 hours. A cell only control was added. A) Cells were 
viewed in situ in tissue culture wells using an inverted microscope (400x magnification) after 27 
hours incubation with oxLDL. Images were taken using a Leica C-Mount camera and processed using 
Leica Application Suite software. B) Cell viability was determined using PI-flow cytometry. Data are 
expressed as percentage of the total number of cells in control samples. Results shown are mean ± 
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 cells/mL) were incubated at 37
o
C in non-phenol red RPMI-1640 with 
increasing concentrations of apocynin for 3 hours followed by treatment of LC50 concentration (0.8 
mg/mL) of oxLDL for 24 hours. A cell only control was included. A) Cells were viewed in situ in 
tissue culture wells using an inverted microscope (400x magnification) after 27 hours incubation. 
Images were taken using a Leica C-Mount camera and processed using Leica Application Suite 
software. B) Cell viability was determined using PI-flow cytometry. Data are expressed as percentage 
of the total number of cells in control samples. Results shown are mean ± SEM of triplicates from a 
representative experiment. Statistical significance (two-factor ANOVA, Sidak’s post test) is indicated 
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Figure ‎4.12: Effect of different concentrations of apocynin on HMDM cells. 
HMDM cells (1×10
6
 cells/mL) were incubated at 37
o
C in non-phenol red RPMI-1640 with increasing 
concentrations of apocynin for 27 hours. A cell only control was added. A) Cells were viewed in situ 
in tissue culture wells using an inverted microscope (400x magnification) after 27 hours incubation. 
Images were taken using a Leica C-Mount camera and processed using Leica Application Suite 
software. B) Cell viability was determined using PI-flow cytometry. Data are expressed as percentage 
of the total number of cells in control samples. Results shown are mean ± SEM of triplicates from a 
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Figure ‎4.13: Effect of different concentrations of apocynin and oxLDL on HMDM cells. 
HMDM cells (1×10
6
 cells/mL) were incubated at 37
o
C in non-phenol red RPMI-1640 with increasing 
concentrations of apocynin for 3 hours followed by treatment of LC50 concentration (1.5 mg/mL) of 
oxLDL for 24 hours. A cell only control was included. A) Cells were viewed in situ in tissue culture 
wells using an inverted microscope (400x magnification) after 27 hours incubation. Images were 
taken using a Leica C-Mount camera and processed using Leica Application Suite software. B) Cell 
viability was determined using PI-flow cytometry. Data are expressed as percentage of the total 
number of cells in control samples. Results shown are mean ± SEM of triplicates from a 
representative experiment. Statistical significance (two-factor ANOVA, Sidak’s post test) is indicated 
from: PI negative cells - control vs oxLDL, ***, p<0.001; PI positive cells – control vs oxLDL, ^^^, 
p<0.001.   
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Cells were incubated with different concentrations of VAS2870 for 30 minutes before 
addition of oxLDL and cell viability (PI negative and PI positive stained cells) was measured 
using PI-flow cytometry assay. The same experiments in the absence of oxLDL were also 
carried out to examine the effects of VAS2870 itself on U937 cells, human monocytes and 
HMDM cells.  
From this study, VAS2870 of 5 µM and above was toxic to U937 cells.  Cell viability loss of 
10 to 15%% (PI negative cells) was observed with 1 µM and 2 µM VAS2870 but was 
statistically insignificant compared to cell only control. Statistically significant cell viability 
loss (PI negative cells) of about 20, 60 and 80% were recorded in U937 cells incubated with 
5, 10 and 15 µM VAS2870 respectively (Figure 4.14). An increase in cell death (PI positive 
cells) was also significant in cells incubated with 5, 10 and 15 µM VAS2870. In the presence 
of oxLDL, VAS2870 has shown no protection against oxLDL-induced cell death in U937 
cells. After 24 hours, U937 cells incubated with LC50 oxLDL only had cell viability loss (PI 
negative) of about 70%. As expected, prior treatment with VAS2870 before addition of 
oxLDL did not help in preserving cell viability against oxLDL insult. With the presence of 
oxLDL, cell viability loss (PI negative) was about 70% for cells treated with both 1 and 2 µM 
VAS2870 while 80 to 95% of cell viability loss was observed in cells incubated with 5 to 15 
µM VAS2870 (Figure 4.15). 
VAS2870 itself was also found to be cytotoxic to human monocytes. Cells incubated with 5, 
10 and 15 µM VAS2870 had significantly reduced cell viability (PI negative cells) by 15, 40 
and 50% respectively compared to cell only control (Figure 4.16). With the presence of 
oxLDL, cell viability loss was further increased with increasing concentrations of VAS2870. 
OxLDL had caused loss of human monocytes viability (PI negative cells) by 35%. In the 
presence of oxLDL, cell viability loss (PI negative cells) was significantly reduced to 
approximately 30 to 20% in cells treated with 1 to 15 µM of VAS2870 (Figure 4.17). 
Surprisingly, VAS2870 alone had only caused a smaller percentage of cell loss to HMDM 
cells compared to U937 cells and human monocytes. Incubation of HMDM cells with 10 and 
15 µM VAS2870 for 24 hours had significantly reduced cell viability (PI negative cells) by 
10 and 20% respectively (Figure 4.18). However, in the presence of oxLDL, VAS2870 at 
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Figure ‎4.14: Effect of different concentrations of VAS2870 on U937cells. 
U937 cells (0.5×10
6
 cells/mL) were incubated at 37
o
C in non-phenol red RPMI-1640 with increasing 
concentrations of VAS2870 for 24 hours.  A cell only control was included. A) Cells were viewed in 
situ in tissue culture wells using an inverted microscope (400x magnification) after 24 hours 
incubation. Images were taken using a Leica C-Mount camera and processed using Leica Application 
Suite software. B) Cell viability was determined using PI-flow cytometry. Data are expressed as 
percentage of the total number of cells in control samples. Results shown are mean ± SEM of 
triplicates from a representative experiment. Statistical significance (two-factor ANOVA, Sidak’s post 
test) is indicated from: PI negative cells - control vs VAS2870, ***, p<0.001; PI positive cells – 
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Figure ‎4.15: Effect of different concentrations of VAS2870 and oxLDL on U937cells. 
U937 cells (0.5×10
6
 cells/mL) were incubated at 37
o
C in non-phenol red RPMI-1640 with increasing 
concentrations of VAS2870 for 30 minutes before addition of LC50 concentration of oxLDL (0.4 
mg/mL) and incubated for 24 hours. A cell only control was included A) Cells were viewed in situ in 
tissue culture wells using an inverted microscope (400x magnification) after 24 hours incubation with 
oxLDL. Images were taken using a Leica C-Mount camera and processed using Leica Application 
Suite software. B) Cell viability was determined using PI-flow cytometry. Data are expressed as 
percentage of the total number of cells in control samples. Results shown are mean ± SEM of 
triplicates from a representative experiment. Statistical significance (two-factor ANOVA, Sidak’s post 
test) is indicated from: PI negative cells - control vs oxLDL and oxLDL vs VAS2870 + oxLDL, ***, 
p<0.001; PI positive cells – control vs oxLDL and oxLDL vs VAS2870 + oxLDL, ^, p<0.05, ^^^, 
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Figure ‎4.16: Effect of different concentrations of VAS2870 on human monocytes. 
Human monocytes (1×10
6
 cells/mL) were incubated at 37
o
C in non-phenol red RPMI-1640 with 
increasing concentrations of VAS2870 for 24 hours. A cell only control was included A) Cells were 
viewed in situ in tissue culture wells using an inverted microscope (400x magnification) after 24 
hours incubation with oxLDL. Images were taken using a Leica C-Mount camera and processed using 
Leica Application Suite software. B) Cell viability was determined using PI-flow cytometry. Data are 
expressed as percentage of the total number of cells in control samples. Results shown are mean ± 
SEM of triplicates from a representative experiment. Statistical significance (two-factor ANOVA, 
Sidak’s post test) is indicated from: PI negative cells - control vs VAS2870, ***, p<0.001; PI positive 
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 cells/mL) were incubated at 37
o
C in non-phenol red RPMI-1640 with 
increasing concentrations of VAS2870 for 30 minutes before addition of LC50 concentration (0.8 
mg/mL) of oxLDL and incubated for 24 hours. A cell only control was included. A) Cells were 
viewed in situ in tissue culture wells using an inverted microscope (400x magnification) after 24 
hours incubation with oxLDL. Images were taken using a Leica C-Mount camera and processed using 
Leica Application Suite software. B) Cell viability was determined using PI-flow cytometry. Data are 
expressed as percentage of the total number of cells in control samples. Results shown are mean ± 
SEM of triplicates from a representative experiment. Statistical significance (two-factor ANOVA, 
Sidak’s post test) is indicated from: PI negative cells - control vs oxLDL and oxLDL vs VAS2870, **, 
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Figure ‎4.18: Effect of different concentrations of VAS2870 on HMDM cells. 
HMDM cells (1×10
6
 cells/mL) were incubated at 37
o
C in non-phenol red RPMI-1640 with increasing 
concentrations of VAS2870 for 24 hours. A cell only control was included. A positive control of cell 
only treatment and a negative control of cells treated with oxLDL were included A) Cells were 
viewed in situ in tissue culture wells using an inverted microscope (400x magnification) after 24 
hours incubation with oxLDL. Images were taken using a Leica C-Mount camera and processed using 
Leica Application Suite software. B) Cell viability was determined using PI-flow cytometry. Data are 
expressed as percentage of the total number of cells in control samples. Results shown are mean ± 
SEM of triplicates from a representative experiment. Statistical significance (two-factor ANOVA, 
Sidak’s post test) is indicated from: PI negative cells - control vs VAS2870, **, p<0.01, ***, p<0.001; 
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Figure ‎4.19: Effect of different concentrations of VAS2870 and oxLDL on HMDM cells. 
HMDM cells (1×10
6
 cells/mL) were incubated at 37
o
C in non-phenol red RPMI-1640 with increasing 
concentrations of VAS2870 for 30 minutes before addition of LC50 concentration (1.5 mg/mL) of 
oxLDL and incubated for 24 hours. A cell only control was included. A) Cells were viewed in situ in 
tissue culture wells using an inverted microscope (400x magnification) after 24 hours incubation with 
oxLDL. Images were taken using a Leica C-Mount camera and processed using Leica Application 
Suite software. B) Cell viability was determined using PI-flow cytometry. Data are expressed as 
percentage of the total number of cells in control samples. Results shown are mean ± SEM of 
triplicates from a representative experiment. Statistical significance (two-factor ANOVA, Sidak’s post 
test) is indicated from: PI negative cells - control vs oxLDL and oxLDL vs VAS2870, ***, p<0.001; 
PI positive cells – control vs oxLDL and oxLDL vs VAS2870, ^^, p<0.0, ^^^, p<0.001.   
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7,8-dihydroneopterin (7,8-NP) protection against oxLDL-induced oxidative 
stress and cell death 
Previous researchers in this lab have shown that 7,8-dihydroneopterin (7,8-NP) protects cells 
from oxLDL-induced cell death. 7,8-NP has been shown to prevent oxLDL-induced cell 
viability loss by scavenging radical flux and reducing oxidative stress (Baird et al., 2005; 
Gieseg et al., 2009b). In order to ascertain the contribution of NOX-derived oxidative stress 
to oxLDL-induced cell death, another experiment using HMDM cells which included 7,8-NP 
together with apocynin and VAS2870 was carried out (Figure 4.20). 
Results showed that 200 µM apocynin, 2 µM VAS2870 as well as 200 µM 7,8-NP alone 
were not toxic to HMDM cells. Cell viability experiments using different concentrations of 
7,8-NP was done earlier during this study whereby 200 µM 7,8-NP was found to be the 
optimum concentration of 7,8-NP. Cell viability loss (PI negative cells) was about 40% in 
cells incubated with oxLDL only. Likewise, pre-incubation of cells with apocynin and 
VAS2870 did not restore cell viability in the presence of oxLDL. Cells pre-incubated with 
7,8-NP had a significant increased in cell viability (PI negative cells) of about 77% compared 
to oxLDL only treated cells. The number of PI positive were also decreased compared to 
oxLDL treated cells but was not statistically significant. 
In the presence of oxLDL, the increased in cell viability in cells pre-incubated with 7,8-NP 
might be due to the ability of 7,8-NP to scavenge intracellular oxidants generated by oxLDL. 
Therefore, in the next section, experiments were carried out to investigate the effects of 7,8-
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 cells/mL) were treated with LC50 concentration oxLDL (1.25 mg/mL) after pre-
incubation at 37
o
C in non-phenol red RPMI-1640 with either 200 µM 7,8-NP for 10 minutes, 5 µM 
VAS2870 for 30 minutes or 200 µM apocynin for 3 hours. A positive control of cell only treatment, a 
negative control with oxLDL only and cells incubated with the same concentration of 7,8-NP, 
VAS2870 and apocynin without oxLDL were also included as controls. After 24 hours of incubation 
with oxLDL, cell viability was determined using PI-flow cytometry. Data are expressed as percentage 
of the total number of cells in control samples. Results shown are mean ± SEM of triplicates from a 
representative experiment. Statistical significance (two-factor ANOVA, Sidak’s post test) is indicated 
from: PI negative cells - control vs oxLDL and oxLDL vs 7,8-NP, ***, p<0.001; PI positive cells – 




Effects of apocynin, VAS2870 and 7,8-NP on oxLDL-mediated intracellular 
ROS production 
Further investigations were carried out to ascertain the effects of apocynin, VAS2870 and 
7,8-NP on intracellular ROS levels. There was no significant difference between the control 
and cell treated with various concentrations of apocynin, VAS2870 and 7,8-NP only (Figure 
4.21 A, B and C) in all types of cells. This suggests that apocynin, VAS2870 and 7,8-NP do 
not induce ROS production in these cells. In the presence of oxLDL, cells pre-treated with 
apocynin and 7,8-NP showed a significant decrease in DHE fluorescence intensities for U937 
cells. There was no protection against increased DHE fluorescence observed in cell pre-
treated with VAS2870 (Figure 4.21 A). In contrary, in the presence of oxLDL, the increase 
in DHE fluorescence intensities was not blocked in human monocytes and HMDM cells pre-
treated with apocynin. However, when incubated with oxLDL, a reduction in DHE 
fluorescence was observed in cells pre-treated with 7,8-NP. Likewise, VAS2870 did not 
convey any reduction to DHE fluorescence intensities when challenged with oxLDL (Figure 
4.21 B and C). 
These results clearly showed that 7,8-NP was able to scavenge ROS in all types of cells and 
oxLDL-induced DHE fluorescence was largely suppressed. In the presence of oxLDL, 
apocynin was able to reduce DHE fluorescence only in U937 cells but not human monocytes 
and HMDM cells. This is in agreement with the work of Chen (2012) in this lab, who showed 
a significant reduction in oxLDL-induced fluorescence increase in U937 cells treated with 10 
to 100 µM apocynin using fluorescence microscopy. This may indicate the involvement of 
NOX for the intracellular ROS generation in response to oxLDL activation but this appeared 
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B) Human monocytes 
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C) HMDM cells 
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Figure ‎4.21: Effect of apocynin, VAS2870 and 7,8-NP on intracellular ROS production 
in U937, human monocytes and HMDM cells. 
U937 cells (0.5×10
6
 cells/mL), human monocytes (1×10
6
 cells/mL) and HMDM cells (1×10
6
 cells/mL) 
were treated with LC50 concentration oxLDL (0.5, 1 and 1.5 mg/mL oxLDL for U937, human 
monocytes and HMDM cells, respectively) after pre-incubation at 37
o
C in non-phenol red RPMI-1640 
with either 200 µM 7,8-NP for 10 minutes, 5 µM VAS2870 for 30 minutes or 200 µM apocynin for 3 
hours. A cell only control was included. After 6 hours of incubation with oxLDL (3 hours for U937), 
cells were washed and stained with 10 µM DHE for 20 minutes in the dark before analysis using PI-
flow cytometry. Results shown are mean ± SEM of triplicates from a representative experiment. 
Statistical significance (two-factor ANOVA, Sidak’s multiple test) is indicated from: Control vs 




Mechanism of NOX activation 
It is believed that NOX is the major producer of ROS leading to oxidative stress. In the 
previous study done in this laboratory, oxLDL has been shown to activate NOX in U937 cells 
(Chen, 2012). A time course experiments were performed to study p47
phox
 protein expression 
upon stimulation with oxLDL to prove that oxLDL directly activates NOX. Thus, it is clearly 
showed in this study that oxLDL activates NOX in U937, human monocytes and HMDM 
cells (Figure 4.22, 4.23 and 4.24) in a time-dependent manner. Phosphorylated p47
phox
 had 
generally increased after 1 hour incubation with oxLDL and peaked at 3 hour. This was 
followed by gradual decrease in p47
phox
 protein. The protein band intensities were quantified 
and corrected with β-actin. The maximum increase of p47
phox
 protein was found to be around 
30% (average) compared to 0 hour control for both U937 and HMDM cells whereas for 
human monocytes the increase was 70% (average). 
Studies have implicated that apocynin inhibits the translocation of p47
phox
 in different types 
of cells including human monocytes (Barbieri et al., 2004) and vascular cells (Kinkade et al., 
2013) leading to inactivation of NOX. Previous studies in this lab by Chen (2012) showed 
that apocynin was able to inhibit oxLDL-induced NOX in U937 cells by suppressing p47
phox
 
phosphorylation that consequently protected against oxLDL-induced oxidative stress. The 
ability of oxLDL to activate NOX and apocynin to inhibit NOX was examined through 
p47
phox
 protein expression by western blot in HMDM cells.  PMA, an agonist which activates 
protein kinase C (PKC) that phosphorylates p47
phox
 in phagocytic cells ( Li et al., 2002) was 
included as a positive control. HMDM cells were incubated with apocynin for 3 hours 
followed by treatment with oxLDL for another 6 hours before cells were collected and 
processed for western blot to analyse p47
phox
 protein expression. Western blot results (Figure 
4.25) revealed that apocynin was not able to inhibit NOX in HMDM cells. This is further 
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Figure ‎4.22: Time course study of p47phox activation by oxLDL in U937 cells. 
U937 cells (0.5×10
6
 cells/mL) were treated with LC50 concentration (0.25 – 0.40 mg/mL) of oxLDL 
in RPMI-1640. A) After the designated incubation time, whole cell lysate was prepared and the 
presence of activated p47
phox
 was examined by western blotting. B) The protein band intensities were 
quantified using Image J software and corrected for β-actin. Data are expressed as percentage of the 0 
hour control and significance is indicated from this control. Results are displayed as mean ± SEM of 












   
 
Time (hour) 0 1 3 6 9 
β-actin   
 










































Figure ‎4.23: Time course study of p47phox activation by oxLDL in human monocytes. 
Human monocytes (1×10
6
 cells/mL) were treated with LC50 concentration (0.75 – 1 mg/mL) of 
oxLDL in RPMI-1640. A) After the designated incubation time, whole cell lysate was prepared and 
the presence of activated p47
phox
 was examined by western blotting. B) The protein band intensities 
were quantified using Image J software and corrected for β-actin. Data are expressed as percentage of 
the 0 hour control and significance is indicated from this control. Results are displayed as mean ± 
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Figure ‎4.24: Time course study of p47phox activation by oxLDL in HMDM cells. 
HMDM cells (1×10
6
 cells/mL) were treated with LC50 concentration (1.25 – 1.50 mg/mL) of oxLDL 
in RPMI-1640. A) After the designated incubation time, whole cell lysate was prepared and the 
presence of activated p47
phox
 was examined by western blotting. B) The protein band intensities were 
quantified using Image J software and corrected for β-actin. Data are expressed as percentage of the 0 
hour control and significance is indicated from this control. Results are displayed as mean ± SEM of 






















































































Figure ‎4.25: Effect of apocynin on NADPH oxidase subunit p47phox protein expression in 
HMDM cells.  
HMDM cells (1×10
6 
cells/ml) were pre-treated with 200 μM apocynin in RPMI-1640 at 37
o
C for 3 
hours, followed by incubation with LC50 concentration of oxLDL (1.25 - 1.5 mg/mL) for 6 hours. A 
positive control with 5 μM PMA treatment and a negative control with oxLDL only treatment were 
also included. A) At the end of treatment, the presence of activated p47
phox
 in the whole cell lysate 
was examined by western blotting. A representative western blot of p47
phox
 is shown. B) The protein 
band intensities were quantified using Image J software and corrected with β-actin. Data are expressed 
as percentage of the positive cell only control data. Results are displayed as mean ± SEM of three 
separate experiments. Significance (one-way ANOVA, Dunnett’s multiple comparison) is indicated 











Pathological increase in cytosolic Ca
2+
 could also trigger a cascade of cellular events. 
Elevated cytosolic Ca
2+
 could promote NOX activation by inducing PKC and PLA2 which 
could also trigger the phosphorylation of NOX subunit, p47
phox
 (Cathcart, 2004). Both ROS 
generation and intracellular Ca
2+
 increase (Chapter Five – Role of calcium in oxLDL-
induced cell death) have been shown to be the early events of oxLDL-induced toxicity. 
Thus, the following experiments were carried out to investigate the involvement of ROS in 
oxLDL-induced intracellular Ca
2+
 rise.  
A time-course study to investigate the effect of apocynin, VAS2870 and 7,8-NP on oxLDL-
induced Ca
2+
 increase was carried out using flow cytometry over a period of 6 hours in U937, 
human monocytes and HMDM cells (Figure 4.26 A, B and C). In the absence of oxLDL, 
cells treated with 200 µM apocynin, 2 µM VAS2870 or 200 µM 7,8-NP displayed similar 
mean fluorescence intensities as the cell only control. OxLDL triggered a rapid fluorescence 
increase in the first 3 to 4 hours in all types of cells. U937 cells pre-treated with apocynin 
demonstrated a slightly lower oxLDL-induced fluorescence intensity increase compared to 
oxLDL only treated cells (Figure 4.26 A). However, the same decreasing trend was not 
observed in apocynin pre-treated human monocytes and HMDM cells in the presence of 
oxLDL (Figure 4.26 B and C).  
The oxLDL-induced fluorescence intensities increase was significantly reduced in the 
presence of 7,8-NP especially after the first 3 hours incubation with oxLDL. The similar 
pattern of oxLDL-induced fluorescence intensities decrease occurred U937, human 
monocytes and HMDM cells. These results indicate that 7,8-NP inhibited oxLDL-induced 
intracellular Ca
2+
 influx but this protection seemed to occur after 3 hours. The role of Ca
2+
 in 
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B) Human monocytes 
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Figure ‎4.26: Effects of apocynin, VAS2870 and 7,8-NP on oxLDL-induced intracellular 
Ca
2+ 
in U937, human monocytes and HMDM cells 
U937 cells (0.5×10
6
 cells/mL), human monocytes (1×10
6
 cells/mL), HMDM cells (1×10
6
 cells/mL) 
were pre-incubated with 1.5 μM of Fluro-3AM with or without 200 μM apocynin/5 µM 
VAS2870/200 μM 7,8-NP for 40 minutes, followed by treatment with LC50 concentration (0.25, 0.75, 
1.25 mg/mL oxLDL for U937, human monocytes and HMDM cells, respectively)of oxLDL in non-
phenol red RPMI-1640 at 37
o
C. At various times, cell samples were removed and analyzed by flow 
cytometry. Mean fluorescence intensities are measured by flow cytometry over 6 hours. Results 
shown are mean fluorescence intensities (MFI) ± SEM of triplicates of a representative experiment. 
At each time point, intracellular Ca
2+
 levels were significantly elevated with the addition of oxLDL 
(p<0.05). Significance indicated in the graph was detected from the oxLDL treated cells and cells pre-





Oxidative stress: effects of oxLDL on ROS production 
Results from the experiments in this chapter clearly showed that oxLDL was able to induced 
ROS generation, most likely as superoxide. Investigations of intracellular ROS productions 
using DHE and MitoSOX demonstrated that oxLDL caused a time-dependent increased level 
of intracellular and intra-mitochondrial superoxide generations as early as 1 hour after 
incubation with oxLDL (Figure 4.4, 4.5, 4.6 and 4.7). The increase in intracellular ROS 
generation also depends on oxLDL concentration as well as the type of cells (Figure 4.2 and 
4.3). These results showed that abnormal increase in intracellular ROS production (oxidative 
flux) is an early event and one of the key features in oxLDL toxicity. Nevertheless, the exact 
mechanism of how oxLDL initiates ROS generation within the cells is not fully understood.  
OxLDL treated with different antioxidants before incubation with the cells did not reduce its 
toxicity or ROS generations (Gieseg et al., 2009b). This suggests that oxLDL might be 
activating or stimulating the oxidant generating system in the cells such as NOX and 
mitochondrial electron transport chain (mETC) by initiating a shift in redox balance and 
subsequent induction of downstream signalling cascades (Gieseg et al., 2009b; Gieseg et al., 
2009a). Studies have also showed that H2O2 and MitoSOX levels were elevated in U937 cells 
after 5 and 4 hours treatment with copper oxLDL (Al Gadban et al., 2010; Ermak et al., 
2010). In our lab, Gieseg et al. (2010) have demonstrated that oxLDL induced a DHE 
detected oxidative stress over the first six hours which was also supported by the work of 
Shchepetkina (2013) in HMDM cells.  
The increase in mitochondrial ROS (MitoSOX levels) could lead to mitochondrial 
dysfunction which eventually causes cell death. This could be a secondary event due to 
oxLDL-induced excessive ROS production and other cellular oxidative damage happened in 
the cytosol. Possibly, this could also be due to the oxidants generated by the mETC. 
Additionally, Cadenas and Davies (2000) have reported that the production of mitochondrial 
superoxide is estimated to be 5 to 10-fold higher than that of cytosol and nucleus.  
In this study, DHE and MitoSOX have been used to detect intracellular production of ROS. 
To date, there are many fluorescent probes and assays available for ROS detection but 
choosing the appropriate probes for detection of specific ROS is often difficult. DHE is 
suitable for the detection of intracellular superoxide and oxidants even though is not 
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exclusively specific (Kalyanaraman et al., 2012; Tarpey et al., 2004). Thus, DHE as a probe 
of superoxide is sufficient for this study since no identification of specific source of ROS is 
required. Moreover, there is no perfect assay for ROS detection and almost all have some 
limitations over the other (Maghzal et al., 2012).    
One obvious observation from this study was that U937 cells always demonstrate higher 
fluorescence value compared to human monocytes and HMDM cells. This could be due to 
higher cell surface volume due to greater cell size compared to human monocytes and 
HMDM cells or the U937 cells are easily penetrable by the dye. 
NOX activation by oxLDL - effect of apocynin  
Since NOX plays a vital role in ROS generation, studies have suggested that inhibition of 
NOX and ROS reduction could compensate oxidative stress, thus improved cell survival 
(Aviram et al., 1996; Sukhanov et al., 2006). Apocynin has been widely known and used as 
NOX inhibitor (Bedard & Krause, 2007) in many studies involving various types of cells 
(phagocytes and non-phagocytes).  
Apocynin is activated by cellular peroxidases including myeloperoxidase (MPO) (Stolk et al., 
1994a) into an activated dimer form. In our setting, HMDM cells are cultured with GM-CSF 
(Sugiyama et al., 2001), thus MPO should be present in the cells. Moreover, the presence of 
NOX2 is common in macrophages whereby apocynin is believed to act by inhibiting the 
translocation of the cytosolic subunits to the plasma membrane (Bedard & Krause, 2007; 
Meyer et al., 1999; Stolk et al., 1994a). 
In our lab, Chen (2012) has demonstrated that apocynin protected U937 cells from oxLDL-
mediated cell death. However, the protection from cell loss was only about 10 to 15% 
compared to oxLDL treated cells despite an increase of 60% of GSH levels compared to 
control cells. Additionally, western blot analysis for the activation of p47
phox
 in U937 cells in 
response to oxLDL stimulation revealed the involvement of NOX with maximum activity 
peaked at 3 hours after incubation with oxLDL. Chen (2012) also showed that apocynin was 
able to block the translocation of p47
phox
 subunit of NOX resulting in NOX inactivation in 
U937 cell system. Taken together, this finding suggests that oxLDL was able to activate 
NOX and give rise to ROS generation in U937 cells. Inhibiting NOX activation by apocynin 
may result in preventing cell death to certain extend but there might be other sources of ROS 
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in U937 cell system other than NOX that could cause death to the remaining of the cells. 
Possibly, an excessive increase in GSH level might impose adverse effects on cell survival. 
Meanwhile, apocynin has also been reported to increase GSH synthesis in alveolar epithelial 
cells (Lapperre et al., 1999).  
The current study showed that apocynin has no protection against oxLDL-induced cell death 
in human monocytes and HMDM cells (Figure 4.11 and 4.13). OxLDL is shown to induce 
NOX activation in U937, human monocytes and HMDM cells as indicated by western blot 
results (Figure 4.22, 4.23 and Figure 4.24). However, the percentage of NOX activation 
increased was only about 30% in HMDM cells after 3 hours incubation with oxLDL (Figure 
4.24 B). These results showed the involvement of NOX2 in oxLDL-induced ROS generation 
because NOX2 is dependent on p47
phox
 activation. Nevertheless, western blot analysis 
revealed that apocynin was unable to inhibit p47
phox
 phosphorylation induced by oxLDL in 
HMDM cells (Figure 4.25). Based on the proposed mechanism of action, apocynin targets 
NOX homolog with the presence of p47
phox
 (which is NOX2), thus it should not interfere 
with other NOX types that are independent of p47
phox
 like NOX4. In their recent studies, Lee 
et al. (2010) have discovered the existence of NOX4 in human monocytes and macrophages 
which was inducible by oxLDL. They have also showed that NOX4 localised in intracellular 
compartment (ER and nucleus) and colocalises with p22
phox
 which formed a functional ROS-
producing enzyme complex (Bedard & Krause, 2007). Lee et al. (2010) also suggested that 
NOX4 in HMDM cells is present as NOX4/p22
phox
 dimers and constitutively active. 
Therefore, this might affect the action of apocynin due to the existence of both NOX isoforms 
(NOX2 and NOX4).  
Another possibility that could cause apocynin not to be functioning is that it needs to be 
activated by peroxidases (Figure 4.1) and these enzymes might not be present in all types of 
cells. However, this is unlikely since MPO has known to be present in HMDM cells cultured 
with GM-CSF (Sugiyama et al., 2001). Additionally, Riganti et al. (2006) and Vejrazka et al. 
(2005) have shown that apocynin increases ROS generation in neuronal cells and vascular 
fibroblasts instead of decreasing it. For those reasons, results obtained with apocynin should 
always be treated and interpreted with caution. 
In this study, apocynin was able to provide a small percentage of protection to U937 cells 
against oxLDL-mediated cell death (Figure 4.9). This finding is in line with the work of 
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Chen (2012) in this lab, who also showed that apocynin inhibited NOX activation by 
preventing p47
phox
 translocation. However, apocynin at various concentrations did not offer 
any protection against oxLDL-induced toxicity to human monocytes and HMDM cells 
(Figure 4.11 and 4.13). This is in line with Shchepetkina (2013) who demonstrated that 
apocynin partially prevented 7,8-NP oxidation to neopterin by oxLDL in HMDM cells but 
did not convey protection against oxLDL-induced cell death. This may correspond to the 
inability of apocynin to inhibit p47
phox
 phosphorylation in HMDM cells which was 
demonstrated in this study. Although there are much evidence on ROS-generating effect of 
NOX in macrophages and other cells (Bedard & Krause, 2007; Brandes et al., 2010), data 
showing direct effects of NOX on cell viability with oxLDL treatment in macrophages is still 
lacking. This could possibly be due to the specificity problems associated with NOX 
inhibitors (Altenhofer et al., 2012). Apocynin has also been proven to lacking NOX 
specificity (Aldieri et al., 2008) which suggested that apocynin is not a NOX specific 
inhibitor. Moreover, Shchepetkina (2013) had showed that the increase in intracellular 7,8-
NP oxidation to neopterin was prevented by half when apocynin pre-treated HMDM cells 
were incubated with 7,8-NP in the presence of oxLDL. This suggested that NOX is one of the 
key sources of ROS that lead to 7,8-NP oxidation though the inhibition was incomplete. 
Shchepetkina (2013) also proposed that in HMDM cells, NOX-generated superoxide reacted 
with chloride ion (Cl
-
) via myeloperoxidase (MPO) to produce HOCl that oxidises 7,8-NP to 
neopterin. Therefore, since NOX inhibition by apocynin did not prevent 7,8-NP oxidation 
completely, the remaining HOCl could have been generated form a different source such as 
the mitochondria. Moreover, it has been shown in this study that mitochondrial superoxide 
level was increased in HMDM cells upon exposure to oxLDL (Figure 4.7).  Furthermore, 
apocynin and AEBSF have been shown by Sukhanov et al. (2006) to offer only partial 
prevention of GAPDH down regulation by oxLDL. 
Non-NOX sources of ROS could also be generated by the cells and are sufficient to induce 
cell death. Mitochondrial ROS generation could be the most possible source of ROS in 
HMDM cells since Complex III of the mETC was identified as the superoxide source in 
compromised cells (Turrens, 2003). This study and previous work by Chen (2012) have 
showed that mitochondrial superoxide level was elevated upon oxLDL treatment of HMDM 
(Figure 4.7) and U937 cells, respectively. In addition, it has been demonstrated that oxLDL-
induced mitochondrial depolarisation and dysfunction contribute to macrophage cell death 
(Asmis & Begley, 2003). In addition, Hampton et al. (1998) suggested in their review that 
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ROS generated by NOX2 are either directed to extracellular space or to the phagosomes, thus 
making it not a likely source of the intracellular ROS observed in macrophages when 
stimulated with oxLDL (Lee et al., 2010). 
With regards to intracellular ROS production, a decrease in oxLDL-induced DHE 
fluorescence which was only seen in U937 cells but not in human monocytes or HMDM cells 
(Figure 4.21) also suggest the unspecific effects of apocynin. 
NOX activation by oxLDL - effect of VAS2870   
VAS2870 is a new class of NOX inhibitor developed with improved specificity (Wingler et 
al., 2011) and was chosen as an alternative to apocynin. It has been shown in this study that 
VAS2870 does not protect U937 cells, human monocytes and HMDM cells from oxLDL-
mediated cell death (Figure 4.15, 4.17, 4.19 and 4.20). In fact, VAS2870 itself was toxic to 
the cells at high concentrations (10 µM and above) (Figure 4.14, 4.16 and 4.18). Moreover, it 
was found that VAS2870 did not prevent oxidative stress mediated by oxLDL. The DHE 
levels measured showed no difference in cells pre-incubated with VAS2870 in the presence 
of oxLDL compared to oxLDL treated cells (Figure 4.21 A, B and C). In addition, VAS2870 
was also unable to inhibit intracellular Ca
2+
 rise when challenged with oxLDL in all types of 
cells used in this study (Figure 4.26 A, B and C). 
In other studies using VAS2870, Stielow et al. (2006) showed the suppression of superoxide 
in HUVEC (non-phagocytic cells) which expressed NOX4 as the major isoform before 
stimulation with oxLDL but no indication of VAS2870 protection from cell viability loss was 
mentioned from his observations. In addition, ten Freyhaus et al. (2006) have shown that 
VAS2870 does not affect PMA stimulated p47
phox
 translocation in human PMN cells which 
indicates that VAS2870 is not inhibiting NOX2. VAS2870 and its derivative, VAS3947 have 
been shown to inhibit NOX activity in cells that are predominantly express NOX4 since 




 (Ago et al., 2004; Shiose 
et al., 2001). Since NOX2 is mainly associated with macrophages (phagocytic cells), this 
may be the main reason why VAS2870 was not working in inhibiting oxLDL-induced NOX 
and protecting the cells. Nevertheless, the exact mechanism of action of VAS2870 is still not 
well developed. On the other hand, there is a possibility that ROS were also generated by 
other sources such the mETC or xanthine oxidase which was not reduced by VAS2870.  
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Results gained through this study have showed that intracellular ROS production in U937, 
human monocytes and HMDM cells was not inhibited by VAS2870 (Figure 4.21). 
Therefore, it is suggested that a more specific NOX inhibitor, for example gp91-ds-tat (Rey et 
al., 2001) which is specific to NOX2 to be used in future studies investigating the 
involvement of NOX in oxLDL related studies. 
7,8-NP protection against oxLDL-induced intracellular ROS production 
and cell death 
Studies from our lab have showed that 7,8-NP protects cells of myelocytic origin from 
oxLDL cytotoxicity (Baird et al., 2005; Gieseg et al., 2010; Gieseg et al., 2001b), which is 
one of the main events in atherosclerotic plaque development. Studies in this lab has 
demonstrated a maximum protection against oxLDL-induced cell death in U937 and HMDM 
cells at 200 µM 7,8-NP (Baird, 2003). Although the exact mechanism of 7,8-NP protection 
against oxLDL-induced cell death is not exactly clear, available data suggest that this 
protection could be attributed to the antioxidant capacity of 7,8-NP as well as 7,8-NP-
mediated reduction of oxLDL uptake by macrophages (Gieseg et al., 2010). 
Results from this study clearly demonstrated that 7,8-NP reduced oxLDL-induced DHE-
reactive intracellular ROS levels in all three types of cells (Figure 4.21 A, B and C), 
proposed to be primarily superoxide and H2O2 (Rothe & Valet, 1990; Tarpey et al., 2004) . 
These results suggest that oxLDL triggered oxidative stress in the cells and 7,8-NP itself as 
an antioxidant could be scavenging the intracellular oxidants generated. Moreover, in the 
presence of oxLDL, intracellular Ca
2+
 increase induced by oxLDL was also reduced by 7,8-
NP compared to the oxLDL only treated cells (Figure 4.26 A, B and C). This also suggests 
that 7,8-NP scavenges intracellular ROS, which in turn reduces the intracellular Ca
2+
 
increase. Taken together, this may eventually leads to the protection of the cells from oxLDL 
insult.  
Monocyte-like U937 cells have been used as an excellent model for human macrophages due 
to the similar characteristics in manifesting oxLDL-induced cytotoxicity such as rapid 
oxidative stress, absence of caspase activation and necrotic type of cell death (Baird et al., 
2004; Katouah, 2012). The inability of 7,8-NP to inhibit oxLDL-induced NOX activation of  
p47
phox
 protein demonstrated by Chen (2012) in U937 cells through western blot, strongly 
indicates that the mechanism of action of 7,8-NP is by scavenging NOX-derived ROS and 
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not directly inhibits NOX activation. Since 7,8-NP has also been shown to protect both U937 
and HMDM cells (Baird et al., 2005; Gieseg et al., 2010), it is therefore suggests that 7.8-NP 
might act similarly in HMDM cells. For these reasons, 7,8-NP was not included in the 
western blot done to determine the effect of NOX inhibitors on the activation of p47
phox
 
protein (Figure 4.25). 
These findings are in-line with other studies which showed that 7,8-NP might protect cells 
from oxLDL-mediated oxidative damage through scavenging various types of radicals 
including superoxide, peroxyl and hydroxyl as well as hypochlorite (Duggan et al., 2002; 
Gieseg et al., 2001a; Oettl et al., 1997). This radical scavenging property of 7,8-NP may 
provide explanation to the inhibition of radical-induced damages to cells and cellular 
substrates where this compound is presence (Duggan et al., 2001; Duggan et al., 2002). 
Moreover, 7.8-NP has been shown to prevent oxLDL-mediated GSH loss in U937 and 
HMDM cells by scavenging oxLDL induced intracellular oxidants, which eventually 
balanced the redox environment and maintained cell survival (Baird et al., 2004; Baird et al., 
2005; Gieseg et al., 2010).  
The ability of 7,8-NP to down-regulate the scavenger receptor, CD36 might also protects 
cells against oxLDL-induced toxicity. Studies have shown that the inhibition of CD36 by 
anti-CD36 antibody has significantly reduced ROS production level, caspase activation and 
cell death (Sukhanov et al., 2006; Wintergerst et al., 2000). Gieseg et al. (2010) have 
demonstrated that 7,8-NP induced a down-regulation of plasma membrane glycoform of 
CD36 (100 kDa) in HMDM cells. Recent studies by Shchepetkina (2013) have also showed 
the reduction of CD36 scavenger receptor and mRNA levels by 7,8-NP in HMDM cells. 
Nonetheless, protective effects of 7,8-NP may be cell specific whereby it depends on the type 
and nature of the cells. Baird et al. (2005) have shown that 7,8-NP protects U937 and 
HMDM cells from oxLDL-mediated cell death and prevents loss of intracellular GSH but no 
protection against oxLDL toxicity as well as cellular thiol restoration were noticed with THP-
1 cells. Moreover, CD36 expression on THP-1 surface is significantly lower compared to 
U937 cells (Alessio et al., 1996) which may explain why 7,8-NP failed to protect THP-1 cells 
against oxLDL toxicity. Additionally, low expression of CD36 may also reduce oxLDL 
uptake by THP-1 cells resulting in lower ROS production as seen in Figure 4.3.  
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Mechanism of NOX activation by oxLDL 
Immunoblotting results from this study revealed that oxLDL activated NOX and increased 
the protein levels of p47
phox
 subunit of NOX (Figure 4.22, 4.23 and 4.24). This shows that 
NOX may contribute to the generation of ROS mediated by oxLDL. However, the increased 
in NOX activity that peaked at 3 hours was only about 30% compared the 0 hour control. It is 
not known how much p47
phox
 is needed for NOX activation to occur but an increased in NOX 
subunit protein levels may further increase NOX activity (Cifuentes et al., 2000). Likewise, 
how oxLDL stimulates NOX activation is not precisely known. For future studies, it is 
recommended that both phosphorylated and total p47
phox
 to be included for western blotting. 
This could provide a better understanding regarding NOX activation by oxLDL. 
Studies have found that lysophosphatidylcholine (lysoPC) present in oxLDL could activate 
protein kinase C (PKC) upon oxLDL uptake (Kugiyama et al., 1992; Ohgushi et al., 1993) 
whereby PKC activation could stimulate p47
phox 
phosphorylation and subsequent NOX 
activation. Other studies have proposed scavenger receptor CD36 to be a key activator of 
NOX which involved the binding of lipid and protein components of oxLDL (Nguyen-Khoa 
et al., 1999). It has been shown that oxLDL-induced NOX activation level in U937 cells was 
significantly higher than that in THP-1 cells, which corresponded to the higher CD36 
expression levels in U937 cells (Nguyen-Khoa et al., 1999). Nevertheless, Gieseg et al. 
(2010) have shown that CD36 is down regulated by 7,8-NP and study by Chen (2012) 
demonstrated the failure of 7,8-NP to prevent oxLDL-mediated activation of NOX. Taken 
together, this may imply the involvement of receptors other than CD36 in the mechanism of 
oxLDL-induced NOX activation. 




Time course studies of oxLDL-induced Ca
2+
 influx showed that intracellular Ca
2+
 increase 
was reduced by 7,8-NP after 3 hours incubation with oxLDL (Figure 4.26). The ability of 
7,8-NP to scavenge oxLDL-induced ROS shown in the earlier experiments may contribute to 
the reduced intracellular Ca
2+
 rise. However, the failure of 7,8-NP inhibition of oxLDL-
stimulated NOX activation showed by (Chen, 2012) indicates that 7,8-NP did not protect 




Oxidative stress is one of the key features associated with oxLDL-mediated cell death. 
Results from this study clearly showed that oxLDL caused intracellular generation of ROS 
(possibly superoxide) in the cytosol and mitochondria. Further investigation in this chapter by 
measuring p47
phox
 activation indicates that oxLDL induced NOX activation which suggests 
that NOX might be the possible generator of ROS. However, the amount of p47
phox
 required 
for NOX activation was not quantified. In addition, the inability of both apocynin and 
VAS2870 to inhibit NOX may also suggest that either these NOX inhibitors are not specific 
for the targeted NOX or other sources of ROS might exist and contributed to the oxidative 
flux. 7,8-NP is shown is this study to scavenge oxLDL-induced ROS that could in turn 
reduce Ca
2+









This chapter will study the position and function of calcium (Ca
2+
) in oxLDL-mediated cell 
death. This will include investigating the effects of oxLDL on Ca
2+ 
levels (intracellular and 





chelators will also be examined related to intracellular Ca
2+
 and ROS 
generation as well as cell viability in oxLDL-induced cells. 
Ca
2+
 is an important signalling molecule or secondary messenger involved and responsible in 
numerous cellular processes including proliferation, gene transcription, post-translational 
protein modifications and metabolism (Clapham, 2007). Therefore, it is mandatory for cell to 
maintain a very low cytosolic Ca
2+
 concentration in order to exquisitely
 
control and 
coordinate these processes (Rasola & Bernardi, 2011).  
In general, regulation of Ca
2+ 
homeostasis is common in all eukaryotic cells. However, each 
cell type expresses a unique complement of molecules which enables it to specifically 
modulate amplitude, kinetics and subcellular distribution of Ca
2+
 signals (Rasola & Bernardi, 
2011). Extracellular Ca
2+ 
can cross the plasma membrane via two different channels i.e. 
voltage-gated Ca
2+ 
channels (VOCCs) and receptor-operated Ca
2+ 
channels (ROCCs) (Pinilla 
et al., 2005). On the other hand, Ca
2+ 
can be mobilised from intracellular organelles through 
the stimulation of ryanodine receptors (RyRs) and IP3 receptors (IP3Rs) on the ER (Alberdi 
et al., 2005; Duchen et al., 2008). Both conditions resulted in increased level of intracellular 
Ca
2+
.  Buffering of Ca
2+
 in the cytosol occurred through sequestering of Ca
2+
 into the ER/SR 
by SERCA or pump out of the plasma membrane by PMCA (Clapham, 2007). Besides, 
mitochondria have been implicated to actively taking part in regulating intracellular Ca
2+
 due 
to their capacity to rapidly accumulate Ca
2+
 (Carafoli, 2010). Figure 5.1 illustrates the 
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position of mitochondria in Ca
2+
 signalling. General Ca
2+
 homeostasis has been described in 
detail in Chapter One.  
Studies have implicated the importance of Ca
2+
 signalling in atherosclerosis (Berthier et al., 
2004; Meilhac et al., 1999). OxLDL-induced increase in cytosolic Ca
2+
 appears to be the 
common event in triggering necrosis or apoptosis in various types of cells (Berthier et al., 
2004; Deng et al., 2009; Porn-Ares et al., 1998). OxLDL has been found to cause a Ca
2+ 
rise 
in variety of cells including vascular smooth muscle cells (Augé et al., 1996; Massaeli et al., 
2001; Weisser et al., 1992), endothelial cells (Negre-Salvayre et al., 1992; Zhao et al., 1997), 
leukocytes (van Tits et al., 2000), lymphocytes (Maziere et al., 2005), lymphoblastoid 
cultured cells (Escargueil-Blanc et al., 1994) and U937 cells (Deng et al., 2005). Studies have 
also demonstrated that increased intracellular Ca
2+ 
has been associated with enhance ROS 
generation in intact cultured cells including cardiomyocytes (Przygodzki et al., 2005), striatal 
neurons (Peterson et al., 2000), astrocytes (Jou et al., 2010) and human keratinocytes 
(Goldman et al., 1998). 
 
Figure ‎5.1: Calcium signalling and and its involvement in the mitochondria  
(Duchen et al., 2008) 
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Abnormal rise in cytosolic Ca
2+
 might activate phopholipase A2, which could then, cleaves 
membrane phospholipids and cause the disruption of membrane organization, activation of 
Ca
2+
-dependent endonucleases triggering DNA disruption and activation of transglutaminases 
catalysing the cross-linking of proteins to produce insoluble aggregates (Kowaltowski et al., 
2001). Additionally, excessive increase in cytosolic Ca
2+
 could also activate Ca
2+
-dependent 
calpains which subsequently resulted in the cleavage of cytoskeletal proteins including 
spectrin, talin, and α-actin. This will eventually cause the elimination of plasma membrane 
anchorage to the cytoskeleton and contribute to plasma membrane blebbing (Miyoshi et al., 
1996; Weber et al., 2005). Membrane blebbing is also facilitated by oxidation of thiol groups 
on cytoskeletal proteins by ROS and loss of intracellular ATP, which is required for the 
maintenance of cytoskeletal integrity. If the blebbing extends to a point where rupture occurs 
without immediate resealing, cell loses its ion gradient thus causing necrotic type of cell 
death whereby the cellular contents will be released into the surrounding area. 
Research in this chapter was carried out to investigate the effect of oxLDL on intracellular 
Ca
2+
 level in three different types of cells (U937, human monocytes and HMDM cells) 
followed by experiments using various types of calcium channel blockers and calcium 
chelators. This chapter also examined the intracellular ROS production induced by oxLDL 
and the effect of various calcium channels blockers and calcium chelators on intracellular 
ROS levels. Additionally, the effect of calcium channel blockers and calcium chelators on 
cell viability in the absence and presence of oxLDL was also examined. 
Mitochondrial permeability transition (MPT) and mitochondrial membrane potential 
(ΔΨm) – association between ROS and Ca
2+
 
Mitochondria play key role in vital cellular functions such as ATP production, regulation of 
cellular metabolism and cell death. Thus, mitochondrial dysfunction may contribute to a lot 
of diseases and at cellular level which leads to cell death (Lemasters et al., 2009). Cytosolic 
Ca
2+ 
overload can be taken up by the mitochondria, causing the mitochondrial permeability 
transition pore (MPTP) opening. This will then cause an increase of the inner mitochondrial 
membrane (IMM) to ions and solutes up to 1500 daltons (Bernardi, 1999; Crompton, 1999) 
due to the loss of mitochondrial membrane potential (ΔΨm), which eventually starts the cell 
death cascade that leads to necrotic or apoptotic cell death (Deng et al., 2009; Madamanchi & 
Runge, 2007; Whiteman, et al., 2004). 
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Mitochondrion consists of two membranes, inner membrane (IMM) and outer membrane 
(OMM) and the electron transport chain (ETC) located at IMM. ΔΨm is created as a result of 
H
+
 pumping from the matrix to the intermembrane space (IMS) through complex I to IV of 
the ETC. At complex IV, ATP synthase uses these H
+
 ions to produce ATP. Thus, the ΔΨm 
decreases as the protons are used to produce energy. Studies have also showed that during 
Ca
2+
 uptake, ΔΨm decreases and the decrease is proportional to the amount of Ca
2+
 uptake by 
the mitochondria (Nicotera et al., 1992). However, the membrane potential is maintained by 
pumping more protons across the membrane (from matrix to the IMS). In order to maintain 
this critical gradient, transport across the IMM is tightly regulated by many specific 













 antiporter, and uncoupling proteins. Additionally, the 
IMM also contains protein channels and the adenine translocator (ANT) that exchanges ADP 
and ATP between the matrix and IMS. Moreover, many of the apoptosis-inducing proteins 
reside in the IMS, including cytochrome c, apoptosis inducing factor (AIF) and few pro-
caspases (Giorgi et al., 2012). Thus, a change in ΔΨm is a signal for mitochondrial 
dysfunction which also reflects the metabolic state of the mitochondria. 
Stimulation of the Krebs/TCA cycle and oxidative phosphorylation by Ca
2+
 can accelerate 
ROS generation by increasing mitochondrial metabolism and oxygen consumption which 
trigger more superoxide leakage from the mitochondrial respiratory chain (Brookes et al., 
2004; Nicotera & Orrenius, 1998). In addition, mitochondrial ROS can serve as the oxidising 
agent for MPTP via the activation of essential thiol groups of the membrane proteins (Inoue 
et al., 2008; Kowaltowski et al., 1997). MPTP opening causes ΔΨm loss and the subsequent 
rupture of OMM and mitochondrial dysfunctions (Deng et al., 2009;  Yang et al., 2012a). 
MPTP opening could also resulted in the released of apoptotic factors such as cytochrome c, 
leading to caspase-3 activation followed by apoptotic cell death (Nicotera & Orrenius, 1998) 
but MPTP opening has always been associated with necrotic cell death (Zhivotovsky & 
Orrenius, 2011). Having stated the importance and association of Ca
2+
 and MPT, cell death 
could be prevented by inhibitors of mitochondrial Ca
2+
 uptake and MPTP formation such as 
ruthenium red and cyclosporin A, respectively (Zhivotovsky & Orrenius, 2011). This will 





Effects of oxLDL on intracellular Ca
2+
 levels in U937 cells, human 
monocytes and HMDM cells 
Previous study in our laboratory showed that HOCl-induced oxidative stress had caused the 
opening of Ca
2+
 channels leading to intracellular Ca
2+
 influx which is important in HOCl-
mediated cell death (Yang et al., 2012a). In the current study, the association between 
intracellular Ca
2+
 changes and the increased in oxidative stress was further explored with 
oxLDL. In the first part of this chapter, experiments were carried out to examine the effect of 
oxLDL on intracellular Ca
2+
 levels in U937 cells, human monocytes and HMDM cells over a 
period of time. 
Cells were pre-incubated with a fluorescent dye, Fluo-3AM, to detect intracellular (cytosolic) 
free Ca
2+ 
(see Chapter 2 - Fluo-3-acetoxymethyl ester (Fluo-3 AM)). The AM form of the 
dye can easily penetrate through the plasma membrane whereby upon cleavage of the ester 
group by cytoplasmic esterases, it is entrapped within the cells. Cells were then treated with 
oxLDL followed by flow cytometry measurements at different time points. Results have 
showed a similar time-dependent shifts in the fluorescence intensities over time in all types of 
cells (Figure 5.2 A, 5.3 A and 5.4 A). This finding is in agreement with the work of Chen 
(2012) in this lab using U937 cells, who showed that the fluorescence intensity increase was 
observed as early as 5 minutes after incubation with oxLDL compared to the starting point (0 
hour).  This suggests that oxLDL caused a rapid intracellular Ca
2+
 influx which is the primary 
event upon the exposure of the cells to oxLDL.  
In U937 cells, there was a 3-fold increase in fluorescence intensity after 1 hour incubation 
with oxLDL compared to the 0 hour. The fluorescence intensity increased by 4- and 6-fold 
after 2 hours and 3 hours incubation with oxLDL, respectively. The increased in fluorescence 
intensities has been observed up till 6 hours (Figure 5.2). As for human monocytes, a sharp 
increase in fluorescence intensity has been observed from the starting point (0 hour) until 3 
hours incubation with oxLDL indicating the continuous rise in the intracellular Ca
2+
 levels in 
the first 3 hours.. After the 3 hour point, the increase in fluorescence intensity was minimal 
compared to the increase in the first 3 hours (Figure 5.3). Incubation of HMDM cells with 
oxLDL had also resulted in the increase in fluorescence intensities indicating increasing 
intracellular Ca
2+
 levels. The increase was about 2.5-fold after 1 hour incubation with oxLDL 
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compared to the 0 hour which then continued to rise until the next 2 hour. The fluorescence 
intensities seemed to stay stable over the next 3 hour treatment with oxLDL (Figure 5.4). 
These results suggest that the increase in cytosolic free Ca
2+
 occurred rapidly and it appears 
to be the primary event when cells are being exposed to oxLDL which may be responsible for 
the subsequent cellular oxidative events. 
Experiment was also performed to examine the effect of different concentrations of oxLDL 
on intracellular Ca
2+
 levels over time. A time course study over a period of 6 hours was 
carried out using oxLDL concentrations of 0.25, 0.50, 0.75 and 1.00 mg/mL on U937 cells. 
Results showed that the mean fluorescence intensity increases with higher concentration of 
oxLDL (Figure 5.5) which indicates increased influx with increasing concentration of 
oxLDL. This finding is in agreement with Maziere et al. (2005) who showed that oxLDL-
mediated increase in intracellular Ca
2+
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Figure ‎5.2: Effect of oxLDL on intracellular calcium levels in U937 cells. 
U937 (0.5×10
6
 cells/mL) were pre-incubated with 1.5 µM Fluo-3 AM for 40 minutes, followed by 
treatment with 0.5 mg/mL oxLDL in non-phenol red RPMI1640 at 37
o
C. At various times, cells were 
removed and analysed by flow cytometer. A) shows the median cellular fluorescence measured by 
flow cytometer over 6 hours (10,000 events were collected in the gated area for analysis). B) shows 
the representative cytometry histogram plot of cell counts against Fluo-3 AM over 4 hours 
Significance is indicated from the 0 hour data. Results displayed as mean fluorescence intensity (MFI) 
± SEM of triplicate measurements from a representative experiment. Significance (two-way ANOVA, 
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Figure ‎5.3: Effect of oxLDL on intracellular calcium levels in human monocytes. 
Human monocytes (1×10
6
 cells/mL) were pre-incubated with 1.5 µM Fluo-3 AM for 40 minutes, 
followed by treatment with 1 mg/mL oxLDL in non-phenol red RPMI1640 at 37
o
C. At various times, 
cells were removed and analysed by flow cytometer. A) shows the median cellular fluorescence 
measured by flow cytometer over 6 hours (10,000 events were collected in the gated area for analysis). 
B) shows the representative cytometry histogram plot of cell counts against Fluo-3 AM over 4 hours 
Significance is indicated from the 0 hour data. Results displayed as mean fluorescence intensity (MFI) 
± SEM of triplicate measurements from a representative experiment. Significance (two-way ANOVA, 
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Figure ‎5.4: Effect of oxLDL on intracellular calcium levels in HMDM cells. 
HMDM cells (1×10
6
 cells/mL) were pre-incubated with 1.5 µM Fluo-3 AM for 40 minutes, followed 
by treatment with 1.5 mg/mL oxLDL in non-phenol red RPMI1640 at 37
o
C. At various times, cells 
were removed and analysed by flow cytometer. A) shows the median cellular fluorescence measured 
by flow cytometer over 6 hours, 10,000 events were collected in the gated area for analysis. B) shows 
the representative cytometry histogram plot of cell counts against Fluo-3 AM over 4 hours 
Significance is indicated from the 0 hour data. Results displayed as mean fluorescence intensity (MFI) 
± SEM of triplicate measurements from a representative experiment. Significance (two-way ANOVA, 
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 cells/mL) were pre-incubated with 1.5 µM Fluo-3 AM for 40 minutes, followed by 
treatment with different concentrations of oxLDL in non-phenol red RPMI1640 at 37
o
C. After 3 hours 
of incubation, cells were removed and analysed by flow cytometry. A) shows the mean fluorescence 
intensity (MFI) measured by flow cytometry (10,000 events were collected in the gated area for 
analysis). B) shows the representative cytometry histogram plot of cell counts against Fluo-3 AM. 




Effects of oxLDL on intracellular Ca
2+ 
in different types of media – 










Experiments were also carried out to examine the effect of oxLDL on intracellular Ca
2+
 levels 











contains potassium chloride (KCl), sodium bicarbonate (NaHCO3), sodium chloride 





contains the same ingredients but Ca
2+ 
was added to resemble the Ca
2+
 concentration in 
RMPI1640. Subsequent experiments studying the effect and source 
(intracellular/extracellular) of Ca
2+ 




. It has also 
been noted through morphological observations throughout the study that condition of the 
cells incubated in these media were not as good as they were in RMPI1640 which is the best 
media for cell culture. Nevertheless, most experiments conducted using EBSS required only 
short incubation time (e.g. 3 and 6 hours). 
Results illustrated a consistent similar pattern of Ca
2+ 
levels in all three types of cells (Figure 
5.6). Highest fluorescence level depicting highest intracellular Ca
2+ 
influx was obtained from 
cells in EBSS+Ca
2+
 followed by RPMI1640 and EBSS-Ca
2+ 
(with or without the presence of 
oxLDL). These results also implicated the effect of extracellular Ca
2+ 
influx to the increase in 
intracellular Ca
2+




has also been 
observed from cells incubated in EBSS-Ca
2+





, the rise in intracellular Ca
2+
 suggests that the source of Ca
2+ 
was from 
intracellular organelles particularly ER. This finding will be further studied using specific 
Ca
2+ 
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 cells/mL), human monocytes (1×10
6
 cells/mL) and HMDM cells (1×10
6
 cells/mL) were pre-incubated with 1.5 µM Fluo-3 AM for 40 
minutes, followed by treatment with LC50 concentration of oxLDL (0.5 mg/mL, 1 mg/mL, 1.75 mg/mL for U937, human monocytes and HMDM cells, 






C. Cells were removed after 3 hours incubation with oxLDL and analysed by 
flow cytometry. A), B) and C) show the mean cellular fluorescence measured by flow cytometry over 3 hours (10,000 events were collected in the gated area 
for analysis) for U937 cells, human monocytes and HMDM cells, respectively. Results displayed as mean fluorescence ± SEM of triplicate measurements 





) vs Control (EBSS-Ca
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), @, p<0.05, @@, p<0.01 and oxLDL (EBSS+Ca
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Calcium ionophore A23187 (BrA) was used as a positive control to confirm that the increase 
in fluorescence detected by flow cytometer resulted from Ca
2+
 reacting with the Fluo 3AM 
dye and not oxLDL reacting with the dye. BrA is a lipid soluble molecule that has been 
widely used to study calcium dynamics. It is highly selective for Ca
2+
 and enhances the 
ability of Ca
2+ 
to cross the cell membrane and increases cytoplasmic Ca
2+
. The fluorescence 
pattern showed that U937 cells (Figure 5.7 A) exhibited a concentration dependent increase 
in fluorescence intensity by 25% to 40% when treated with 5 and 7 µM of BrA respectively. 
The same pattern occurred for human monocytes and HMDM cells as shown in Figure 5.7 B 
and 5.7 C. 
Experiments were performed to further confirm that the cytosolic Ca
2+
 increase was able to 
cause cell viability loss in U937 cells, human monocytes and HMDM cells. Cells were 
exposed to different concentrations of Ca
2+
 ionophore A23187 (BrA) and cell viability was 
analysed after 24 hours. BrA at 3 μM did not cause any significant cell viability loss after 24 
hour post-treatment but 5 and 7 μM BrA caused approximately 40 to 80% cell viability loss 
(Figure 5.8 A, B and C). These results suggest that the cytosolic Ca
2+
 increase induced by 
BrA treatment did cause loss of cell viability. No significant loss of cell viability was 
observed in cells incubated with 3 μM BrA indicates that a certain intracellular concentration 
of cytosolic Ca
2+
 is needed to cause decrease in cell viability. This finding is in agreement 
with Yang (2009) who also observed a rapid cell viability loss in HMDM cells after 5 
minutes treatment with BrA of 5 µM and above in concentration. In the current study, 5 µM 
BrA was found to cause cell viability loss of 40 to 50% compared to the cell only control. 
This specific BrA concentration was used in the subsequent experiments involving BrA 
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 cells/mL) were pre-incubated with 1.5 µM Fluo 3AM for 40 minutes, followed by treatment with increasing concentrations of calcium 
ionophore A23187 (BrA) in non-phenol red RPMI1640 at 37
o
C for 3 hours. A cell only control (0 µM BrA) was included. Mean fluorescence intensity (MFI) 
was measured by flow cytometry (10,000 events were collected in the gated area for analysis) Significance is indicated from the cell only control. Results 
shown are mean fluorescence ± SEM of triplicate measurements from a representative experiment. Significance (two-way ANOVA, Sidak’s post test) is 
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Figure ‎5.8: Calcium ionophore A23187 (Br-A) caused cell viability loss in U937, human monocytes and HMDM cells. 
U937 (0.5×10
6
 cells/mL), human monocytes (1×10
6
 cells/mL) or HMDM cells (1×10
6
 cells/mL) were incubated with increasing concentrations of calcium 
ionophore A23187 (BrA) in non-phenol red RPMI1640 at  37
o
C for 24 hours. A cell only control (0 µM BrA) was included. A, B and C show cell viability 
measured via PI-flow cytometry after 24 hours for U937 cells, human monocytes and HMDM cells, respectively. Data are expressed as percentage of the cell 
only control ± SEM of triplicate measurements from a representative experiment. Significance is indicated from the cell only control (two-way ANOVA, 













and removal of oxLDL on intracellular Ca
2+
 level and cell viability 
Experiments were also conducted to ascertain the effect of Ca
2+
 and removal of oxLDL on 
intracellular Ca
2+
 level and cell death. U937 cells, human monocytes and HMDM cells were 








) for 6 
hours. At 6 hours, intracellular Ca
2+
 levels were measured. Cells were then washed to remove 
oxLDL and were further incubated in RPMI1640 for 18 hours. At the end of experiment, cell 
viability was determined.  
The same patterns of results were seen for all types of cells. After 6 hours incubation with 
oxLDL, intracellular Ca
2+ 
levels were increased. The increase was relatively higher in 
EBSS+Ca
2+
 compared to EBSS-Ca
2+ 
which indicates the influx of extracellular Ca
2+
 into 
intracellular compartment. Intracellular Ca
2+ 
increase in cells incubated in EBSS-Ca
2+
 was 
most likely due to Ca
2+ 
mobilisation from intracellular organelles (Figure 5.9 A, 5.10 A and 
5.11 A). Removal of oxLDL (which is the toxic agent causing Ca
2+
 rise) from the media at 6 
hours followed by incubation in fresh culture media for 18 hours did not restore cell viability 
despite lesser increase in intracellular Ca
2+
 level in cells incubated in EBSS-Ca
2+
 (Figure 5.9 
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Figure ‎5.9: Effect of different media and removal of oxLDL on intracellular calcium 
and cell viability in U937 cells. 
U937 (0.5×10
6







C for 6 hours. OxLDL was removed and cells were incubated in 
fresh RPMI1640 media for 18 hours. A) shows the mean fluorescence intensity (MFI) (Fluo-3AM) 
measured by flow cytometry after 6 hours (10,000 events were collected in the gated area for analysis). 
B) shows cell viability measured via PI-flow cytometry after 18 hours. Data are expressed as MFI and 




) ± SEM of triplicate measurements from 
a representative experiment, respectively. A) Significance (two-way ANOVA, Sidak’s multiple test) 
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Figure ‎5.10: Effect of different media and removal of oxLDL on intracellular calcium 
and cell viability in human monocytes. 
Human monocytes (1×10
6







C for 6 hours. OxLDL was removed and cells were incubated in 
fresh RPMI1640 media for 18 hours. A) shows the mean fluorescence intensity (MFI) (Fluo-3AM) 
measured by flow cytometry after 6 hours (10,000 events were collected in the gated area for analysis). 
B) shows cell viability measured via PI-flow cytometry after 18 hours. Data are expressed as MFI and 




) ± SEM of triplicate measurements 
from a representative experiment, respectively. A) Significance (two-way ANOVA, Sidak’s multiple 
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Figure ‎5.11: Effect of different media and removal of oxLDL on intracellular calcium 
and cell viability in HMDM cells. 
HMDM cells (1×10
6







C for 6 hours. OxLDL was removed and cells were incubated in 
fresh RPMI1640 media for 18 hours. A) shows the mean fluorescence intensity (MFI) (Fluo-3AM) 
measured by flow cytometry after 6 hours (10,000 events were collected in the gated area for analysis). 
B) shows cell viability measured via PI-flow cytometry after 18 hours. Data are expressed as MFI and 




) ± SEM of triplicate measurements 
from a representative experiment, respectively. A) Significance (two-way ANOVA, Sidak’s multiple 
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Effects of calcium channels blockers and calcium chelators on oxLDL-
induced intracellular Ca
2+
, ROS generation and cell viability 
Results in the earlier part of this chapter have clearly demonstrated the ability of oxLDL to 
initiate an increase in intracellular Ca
2+
. In Chapter Four, it has been shown that oxLDL 
caused intracellular ROS production including in the mitochondria. It has also been shown in 
the same chapter that oxLDL activated NOX and increased NOX subunit p47
phox
 protein 
levels which may indicate NOX as a key source of intracellular oxidants (superoxide) 
mediated by oxLDL. Thus, it is suspected that these oxidants induced plasma membrane Ca
2+ 
channels, ryanodine receptors (RyRs) and inositol triphosphate receptors (IP3Rs) on the ER 
membrane to open via thiol alterations on the protein complex. This will then lead to Ca
2+ 
influx from the extracellular space and ER Ca
2+ 
release. The accumulation of Ca
2+ 
in the 




uniporter that will cause 
oxidative stress in the mitochondria. This results in series of events including calpain 
activation, opening of MPTP and loss of ΔΨm which will eventually lead to cell death. 
Studies have demonstrated the relation between Ca
2+
 levels and oxidative stress. It has been 
suggested that an increase in intracellular Ca
2+ 
caused an elevation in oxidative stress and 
vice versa (Sun et al., 2013). 
Therefore, further investigation will examine the effects of L-type and T-type Ca
2+ 
channel 
blockers, RyR blockers, sarcoplasmic/endoplasmic reticulum Ca
2+ 
ATPase (SERCA) blocker, 
and Ca
2+ 
chelators on intracellular Ca
2+
, ROS production and cell viability in U937 cells, 
human monocytes and HMDM cells. Various Ca
2+ 
channel blockers and Ca
2+ 
chelators are 





channel blockers); dantrolene (RyR blocker); thapsigargin (SERCA 
blocker) as well as EGTA and BAPTA-AM (Ca
2+
 chelators).  
Flunarizine and nifedipine are Ca
2+ 
channel blockers that block L-type VOCC. In U937 cells, 
with the addition of oxLDL, cells pre-treated with flunarizine appeared to be having less 
fluorescence compared to oxLDL only treated cells (Figure 5.12 A) which may indicate 
blockage of extracellular Ca
2+
 influx into the intracellular compartment. With the presence of 
oxLDL, fluorescence levels were also lower compared to oxLDL only treated cells. This 
suggests that flunarizine might be blocking the L-type channel but the blocking was not 
complete. Results of the similar trend as found with U937 cells were observed with human 
monocytes but with a lower concentration of flunarizine (10 µM) (Figure 5.12 B). As for 
163 
 
HMDM cells, there was no protection against increased level of intracellular Ca
2+
 observed 
(Figure 5.12 C).  
Compared to oxLDL treated cells, addition of oxLDL to 10 µM nifedipine pre-treated U937 
cells resulted in a slightly lower fluorescence. Lower fluorescence intensity was also seen in 
cells treated with 10 µM nifedipine only compared to control cells (Figure 5.13 A). Slight 
protection against oxLDL-induced intracellular Ca
2+
 increase was observed in human 
monocytes at nifedipine concentration of 10 µM but not 50 µM (Figure 5.13 B). In addition, 
there was also a slight decrease in fluorescence level in HMDM cells pre-treated with 10 µM 
nifedipine with the presence of oxLDL (Figure 5.13 C). Nifedipine alone, at 50 µM caused 
an increase in intracellular Ca
2+
 level in both human monocytes and HMDM cells. 
Another Ca
2+ 
channel blocker used in this study was verapamil which is the T-type VOCC 
blocker. In U937 cells, 10 µM verapamil demonstrated a significant protection against 
oxLDL-induced intracellular Ca
2+
 level increase (Figure 5.14 A). In human monocytes, pre-
treatment with 50 µM verapamil only resulted in a significant increase in cellular 
fluorescence compared to cell only control. With the presence of oxLDL, cells treated with 
both concentrations of verapamil exhibited higher fluorescence levels compared oxLDL only 
treated cells indicating increased intracellular Ca
2+
 influx (Figure 5.14 B). HMDM cells pre-
treated with verapamil had an increased in fluorescence intensity compared to cell only 
control. Likewise, with the presence of oxLDL, fluorescence intensity was greater in cells 
incubated with 50 µM verapamil compared to cells treated with oxLDL only (Figure 5.14 C). 
These results showed the involvement of extracellular Ca
2+
 influx and that all plasma 
membrane Ca
2+ 
channel blockers (flunarizine, nifedipine, verapamil) were unable to fully 
block Ca
2+ 
influx triggered by oxLDL into the cytosol. Another possibility could be that Ca
2+ 
diffused through the different type of VOCC i.e when T-type of VOCC is blocked, Ca
2+ 
influx through the L-type of VOCC could occur. Although a multiple blockade (combination 
of flunarizine, nifedipine and verapamil) was thought during this study, this was not done for 
several reasons. Firstly, there might be adverse reactions between them that could cause 
toxicity to the cells. For example, flunarizine alone caused an increase in intracellular ROS 
and was toxic to U937 cells (Figure 5.15 and 5.18). Additionally, previous study in this lab 
by Yang (2009) on HOCl-induced cytosolic Ca2+ increase had also tested the effects of these 
Ca
2+





rise could possibly be due to the involvement of Ca
2+
 sources which are insensitive to these 
inhibitors (Berthier et al., 2004). Deng et al. (2005) have suggested that cytosolic Ca
2+
 
increase could also occur via other non-specific pathway. It may also indicate that the insult 
caused by oxLDL is upstream to the blocking of Ca
2+ 
channels that it could have damaged to 
the Ca
2+ 
channels. This will be further detailed in the discussion section. 
Moreover, the protective effect of these Ca
2+ 
channel blockers might be cell specific that 
protection against oxLDL toxicity is offered in certain types of cells but not others. In this 
study, flunarizine alone was found to be cytotoxic to U937 cells but non-toxic to human 
monocytes and HMDM cells. Earlier studies by Negre-Salvayre and Salvayre (1992) have 
showed that nifedipine but not verapamil exhibited direct cytoprotective effect against 
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Figure ‎5.12: Effect of flunarizine (Flu) and oxLDL on intracellular calcium levels in U937, human monocytes and HMDM cells. 
U937 cells (0.5×10
6
 cells/mL), human monocytes (1×10
6
 cells/mL) or HMDM cells (1×10
6
 cells/mL) were pre-incubated with 1.5 µM Fluo 3AM for 40 
minutes, followed by treatment with 10 µM and 50 µM Flu for 30 minutes before incubation with LC50 concentration of oxLDL (0.5, 1.0, 1.5 mg/mL for 
U937, human monocytes and HMDM cells, respectively) at 37
o
C in RPMI1640 with no phenol red
 
for 3 hours. A), B) and C) show the mean fluorescence 
intensity measured by flow cytometry in U937 cells, human monocytes and HMDM cells, respectively (10,000 events were collected in the gated area for 
analysis). Results are displayed as mean fluorescence ± SEM of triplicates from a representative experiment. Significance (two-way ANOVA, Sidak’s 
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Figure ‎5.13: Effect of nifedipine (Nif) and oxLDL on intracellular calcium levels in U937, human monocytes and HMDM cells. 
U937 cells (0.5×10
6
 cells/mL), human monocytes (1×10
6
 cells/mL) or HMDM cells (1×10
6
 cells/mL) were pre-incubated with 1.5 µM Fluo-3 AM for 40 
minutes, followed by treatment with 10 µM and 50 µM Nif for 30 minutes before incubation with LC50 concentration of oxLDL (0.5, 1.0, 1.5 mg/mL for 
U937, human monocytes and HMDM cells, respectively) at 37
o
C in RPMI1640 with no phenol red
 
for 3 hours. A), B) and C) show the mean fluorescence 
intensity measured by flow cytometry in U937 cells, human monocytes and HMDM cells, respectively (10,000 events were collected in the gated area for 
analysis). Results are displayed as mean fluorescence ± SEM of triplicates from a representative experiment. Significance (two-way ANOVA, Sidak’s 
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Figure ‎5.14: Effect of verapamil (Ver) and oxLDL on intracellular calcium levels in U937, human monocytes and HMDM cells. 
U937 cells (0.5×10
6
 cells/mL), human monocytes (1×10
6
 cells/mL) or HMDM cells (1×10
6
 cells/mL) were pre-incubated with 1.5 µM Fluo-3 AM for 40 
minutes, followed by treatment with 10 µM and 50 µM Ver for 30 minutes before incubation with LC50 concentration of oxLDL (0.5, 1.0, 1.5 mg/mL for 
U937, human monocytes and HMDM cells, respectively) at 37
o
C in RPMI1640 with no phenol red for 3 hours. A), B) and C) show the mean fluorescence 
intensity measured by flow cytometry in U937 cells, human monocytes and HMDM cells, respectively (10,000 events were collected in the gated area for 
analysis). Results are displayed as mean fluorescence ± SEM of triplicates from a representative experiment. Significance (two-way ANOVA, Sidak’s 





Experiments were then carried out to examine the effects of flunarizine, nifedipine and 
verapamil on intracellular ROS production in U937, human monocytes and HMDM cells. 
Incubation with flunarizine only in U937 cells resulted in increased production of ROS 
compared to control and oxLDL treated cells. With the presence of oxLDL, intracellular ROS 
production was even greater than that observed in oxLDL only treated cells (Figure 5.15 A). 
As for human monocytes and HMDM cells, no protection against oxLDL-induced 
intracellular ROS production was observed with different concentrations of flunarizine 
(Figure 5.15 B and C).  
Increased in DHE fluorescence was observed in U937 cells pre-treated with nifedipine only 
compared to untreated cells (control). In the presence oxLDL, the fluorescence intensities 
were greater in nifedipine pre-treated cells compared to oxLDL treated cells especially at 50 
µM nifedipine (Figure 5.16 A). Similar reaction trend with nifedipine was seen in human 
monocytes (Figure 5.16 B) while no protection against oxLDL-induced intracellular ROS 
production was observed in HMDM cells (Figure 5.16 C). 
U937 cells pre-treated with verapamil exhibited higher DHE fluorescence compared to 
control cells. In the presence of oxLDL, no protection against oxLDL-induced ROS 
production was seen in cells pre-treated with verapamil (Figure 5.17 A). Likewise, similar 
trend of results were observed with human monocytes (Figure 5.17 B) whereas no protection 
against oxLDL-induced ROS generation was seen in HMDM cells. Moreover, 50 µM 
verapamil generated a greater DHE fluorescence in the presence of oxLDL compared to 
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Figure ‎5.15: Effect of flunarizine (Flu) and oxLDL on intracellular ROS levels in U937, human monocytes and HMDM cells. 
U937 cells (0.5×10
6
 cells/mL), human monocytes (1×10
6
 cells/mL) or HMDM cells (1×10
6
 cells/mL) were incubated with 10 µM and 50 µM flunarizine for 
30 minutes before incubation with LC50 concentration of oxLDL (0.5, 1.0, 1.5 mg/mL for U937, human monocytes and HMDM cells, respectively) at 37
o
C in 
RPMI1640 no phenol red for 6 hours. A), B) and C) show the mean fluorescence intensity measured by flow cytometry in U937 cells, human monocytes and 
HMDM cells, respectively. 10,000 events were collected in the gated area for analysis. Results are displayed as mean fluorescence ± SEM of triplicates from 
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Figure ‎5.16: Effect of nifedipine (Nif) and oxLDL on intracellular ROS levels in U937, human monocytes and HMDM cells. 
U937 cells (0.5×10
6
 cells/mL), human monocytes (1×10
6
 cells/mL) or HMDM cells (1×10
6
 cells/mL) were incubated with 10 µM and 50 µM nifedipine for 
30 minutes before incubation with LC50 concentration of oxLDL (0.5, 1.0, 1.5 mg/mL for U937, human monocytes and HMDM cells, respectively) at 37
o
C in 
RPMI1640 no phenol red for 6 hours. A), B) and C) show the mean fluorescence intensity measured by flow cytometry in U937 cells, human monocytes and 
HMDM cells, respectively. 10,000 events were collected in the gated area for analysis. Results are displayed as mean fluorescence ± SEM of triplicates from 




A) U937 cells 
 
B) Human monocytes 
 
C) HMDM cells 
 
















































6 0 0 0 0
1 2 0 0 0 0























































5 0 0 0 0
1 0 0 0 0 0
1 5 0 0 0 0
2 0 0 0 0 0






















































5 0 0 0 0
1 0 0 0 0 0
1 5 0 0 0 0
#
*
+  o x L D L
 
 
Figure ‎5.17: Effect of verapamil (Ver) and oxLDL on intracellular ROS levels in U937, human monocytes and HMDM cells. 
U937 cells (0.5×10
6
 cells/mL), human monocytes (1×10
6
 cells/mL) or HMDM cells (1×10
6
 cells/mL) were incubated with 10 µM and 50 µM verapamil for 
30 minutes before incubation with LC50 concentration of oxLDL (0.5, 1.0, 1.5 mg/mL for U937, human monocytes and HMDM cells, respectively) at 37
o
C in 
RPMI1640 no phenol red for 6 hours. A), B) and C) show the mean fluorescence intensity measured by flow cytometry in U937 cells, human monocytes and 
HMDM cells, respectively. 10,000 events were collected in the gated area for analysis. Results are displayed as mean fluorescence ± SEM of triplicates from 




The effect of flunarizine, nifedipine and verapamil on oxLDL-mediated cell death was 
examined. Flunarizine (L-type Ca
2+ 
channel blocker) alone was found to be cytotoxic to 
U937 cells and resulted in loss of cell viability (PI negative cells) of approximatlely 45% at 
high concentration (50 µM) (Figure 5.18). OxLDL itself caused cell viability loss (PI 
negative cells) by half compared to the control cells. Addition of oxLDL to 10 µM and 50 
µM flunarizine pre-treated cells has reduced cell viability (PI negative cells) to an average of 
44% and 34%, respectively while PI positive cells have also increased. On the other hand, 
flunarizine alone was not toxic to both human monocytes (Figure 5.19) and HMDM cells 
(Figure 5.20). However, flunarizine was also not protective against oxLDL-induced cell 
death for both types of cells. 
Another L-type Ca
2+ 
channel blocker used in this study was nifedipine. Contrary to 
flunarizine, nifedipine alone was not cytotoxic to U937 cells (Figure 5.21), human 
monocytes (Figure 5.22) and HMDM cells (Figure 5.23). When oxLDL was added to the 
nifedipine pre-treated cells, cell viability loss was observed in all cell types (decreased in PI 
negative cells and increased in PI positive cells). OxLDL has caused about 45% to 50% cell 
loss (PI negative cells) in all types of cells. In the presence of oxLDL, cell viability loss was 
also increased (decreased in PI negative cells) in cells pre-treated with nifedipine. This shows 
that nifedipine is not protecting the cells against oxLDL toxicity. 
Verapamil (T-type channel blocker) was also found not protective against oxLDL-induced 
cell death whereby the same trend of cell viability loss occurred in all types of cells. There 
was a significant cell loss of 40% to 50% in oxLDL only treated cells. Likewise, there was no 
protection against oxLDL-induced cytotoxicity seen in cells pre-treated with verapamil 
(Figure 5.24 and 5.25). In addition, oxLDL has further reduced cell viability (decrease in PI 
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Figure ‎5.18: Effect of flunarizine (Flu) and oxLDL on U937 cell viability. 
U937 cells (0.5×10
6
 cells/mL) were treated with different concentrations of flunarizine for 30 minutes 
followed by addition of LC50 concentration (0.5 mg/mL) of oxLDL and incubated at 37
o
C in non-
phenol red RPMI-1640 for 24 hours. A) Cells were viewed in situ in tissue culture wells using an 
inverted microscope (400x magnification) after 24 hours. Images were taken using a Leica C-Mount 
camera and processed using Leica Application Suite software. B) Cell viability was measured using 
PI-flow cytometry assay after 24 hours. Data are expressed as a percentage of the cell only control. 
Results are displayed as mean ± SEM of triplicates from a representative experiment. Significance 
(two-way ANOVA, Sidak’s multiple test) is indicated from: cell only control vs oxLDL and cell only 
control vs 50 µM Flu, ***, p<0.001 (PI negative cells), ^^^, p<0.001 (PI positive cells); oxLDL vs 50 
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Figure ‎5.19: Effect of flunarizine (Flu) and oxLDL on human monocytes viability. 
Human monocytes (1×10
6
 cells/mL) were treated with different concentrations of flunarizine for 30 
minutes followed by addition of LC50 concentration (1 mg/mL) of oxLDL and incubated at 37
o
C in 
non-phenol red RPMI-1640 for 24 hours. A) Cells were viewed in situ in tissue culture wells using an 
inverted microscope (400x magnification) after 24 hours. Images were taken using a Leica C-Mount 
camera and processed using Leica Application Suite software. B) Cell viability was measured using 
PI-flow cytometry assay after 24 hours. Data are expressed as a percentage of the cell only control. 
Results are displayed as mean ± SEM of triplicates from a representative experiment. Significance 
(two-way ANOVA, Sidak’s multiple test) is indicated from: cell only control vs oxLDL, ***, p<0.001 
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Figure ‎5.20: Effect of flunarizine (Flu) and oxLDL on HMDMs cell viability. 
HMDM cells (1×10
6
 cells/mL) were treated with different concentrations of flunarizine for 30 
minutes followed by addition of LC50 concentration (1.5 mg/mL) of oxLDL and incubated at 37
o
C in 
non-phenol red RPMI-1640 for 24 hours. A) Cells were viewed in situ in tissue culture wells using an 
inverted microscope (400x magnification) after 24 hours. Images were taken using a Leica C-Mount 
camera and processed using Leica Application Suite software. B) Cell viability was measured using 
PI-flow cytometry assay after 24 hours. Data are expressed as a percentage of the cell only control. 
Results are displayed as mean ± SEM of triplicates from a representative experiment. Significance 
(two-way ANOVA, Sidak’s multiple test) is indicated from: cell only control vs oxLDL, ***, p<0.001 
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Figure ‎5.21: Effect of nifedipine (Nif) and oxLDL on U937 cell viability. 
U937 cells (0.5×10
6
 cells/mL) were treated with different concentrations of nifedipine for 30 minutes 
followed by addition of LC50 concentration (0.5 mg/mL) of oxLDL and incubated at 37
o
C in non-
phenol red RPMI-1640 for 24 hours. A) Cells were viewed in situ in tissue culture wells using an 
inverted microscope (400x magnification) after 24 hours. Images were taken using a Leica C-Mount 
camera and processed using Leica Application Suite software. B) Cell viability was measured using 
PI-flow cytometry assay after 24 hours. Data are expressed as a percentage of the cell only control. 
Results are displayed as mean ± SEM of triplicates from a representative experiment. Significance 
(two-way ANOVA, Sidak’s multiple test) is indicated from: cell only control vs oxLDL, ***, p<0.001 
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Figure ‎5.22: Effect of nifedipine (Nif) and oxLDL on human monocytes viability. 
Human monocytes (1×10
6
 cells/mL) were treated with different concentrations of nifedipine for 30 
minutes followed by addition of LC50 concentration (1 mg/mL) of oxLDL and incubated at 37
o
C in 
non-phenol red RPMI-1640 for 24 hours. A) Cells were viewed in situ in tissue culture wells using an 
inverted microscope (400x magnification) after 24 hours. Images were taken using a Leica C-Mount 
camera and processed using Leica Application Suite software. B) Cell viability was measured using 
PI-flow cytometry assay after 24 hours. Data are expressed as a percentage of the cell only control. 
Results are displayed as mean ± SEM of triplicates from representative experiment. Significance 
(two-way ANOVA, Sidak’s multiple test) is indicated from: cell only control vs oxLDL, ***, p<0.001 
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Figure ‎5.23: Effect of nifedipine (Nif) and oxLDL on HMDMs cell viability. 
HMDM cells (1×10
6
 cells/mL) were treated with different concentrations of nifedipine for 30 minutes 
followed by addition of LC50 concentration (1.5 mg/mL) of oxLDL and incubated at 37
o
C in non-
phenol red RPMI-1640 for 24 hours. A) Cells were viewed in situ in tissue culture wells using an 
inverted microscope (400x magnification) after 24 hours. Images were taken using a Leica C-Mount 
camera and processed using Leica Application Suite software. B) Cell viability was measured using 
PI-flow cytometry assay after 24 hours. Data are expressed as a percentage of the cell only control. 
Results are displayed as mean ± SEM of triplicates from a representative experiment. Significance 
(two-way ANOVA, Sidak’s multiple test) is indicated from: cell only control vs oxLDL, ***, p<0.001 
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Figure ‎5.24: Effect of verapamil (Ver) and oxLDL on U937 cell viability. 
U937 cells (0.5×10
6
 cells/mL) were treated with different concentrations of verapamil for 30 minutes 
followed by addition of LC50 concentration (0.5 mg/mL) of oxLDL and incubated at 37
o
C in non-
phenol red RPMI-1640 for 24 hours. A) Cells were viewed in situ in tissue culture wells using an 
inverted microscope (400x magnification) after 24 hours. Images were taken using a Leica C-Mount 
camera and processed using Leica Application Suite software. B) Cell viability was measured using 
PI-flow cytometry assay after 24 hours. Data are expressed as a percentage of the cell only control. 
Results are displayed as mean ± SEM of triplicates from representative experiment. Significance 
(two-way ANOVA, Sidak’s multiple test) is indicated from: cell only control vs oxLDL, ***, p<0.001 
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Figure ‎5.25: Effects of verapamil (Ver) and oxLDL on human monocytes viability. 
Human monocytes (1×10
6
 cells/mL) were treated with different concentrations of verapamil for 30 
minutes followed by addition of LC50 concentration (1 mg/mL) of oxLDL and incubated at 37
o
C in 
non-phenol red RPMI-1640 for 24 hours. A) Cells were viewed in situ in tissue culture wells using an 
inverted microscope (400x magnification) after 24 hours. Images were taken using a Leica C-Mount 
camera and processed using Leica Application Suite software. B) Cell viability was measured using 
PI-flow cytometry assay after 24 hours. Data are expressed as a percentage of the cell only control. 
Results are displayed as mean ± SEM of triplicates from a representative experiment. Significance 
(two-way ANOVA, Sidak’s multiple test) is indicated from: cell only control vs oxLDL, ***, p<0.001 
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Figure ‎5.26: Effect of verapamil (Ver) and oxLDL on HMDMs cell viability. 
HMDM cells (1×10
6
 cells/mL) were treated with different concentrations of verapamil for 30 minutes 
followed by addition of LC50 concentration (1.5 mg/mL) of oxLDL and incubated at 37
o
C in non-
phenol red RPMI-1640 for 24 hours.A) Cells were viewed in situ in tissue culture wells using an 
inverted microscope (400x magnification) after 24 hours. Images were taken using a Leica C-Mount 
camera and processed using Leica Application Suite software. B) Cell viability was measured using 
PI-flow cytometry assay after 24 hours. Data are expressed as a percentage of the cell only control. 
Results are displayed as mean ± SEM of triplicates from a representative experiment. Significance 
(two-way ANOVA, Sidak’s multiple test) is indicated from: cell only control vs oxLDL, ***, p<0.001 




Dantrolene blocks ryanodine receptors (RyR) on ER, thus blocking Ca
2+ 
release into the 
cytoplasm from RyR channels (Zhao et al., 2001). In U937 cells, there was no significant 
difference in intracellular Ca
2+
 levels between control cells and dantrolene pre-treated cells. 
With the addition of oxLDL, intracellular Ca
2+
 level was raised in cells pre-treated with 10 
µM dantrolene (Figure 5.27 A). However, in human monocytes, intracellular Ca
2+
 increase 
mediated by oxLDL was significantly lowered in dantrolene pre-treated cells. Fluorescence 
intensity was also lower in cells pre-treated with dantrolene compared to control (Figure 5.27 
B). No protection against oxLDL-induced intracellular Ca
2+
 increase was observed in 
HMDM cells pre-treated with dantrolene. Greater fluorescence level compared to oxLDL was 
also seen in cells treated with 10 µM dantrolene compared with oxLDL only (Figure 5.27 C). 
Results showed that the influx of extracellular Ca
2+
 into the cytoplasm and Ca
2+
 could be 
released from the other channel on the ER i.e. IP3R that caused the overall increase in 
intracellular Ca
2+
 level in response to oxLDL.  
The contribution of intracellular Ca
2+
 to oxLDL-induced Ca
2+
 rise was determined by 
depleting intracellular Ca
2+
 ER store with thapsigargin. Sarco-endoplasmic reticulum calcium 
ATPase (SERCA) is a pump that returns Ca
2+
 from the cytoplasm to the ER. Thapsigargin 
selectively prevents Ca
2+
 binding to SERCA (Sagara et al., 1992) thus increases intracellular 
Ca
2+
 by inhibiting the sequestration of Ca
2+
 into ER. Figure 5.28 A, B and C show that 
stimulation with oxLDL caused a further increase in intracellular Ca
2+
 above that induced by 
thapsigargin. This suggests that extracellular Ca
2+ 
influx into the cells caused by oxLDL 
would otherwise be distributed into the ER (if no blockade by thapsigargin) and potentially 
overloads ER Ca
2+ 
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Figure ‎5.27: Effect of dantrolene (Dan) and oxLDL on intracellular calcium levels in U937, human monocytes and HMDM cells. 
U937 cells (0.5×10
6
 cells/mL), human monocytes (1×10
6
 cells/mL) or HMDM cells (1×10
6
 cells/mL) were pre-incubated with 1.5 µM Fluo-3 AM for 40 
minutes, followed by treatment with 5 µM and 10 µM Dan for 30 minutes before incubation with LC50 concentration of oxLDL (0.5, 1.0, 1.5 mg/mL for 
U937, human monocytes and HMDM cells, respectively) at 37
o
C in RPMI1640 with no phenol red for 3 hours. A), B) and C) show the mean fluorescence 
intensity measured by flow cytometry in U937 cells, human monocytes and HMDM cells, respectively (10,000 events were collected in the gated area for 
analysis). Results are displayed as mean fluorescence ± SEM of triplicates from a representative experiment. Significance (two-way ANOVA, Sidak’s 
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Figure ‎5.28: Effect of thapsigargin (Tg) and oxLDL on intracellular calcium levels in U937, human monocytes and HMDM cells. 
U937 cells (0.5×10
6
 cells/mL), human monocytes (1×10
6
 cells/mL) or HMDM cells (1×10
6
 cells/mL) were pre-incubated with 1.5 µM Fluo-3 AM for 40 
minutes, followed by treatment with 0.5 µM and 2 µM Tg for 30 minutes before incubation with LC50 concentration of oxLDL (0.5, 1.0, 1.5 mg/mL for U937, 
human monocytes and HMDM cells, respectively) at 37
o
C in RPMI1640 with no phenol red for 3 hours. A), B) and C) show the mean fluorescence intensity 
measured by flow cytometry in U937 cells, human monocytes and HMDM cells, respectively (10,000 events were collected in the gated area for analysis). 
Results are displayed as mean fluorescence ± SEM of triplicates from a representative experiment. Significance (two-way ANOVA, Sidak’s multiple test) is 





Intracellular ROS was determined in cells incubated with dantrolene. U937 cells incubated 
with dantrolene alone had a higher ROS level compared to cell only control. In response to 
oxLDL, a higher ROS level was also observed in cells incubated with dantrolene (Figure 
5.29 A). Almost similar trend of results were seen in human monocytes treated with 
dantrolene alone and with the presence of oxLDL (Figure 5.29 B). There was also no 
protection against oxLDL-induced ROS generation observed in HMDM cells pre-treated with 
dantrolene (Figure 5.29 C). 
The similar pattern of in DHE fluorescence increase was observed in thapsigargin treated 
U937, human monocytes and HMDM cells (Figure 5.30 A, B and C). Cells treated with 
thapsigargin exhibited greater DHE fluorescence compared to cell only control. Likewise, in 
response to oxLDL, thapsigargin treated cells also generated higher DHE fluorescence 
compared to oxLDL only treated cells. These results showed the relation between Ca
2+
 and 
ROS whereby the increase in intracellular Ca
2+
 levels correlates with the increase in 
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Figure ‎5.29: Effect of dantrolene (Dan) and oxLDL on intracellular ROS levels in U937, human monocytes and HMDM cells. 
U937 cells (0.5×10
6
 cells/mL), human monocytes (1×10
6
 cells/mL) or HMDM cells (1×10
6
 cells/mL) were incubated with 5 µM and 10 µM Dan for 30 
minutes before incubation with LC50 concentration of oxLDL (0.5, 1.0, 1.5 mg/mL for U937, human monocytes and HMDM cells, respectively) at 37
o
C in 
RPMI1640 no phenol red for 6 hours. A), B) and C) show the mean fluorescence intensity measured by flow cytometry in U937 cells, human monocytes and 
HMDM cells, respectively. 10,000 events were collected in the gated area for analysis. Results are displayed as mean fluorescence ± SEM of triplicates from 
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Figure ‎5.30: Effect of thapsigargin (Tg) and oxLDL on intracellular ROS levels in U937, human monocytes and HMDM cells. 
U937 cells (0.5×10
6
 cells/mL), human monocytes (1×10
6
 cells/mL) or HMDM cells (1×10
6
 cells/mL) were incubated with 0.5 µM and 2 µM Tg for 30 
minutes before incubation with LC50 concentration of oxLDL (0.5, 1.0, 1.5 mg/mL for U937, human monocytes and HMDM cells, respectively) at 37
o
C in 
RPMI1640 no phenol red for 6 hours. A), B) and C) show the mean fluorescence intensity measured by flow cytometry in U937 cells, human monocytes and 
HMDM cells, respectively. 10,000 events were collected in the gated area for analysis. Results are displayed as mean fluorescence ± SEM of triplicates from 




With regards to cell viability, oxLDL caused approximately 50% of cell viability loss (PI 
negative) in U937 cells. In the presence of oxLDL, approximately the same percentage of cell 
viability loss (PI negative) has been observed in cells pre-treated with dantrolene (Figure 
5.31). OxLDL caused cell viability loss by 45% in human monocytes yet dantrolene has no 
protective effect on oxLDL-induced cell death (Figure 5.32). Likewise, dantrolene was also 
not protective to HMDM cells against oxLDL-mediated cytotoxicity (Figure 5.33).  
Additionally, results showed that cell viability loss caused by oxLDL toxicity was not 
restored by thapsigargin. For U937 cells, an average of 48% of cell viability loss (PI negative 
cells) was observed in oxLDL treated cells. In the presence of oxLDL, there was a significant 
drop in cell viability percentage (PI negative cells) of cells pre-treated with thapsigargin. 
Similarly, this trend was also observed in human monocytes pre-treated with thapsigargin. 
Moreover, in thapsigargin treated cells, oxLDL had caused a further decrease in cell viability 
compared to control cells for both U937 cells and human monocytes (Figure 5.34 and 5.35). 
It was also noted that 2 µM thapsigargin alone had caused a significant loss in cell viability 
for human monocytes. In HMDM cells, thapsigargin was also not protective against oxLDL-
induced cell death. The percentage of cell viability loss in oxLDL-treated cells was similar to 
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Figure ‎5.31: Effects of dantrolene (Dan) and oxLDL on U937 cell viability. 
U937 cells (0.5×10
6
 cells/mL) were treated different concentrations of dantrolene for 30 minutes 
followed by addition of LC50 concentration (0.5 mg/mL) of oxLDL and incubated at 37
o
C in non-
phenol red RPMI-1640 for 24 hours. A) Cells were viewed in situ in tissue culture wells using an 
inverted microscope (400x magnification) after 24 hours. Images were taken using a Leica C-Mount 
camera and processed using Leica Application Suite software. B) Cell viability was measured using 
PI-flow cytometry assay after 24 hours. Data are expressed as a percentage of the cell only control. 
Results are displayed as mean ± SEM of triplicates from a representative experiment. Significance 
(two-way ANOVA, Sidak’s multiple test) is indicated from: cell only control vs oxLDL, ***, p<0.001 
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Figure ‎5.32: Effect of dantrolene (Dan) and oxLDL on human monocytes viability. 
Human monocytes (1×10
6
 cells/mL) were treated with different concentrations of dantrolene for 30 
minutes followed by addition of LC50 concentration (1 mg/mL) of oxLDL and incubated at 37
o
C in 
non-phenol red RPMI-1640 for 24 hours.A) Cells were viewed in situ in tissue culture wells using an 
inverted microscope (400x magnification) after 24 hours. Images were taken using a Leica C-Mount 
camera and processed using Leica Application Suite software. B) Cell viability was measured using 
PI-flow cytometry assay after 24 hours. Data are expressed as a percentage of the cell only control. 
Results are displayed as mean ± SEM of triplicates from a representative experiment. Significance 
(two-way ANOVA, Sidak’s multiple test) is indicated from: cell only control vs oxLDL, ***, p<0.001 
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Figure ‎5.33: Effect of dantrolene (Dan) and oxLDL on HMDM cell viability. 
HMDM cells (1×10
6
 cells/mL) were treated with different concentrations of dantrolene for 30 minutes 
followed by addition of LC50 concentration (1.5 mg/mL) of oxLDL and incubated at 37
o
C in non-
phenol red RPMI-1640 for 24 hours.A) Cells were viewed in situ in tissue culture wells using an 
inverted microscope (400x magnification) after 24 hours. Images were taken using a Leica C-Mount 
camera and processed using Leica Application Suite software. B) Cell viability was measured using 
PI-flow cytometry assay after 24 hours. Data are expressed as a percentage of the cell only control. 
Results are displayed as mean ± SEM of triplicates from a representative experiment. Significance 
(two-way ANOVA, Sidak’s multiple test) is indicated from: cell only control vs oxLDL, ***, p<0.001 
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Figure ‎5.34: Effect of thapsigargin (Tg) and oxLDL on U937 cell viability. 
U937 cells (0.5×10
6
 cells/mL) were treated with different concentrations of thapsigargin for 30 
minutes followed by addition of LC50 concentration (0.5 mg/mL) of oxLDL and incubated at 37
o
C in 
non-phenol red RPMI-1640 for 24 hours. A) Cells were viewed in situ in tissue culture wells using an 
inverted microscope (400x magnification) after 24 hours. Images were taken using a Leica C-Mount 
camera and processed using Leica Application Suite software. B) Cell viability was measured using 
PI-flow cytometry assay after 24 hours. Data are expressed as a percentage of the cell only control. 
Results are displayed as mean ± SEM of triplicates from a representative experiment. Significance 
(two-way ANOVA, Sidak’s multiple test) is indicated from: cell only control vs oxLDL, ***, p<0.001 
(PI negative cells), ^^^, p<0.001 (PI positive cells); oxLDL vs 0.5 µM Tg + oxLDL, #, p<0.05 (PI 




   
Control 0.5 µM Tg 2 µM Tg 
   













































P I  N e g a t iv e P I  P o s it iv e







Figure ‎5.35: Effect of thapsigargin (Tg) and oxLDL on human monocytes viability. 
Human monocytes (1×10
6
 cells/mL) were treated with different concentrations of thapsigargin for 30 
minutes followed by addition of LC50 concentration (1 mg/mL) of oxLDL and incubated at 37
o
C in 
non-phenol red RPMI-1640 for 24 hours. A) Cells were viewed in situ in tissue culture wells using an 
inverted microscope (400x magnification) after 24 hours. Images were taken using a Leica C-Mount 
camera and processed using Leica Application Suite software. B) Cell viability was measured using 
PI-flow cytometry assay after 24 hours. Data are expressed as a percentage of the cell only control. 
Results are displayed as mean ± SEM of triplicates from a representative experiment. Significance 
(two-way ANOVA, Sidak’s multiple test) is indicated from: cell only control vs oxLDL, ***, p<0.001 
(PI negative cells), ^^^, p<0.001 (PI positive cells); oxLDL vs 0.5 µM Tg + oxLDL, #, p<0.05 (PI 
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Figure ‎5.36: Effects of thapsigargin (Tg) and oxLDL on HMDM cell viability. 
HMDM cells (1×10
6
 cells/mL) were treated with different concentrations of thapsigargin for 30 
minutes followed by addition of LC50 concentration (1.5 mg/mL) of oxLDL and incubated at 37
o
C in 
non-phenol red RPMI-1640 for 24 hours.A) Cells were viewed in situ in tissue culture wells using an 
inverted microscope (400x magnification) after 24 hours. Images were taken using a Leica C-Mount 
camera and processed using Leica Application Suite software. B) Cell viability was measured using 
PI-flow cytometry assay after 24 hours. Data are expressed as a percentage of the cell only control. 
Results are displayed as mean ± SEM of triplicates from a representative experiment. Significance 
(two-way ANOVA, Sidak’s multiple test) is indicated from: cell only control vs oxLDL, ***, p<0.001 
(PI negative cells), ^^^, p<0.001 (PI positive cells). 
195 
 
Next, the effect of Ca
2+
 chelators i.e. BAPTA-AM and EGTA were also examined. BAPTA-
AM is a cell permeable Ca
2+ 
chelator which is widely used as the intracellular Ca
2+
 ‘sponge’. 
In U937 cells, pre-incubation with BAPTA-AM reduced intracellular Ca
2+
 level by 50% in 
the presence of oxLDL compared to oxLDL treated cells (Figure 5.37 A). Likewise, in 
response to oxLDL, human monocytes and HMDM cells pre-treated with BAPTA-AM had a 
decrease in intracellular Ca
2+
 by almost 
2
/3 of that induced by oxLDL (Figure 5.37 B and C). 
This indicates that while BAPTA-AM has chelated the intracellular Ca
2+
 yet extracellular 
Ca
2+
 influx still occur in response to oxLDL. 
Incubation with EGTA resulted in the decrease of intracellular Ca
2+
 in all cell types. 
Intracellular Ca
2+
 levels in cells treated with EGTA was lower compared to control only cells. 
With the presence of oxLDL, lower intracellular Ca
2+
 levels were observed in EGTA treated 
cells compared to oxLDL treated cells (Figure 5.38 A, B and C). This shows that Ca
2+
 
chelation with EGTA has completely blocked intracellular Ca
2+
 rise induced by oxLDL. 
Intracellular ROS was measured to examine the effect of Ca
2+
 chelation with EGTA. Results 
showed a significant reduction of DHE fluorescence which indicates a decrease in 
intracellular ROS. However, intracellular ROS generation was not prevented or reduced to 
the same degree as intracellular Ca
2+
. EGTA could not suppress intracellular ROS production 
to the basal level compared to control cells (Figure 5.39 A, B and C). Therefore, these results 
suggest that other Ca
2+
-independent signalling pathway/mechanism might be involved in 
generating ROS in response to oxLDL insult. This observation is in agreement with the 
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Figure ‎5.37: Effect of BAPTA-AM and oxLDL on intracellular calcium levels in U937, human monocytes and HMDM cells. 
U937 cells (0.5×10
6
 cells/mL), human monocytes (1×10
6
 cells/mL) or HMDM cells (1×10
6
 cells/mL) were pre-incubated with 1.5 µM Fluo-3 AM for 40 
minutes, followed by treatment with 5 µM and 10 µM BAPTA-AM for 30 minutes before incubation with LC50 concentration of oxLDL (0.5, 1.0, 1.5 mg/mL 
for U937, human monocytes and HMDM cells, respectively) at 37
o
C in RPMI1640 with no phenol red for 3 hours. A), B) and C) show the mean fluorescence 
intensity measured by flow cytometry in U937 cells, human monocytes and HMDM cells, respectively (10,000 events were collected in the gated area for 
analysis). Results are displayed as mean fluorescence ± SEM of triplicates from a representative experiment. Significance (two-way ANOVA, Sidak’s 
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Figure ‎5.38: Effect of EGTA and oxLDL on intracellular calcium levels in U937, human monocytes and HMDM cells. 
U937 cells (0.5×10
6
 cells/mL), human monocytes (1×10
6
 cells/mL) or HMDM cells (1×10
6
 cells/mL) were pre-incubated with 1.5 µM Fluo-3 AM for 40 
minutes, followed by treatment with 1 mM EGTA for 30 minutes before incubation with LC50 concentration of oxLDL (0.5, 1.0, 1.5 mg/mL for U937, human 
monocytes and HMDM cells, respectively) at 37
o
C in RPMI1640 with no phenol red for 3 hours. A), B) and C) show the mean fluorescence intensity 
measured by flow cytometry in U937 cells, human monocytes and HMDM cells, respectively (10,000 events were collected in the gated area for analysis). 
Results are displayed as mean fluorescence ± SEM of triplicates from a representative experiment. Significance (two-way ANOVA, Sidak’s multiple test) is 




A) U937 cells 
 
B) Human monocytes 
 
C) HMDM cells 
 









































2 0 0 0 0
4 0 0 0 0
6 0 0 0 0
8 0 0 0 0
1 0 0 0 0 0














































1 0 0 0 0
2 0 0 0 0
3 0 0 0 0 # # #
+  o x L D L
*
 









































5 0 0 0
1 0 0 0 0
1 5 0 0 0
2 0 0 0 0




Figure ‎5.39: Effect of EGTA and oxLDL on intracellular ROS levels in U937, human monocytes and HMDM cells. 
U937 cells (0.5×10
6
 cells/mL), human monocytes (1×10
6
 cells/mL) or HMDM cells (1×10
6
 cells/mL) were incubated with 1 mM EGTA for 30 minutes 
before incubation with LC50 concentration of oxLDL (0.5, 1.0, 1.5 mg/mL for U937, human monocytes and HMDM cells, respectively) at 37
o
C in RPMI1640 
no phenol red for 6 hours. A), B) and C) show the mean fluorescence intensity measured by flow cytometry in U937 cells, human monocytes and HMDM 
cells, respectively. 10,000 events were collected in the gated area for analysis. Results are displayed as mean fluorescence ± SEM of triplicates from a single 




Preliminary experiments carried out by incubating BAPTA-AM alone with all three types of 
cells showed an increase in cell viability loss at high concentrations (5 to 20 µM). Cell 
viability loss was worsened with the addition of oxLDL. For U937 cells, oxLDL caused cell 
viability loss (PI negative cells) of close to 50% compared to control. With the addition of 
oxLDL, the percentage of cell viability loss for BAPTA-AM pre-treated cells was similar to 
the oxLDL only treated cells (Figure 5.40). For human monocytes, oxLDL cytotoxicity 
resulted in 45% of cell viability loss (PI negative cells) in oxLDL only treated cells compared 
to control. The percentage of cell viability loss (PI negative cells) was slightly higher but not 
significant when oxLDL was added to the BAPTA-AM pre-treated cells (Figure 5.41). Cell 
viability loss mediated by oxLDL in HMDM cells was approximately 35% compared to 
control cells (PI negative cells). Likewise, there was no difference in cell viability loss 
observed with BAPTA-AM pre-treated cells in the presence of oxLDL compared to oxLDL 
only treated cells (Figure 5.42). These result showed that BAPTA-AM was not protective 
against oxLDL-induced cell death despite its ability to reduce intracellular Ca
2+
 levels. 
EGTA is a general Ca
2+ 
chelator used in this study. In the previous study by Yang (2009), 1 
mM EGTA has been shown to preserve cell viability of HMDM cells exposed to 150 µM 
HOCl (by MTT reduction assay). Results from the present study showed that oxLDL 
cytotoxicity was not prevented with the chelation of Ca
2+
. Approximately, 40 to 50% of cell 
viability loss (PI negative cells) has been measured in cells treated with oxLDL compared to 
control cells (Figure 5.43, 5.44 and 5.45). Chelation of Ca
2+ 
by EGTA did not convey any 
protection against oxLDL toxicity as the percentage of cell viability loss remained 
approximately similar when oxLDL was added to cells pre-treated with EGTA compared to 





   
Control 1 µM BAPTA-AM 2 µM BAPTA-AM 
   
oxLDL 1 µM BAPTA-AM 
+ oxLDL 










































P I  N e g a t iv e P I  P o s it iv e




Figure ‎5.40: Effect of BAPTA-AM and oxLDL on U937 cell viability. 
U937 cells (0.5×10
6
 cells/mL) were treated with different concentrations of BAPTA-AM for 30 
minutes followed by addition of LC50 concentration (0.5 mg/mL) of oxLDL and incubated at 37
o
C in 
non-phenol red RPMI-1640 for 24 hours. A) Cells were viewed in situ in tissue culture wells using an 
inverted microscope (400x magnification) after 24 hours. Images were taken using a Leica C-Mount 
camera and processed using Leica Application Suite software. B) Cell viability was measured using 
PI-flow cytometry assay after 24 hours. Data are expressed as a percentage of the cell only control. 
Results are displayed as mean ± SEM of triplicates from a representative experiment. Significance 
(two-way ANOVA, Sidak’s multiple test) is indicated from: cell only control vs oxLDL, ***, p<0.001 
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Figure ‎5.41: Effect of BAPTA-AM and oxLDL on human monocytes viability. 
Human monocytes (1×10
6
 cells/mL) were treated with different concentrations of BAPTA-AM for 30 
minutes followed by addition of LC50 concentration (1 mg/mL) of oxLDL and incubated at 37
o
C in 
non-phenol red RPMI-1640 for 24 hours. A) Cells were viewed in situ in tissue culture wells using an 
inverted microscope (400x magnification) after 24 hours. Images were taken using a Leica C-Mount 
camera and processed using Leica Application Suite software. B) Cell viability was measured using 
PI-flow cytometry assay after 24 hours. Data are expressed as a percentage of the cell only control. 
Results are displayed as mean ± SEM of triplicates from a representative experiment. Significance 
(two-way ANOVA, Sidak’s multiple test) is indicated from: cell only control vs oxLDL, ***, p<0.001 
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Figure ‎5.42: Effect of BAPTA-AM and oxLDL on HMDM cell viability. 
HMDM cells (1×10
6
 cells/mL) were treated with different concentrations of BAPTA-AM for 30 
minutes followed by addition of LC50 concentration (1.5 mg/mL) of oxLDL and incubated at 37
o
C in 
non-phenol red RPMI-1640 for 24 hours. A) Cells were viewed in situ in tissue culture wells using an 
inverted microscope (400x magnification) after 24 hours. Images were taken using a Leica C-Mount 
camera and processed using Leica Application Suite software. B) Cell viability was measured using 
PI-flow cytometry assay after 24 hours. Data are expressed as a percentage of the cell only control. 
Results are displayed as mean ± SEM of triplicates from a representative experiment. Significance 
(two-way ANOVA, Sidak’s multiple test) is indicated from: cell only control vs oxLDL, ***, p<0.001 
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Figure ‎5.43: Effect of EGTA and oxLDL on U937 cell viability. 
U937 cells (0.5×10
6
 cells/mL) were treated with 1 mM EGTA for 30 minutes followed by addition of 
LC50 concentration (0.5 mg/mL) of oxLDL and incubated at 37
o
C in non-phenol red RPMI-1640 for 
24 hours. A) Cells were viewed in situ in tissue culture wells using an inverted microscope (400x 
magnification) after 24 hours. Images were taken using a Leica C-Mount camera and processed using 
Leica Application Suite software. B) Cell viability was measured using PI-flow cytometry assay after 
24 hours. Data are expressed as a percentage of the cell only control. Results are displayed as mean ± 
SEM of triplicates from a representative experiment. Significance (two-way ANOVA, Sidak’s 
multiple test) is indicated from: cell only control vs oxLDL, ***, p<0.001 (PI negative cells), ^^^, 
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Figure ‎5.44: Effect of EGTA and oxLDL on human monocytes viability. 
Human monocytes (1×106 cells/mL) were treated with 1 mM EGTA for 30 minutes followed by 
addition of LC50 concentration (1 mg/mL) of oxLDL and incubated at 37oC in non-phenol red 
RPMI-1640 for 24 hours. A) Cells were viewed in situ in tissue culture wells using an inverted 
microscope (400x magnification) after 24 hours. Images were taken using a Leica C-Mount camera 
and processed using Leica Application Suite software. B) Cell viability was measured using PI-flow 
cytometry assay after 24 hours. Data are expressed as a percentage of the cell only control. Results are 
displayed as mean ± SEM of triplicates from representative experiment. Significance (two-way 
ANOVA, Sidak’s multiple test) is indicated from: cell only control vs oxLDL, ***, p<0.001 (PI 
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Figure ‎5.45: Effect of EGTA and oxLDL on HMDMs cell viability. 
HMDM cells (1×10
6
 cells/mL) were treated with 1 mM EGTA for 30 minutes followed by addition of 
LC50 concentration (1.5 mg/mL) of oxLDL and incubated at 37
o
C in non-phenol red RPMI-1640 for 
24 hours.A) Cells were viewed in situ in tissue culture wells using an inverted microscope (400x 
magnification) after 24 hours. Images were taken using a Leica C-Mount camera and processed using 
Leica Application Suite software. B) Cell viability was measured using PI-flow cytometry assay after 
24 hours. Data are expressed as a percentage of the cell only control. Results are displayed as mean ± 
SEM of triplicates from a representative experiment. Significance (two-way ANOVA, Sidak’s 
multiple test) is indicated from: cell only control vs oxLDL, ***, p<0.001 (PI negative cells), ^^^, 
p<0.001 (PI positive cells). 
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Effect of oxLDL on MPT activation and mitochondrial membrane 
potential (ΔΨm) 
Studies by Yang (2009) in this lab have showed that HOCl caused the polarisation of 
mitochondrial membrane potential (ΔΨm) in HMDM cells. The effect is concentration 
dependent and ΔΨm loss was followed by cell viability loss. To study the effect of oxLDL on 
mitochondria, cells were tested for ΔΨm loss using tetramethyrhodamine methyl ester 
(TMRM). TMRM is a potentiometric, cell-permeable fluorescent indicator that accumulates 
in the highly negatively charged interior of mitochondria. In order to avoid auto-quenching of 
mitochondrial TMRM, low concentration of TMRM should be used. The fluorescence signal 
of TMRM can be directly correlated to ΔΨm across the inner mitochondrial membrane 
(IMM) whereby a loss of ΔΨm causes TMRM to leak from mitochondria resulting in a loss 
of fluorescence intensity (Joshi & Bakowska, 2011). Results showed that oxLDL caused a 
time-dependent ΔΨm loss in U937, human monocytes and HMDM cells (Figure 5.46 A, B 
and C). This suggests that there may be an interaction between Ca
2+
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Figure ‎5.46: Effect of oxLDL on mitochondrial membrane potential in U937, human monocytes and HMDM cells. 
U937 cells (0.5×10
6
 cells/mL), human monocytes (1×10
6
 cells/mL) or HMDM cells (1×10
6
 cells/mL) were incubated with 100 nM TMRM for 30 minutes 
and washed before incubation with LC50 concentration of oxLDL (0.5, 1.0, 1.5 mg/mL for U937, human monocytes and HMDM cells, respectively) at 37
o
C 
in RPMI1640 no phenol red. Cell samples were taken at the designated time and TMRM fluorescence was measured using flow cytometry. A), B) and C) 
show the mean fluorescence intensity measured by flow cytometry in U937 cells, human monocytes and HMDM cells, respectively (10,000 events were 
collected in the gated area for analysis). Results are displayed as mean fluorescence ± SEM of triplicates from a representative experiment. Significance (two-
way ANOVA, Sidak’s multiple test) is indicated from the 1 hour sample, *, p<0.05, **, p<0.01, ***, p<0.001. 
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Ruthenium red is a mitochondrial uniporter (MCU) inhibitor. It was used in this study to 
examine the effects of blocking Ca
2+ 
from being taken up into the mitochondria. Results 
showed statistically significant protection by ruthenium red against oxLDL cytotoxicity in all 
type of cells (increased in PI negative cells) whereby treatment with oxLDL has resulted in a 
reduction of cell viability (PI negative cells) of 40 to 50% compared to control cells. Cell 
viability increased in ruthenium red pre-treated cells was about 20% compared to oxLDL 
treated cells (Figure 5.47, 5.48 and 5.49).  
In addition, ruthenium red was able to reduce DHE levels in oxLDL treated cells which 
indicates a reduction in intracellular ROS generation (Figure 5.50). Taken together, these 
results suggest that blocking Ca
2+
 uptake into the mitochondria could reduce intracellular 
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Figure ‎5.47: Effect of ruthenium red (RuR) and oxLDL on U937 cell viability. 
U937 cells (0.5×10
6
 cells/mL) were treated with different concentrations of ruthenium red for 30 
minutes followed by addition of LC50 concentration (0.5 mg/mL) of oxLDL and incubated at 37
o
C in 
non-phenol red RPMI-1640 for 24 hours. A) Cells were viewed in situ in tissue culture wells using an 
inverted microscope (400x magnification) after 24 hours. Images were taken using a Leica C-Mount 
camera and processed using Leica Application Suite software. B) Cell viability was measured using 
PI-flow cytometry assay after 24 hours. Results are displayed as mean ± SEM of triplicates from a 
representative experiment. Significance (two-way ANOVA, Sidak’s post test) is indicated from: cell 
only control vs oxLDL, ***, p<0.001 (PI negative cells), ^^^, p<0.001 (PI positive cells); oxLDL vs 5 
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Figure ‎5.48: Effect of ruthenium red (RuR) and oxLDL on human monocytes viability. 
Human monocytes (1×10
6
 cells/mL) were treated with different concentrations of ruthenium red for 
30 minutes followed by addition of LC50 concentration (1 mg/mL) of oxLDL and incubated at 37
o
C in 
non-phenol red RPMI-1640 for 24 hours. A) Cells were viewed in situ in tissue culture wells using an 
inverted microscope (400x magnification) after 24 hours. Images were taken using a Leica C-Mount 
camera and processed using Leica Application Suite software. B) Cell viability was measured using 
PI-flow cytometry assay after 24 hours. Data are expressed as a percentage of the cell only control. 
Results are displayed as mean ± SEM of triplicates from a representative experiment. Significance 
(two-way ANOVA, Sidak’s post test) is indicated from: cell only control vs oxLDL, ***, p<0.001 (PI 
negative cells), ^^^, p<0.001 (PI positive cells); oxLDL vs 5 µM + oxLDL and oxLDL vs 10 µM RuR 
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Figure ‎5.49: Effect of ruthenium red (RuR) and oxLDL on HMDM cell viability.  
HMDM cells (1×10
6
 cells/mL) were treated with different concentrations of ruthenium red for 30 
minutes followed by addition of LC50 concentration (1.5 mg/mL) of oxLDL and incubated at 37
o
C in 
non-phenol red RPMI-1640 for 24 hours. A) Cells were viewed in situ in tissue culture wells using an 
inverted microscope (400x magnification) after 24 hours. Images were taken using a Leica C-Mount 
camera and processed using Leica Application Suite software. B) Cell viability was measured using 
PI-flow cytometry assay after 24 hours. Data are expressed as a percentage of the cell only control. 
Results are displayed as mean ± SEM of triplicates from a representative experiment. Significance 
(two-way ANOVA, Sidak’s post test) is indicated from: cell only control vs oxLDL, ***, p<0.001 (PI 
negative cells), ^^^, p<0.001 (PI positive cells); oxLDL vs 5 µM + oxLDL and oxLDL vs 10 µM RuR 
+ oxLDL, ###, p<0.001 (PI negative cells), @, p<0.05 (PI positive cells). 
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Figure ‎5.50: Effect of ruthenium red (RuR) and oxLDL on intracellular ROS levels in U937, human monocytes and HMDM cells. 
U937 cells (0.5×10
6
 cells/mL), human monocytes (1×10
6
 cells/mL) or HMDM cells (1×10
6
 cells/mL) were incubated with 5 µM and 10 µM ruthenium red for 
30 minutes before incubation with LC50 concentration of oxLDL (0.5, 1 and 1.5 mg/mL for U937, human monocytes and HMDM cells, respectively) at 37
o
C 
in RPMI1640 no phenol red for 6 hours. A), B) and C) show the mean fluorescence intensity measured by flow cytometry in U937 cells, human monocytes 
and HMDM cells, respectively. 10,000 events were collected in the gated area for analysis. Results are displayed as mean fluorescence ± SEM of triplicates 
from a representative experiment. Significance (two-way ANOVA, Sidak’s post test) is indicated from: cell only control vs oxLDL, #, p<0.05, ##, p<0.01; 




Cyclosporin A (CsA) has been shown by Yang (2009) to inhibit HOCl-induced ΔΨm and cell 
viability loss of HMDM cells by inhibiting MPTP formation. Additionally, CsA also 
protected HMDM cells againts lysosomal destabilization mediated by HOCl. Experiments 
were carried out to investigate the effect of CsA with and without oxLDL on cell viability. 
Results showed an increase in cell viability loss (decreased PI negative cells) in U937 cells 
pre-treated with CsA compared to control cells whereby 20% cell loss happened in cells pre-
treated with 10 µM CsA (Figure 5.51). With the presence of oxLDL, further reduction in cell 
viability of 8 to 10% compared to oxLDL treated cells was observed in cells pre-treated with 
5 µM and 10 µM CsA, respectively. For human monocytes, CsA was also found not 
protective against oxLDL toxicity (Figure 5.52). Pre-treatment of cells with CsA did not help 
in preserving cell viability as the percentage of cell viability loss (PI negative cells) obtained 
from oxLDL only treated cells was approximately similar with CsA treated cells in the 
presence of oxLDL. Moreover, incubation with CsA alone caused a slight reduction in cell 
viability but was not statistically significant. Surprisingly, CsA showed some protection to 
HMDM cells against oxLDL insult. OxLDL caused cell viability loss (PI negative cells) of 
approximately 40%, whilst 20-25% of cell viability loss (PI negative cells) was recovered in 
cells treated with CsA in the presence of oxLDL (Figure 5.53). 
Experiments were also conducted to examine the effects of CsA on intracellular ROS 
production and to find out why CsA was not protecting U937 cells and human monocytes 
form oxLDL cytotoxicity. Results showed that CsA alone caused an increase in DHE 
fluorescence levels in both U937 cells and human monocytes (Figure 5.54 A and Figure 
5.54 B) but not in HMDM cells (Figure 5.54 C), thus indicating an elevated production of 
ROS in U937 cells and human monocytes. This finding is in agreement with de Hornedo et al. 
(2007) who found that CsA induced oxidative stress and mitochondrial dysfunction in renal 
tubular cells. In conjunction, CsA had also caused endothelial dysfunction by elevating 
superoxide generation (Diederich et al., 1994). In this study, CsA protects HMDM cells from 
oxLDL-induced cell viability loss. This therefore may indicate the importance of 
mitochondria in cell death as CsA is an agent known to prevent MPT activation but it is 
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Figure ‎5.51: Effect cyclosporin A (CsA) and oxLDL on U937 cell viability. 
U937 cells (0.5×10
6
 cells/mL) were treated with different concentrations of cyclosporin A for 30 
minutes followed by addition of LC50 concentration (0.5 mg/mL) of oxLDL and incubated at 37
o
C in 
non-phenol red RPMI-1640 for 24 hours. A) Cells were viewed in situ in tissue culture wells using an 
inverted microscope (400x magnification) after 24 hours. Images were taken using a Leica C-Mount 
camera and processed using Leica Application Suite software. B) Cell viability was measured using 
PI-flow cytometry assay after 24 hours. Data are expressed as a percentage of the cell only control. 
Results are displayed as mean ± SEM of triplicates from a representative experiment. Significance 
(two-way ANOVA, Sidak’s post test) is indicated from: cell only control vs oxLDL, ***, p<0.001 (PI 
negative cells), ^^^, p<0.001 (PI positive cells); cell only control vs 5 µM CsA, ***, p<0.001 (PI 
negative cells); oxLDL vs 5 µM CsA + oxLDL and oxLDL vs 10 µM RuR + oxLDL, #, p<0.05, ##, 
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Figure ‎5.52: Effect cyclosporin A (CsA) and oxLDL on human monocytes cell viability. 
Human monocytes (1×10
6
 cells/mL) were treated with different concentrations of cyclosporin A for 
30 minutes followed by addition of LC50 concentration (1 mg/mL) of oxLDL and incubated at 37
o
C in 
non-phenol red RPMI-1640 for 24 hours. A) Cells were viewed in situ in tissue culture wells using an 
inverted microscope (400x magnification) after 24 hours. Images were taken using a Leica C-Mount 
camera and processed using Leica Application Suite software. B) Cell viability was measured using 
PI-flow cytometry assay after 24 hours. Data are expressed as a percentage of the cell only control. 
Results are displayed as mean ± SEM of triplicates from a representative experiment. Significance 
(two-way ANOVA, Sidak’s post test) is indicated from: cell only control vs oxLDL, ***, p<0.001 (PI 
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Figure ‎5.53: Effect of cyclosporin A (CsA) and oxLDL on HMDM cell viability. 
HMDM cells (1×10
6
 cells/mL) were treated with different concentrations of cyclosporin A for 30 
minutes followed by addition of LC50 concentration (1.5 mg/mL) of oxLDL and incubated at 37
o
C in 
non-phenol red RPMI-1640 for 24 hours. A) Cells were viewed in situ in tissue culture wells using an 
inverted microscope (400x magnification) after 24 hours. Images were taken using a Leica C-Mount 
camera and processed using Leica Application Suite software. B) Cell viability was measured using 
PI-flow cytometry assay after 24 hours. Data are expressed as a percentage of the cell only control. 
Results are displayed as mean ± SEM of triplicates from a representative experiment. Significance 
(two-way ANOVA, Sidak’s post test) is indicated from: cell only control vs oxLDL, ***, p<0.001 (PI 
negative cells), ^^^, p<0.001 (PI positive cells); oxLDL vs 5 µM CsA + oxLDL and oxLDL vs 10 µM 
RuR + oxLDL, ###, p<0.001 (PI negative cells).  
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Figure ‎5.54: Effect of cyclosporin A (CsA) and oxLDL on intracellular ROS levels in U937, human monocytes and HMDM cells. 
U937 cells (0.5×10
6
 cells/mL), human monocytes (1×10
6
 cells/mL) or HMDM cells (1×10
6
 cells/mL) were incubated with 5 µM and 10 µM cyclosporin A for 
30 minutes before incubation with LC50 concentration of oxLDL (0.5, 1 and 1.5 mg/mL for U937, human monocytes and HMDM cells) at 37
o
C in RPMI1640 
no phenol red for 6 hours. A), B) and C) show the mean fluorescence intensity measured by flow cytometry in U937 cells, human monocytes and HMDM 
cells, respectively. 10,000 events were collected in the gated area for analysis. Results are displayed as mean fluorescence ± SEM of triplicates from a 
representative experiment. Significance (two-way ANOVA, Sidak’s post test) is indicated from: cell only control vs oxLDL, #, p<0.05, ##, p<0.01; cell only 
control vs CsA, @, p<0.05, @@, p<0.01; oxLDL vs CsA + oxLDL, *, p<0.05, **, p<0.01, ***, p<0.001. 
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Effects of BrA and oxLDL on intracellular Ca
2+
 levels, ROS production 
and cell viability 
Previous results in this chapter have clearly illustrated the ability of both calcium ionophore 
A23187 (BrA) and oxLDL to induce the increase in intracellular Ca
2+
, ROS generation and 
subsequent cell death. Experiments were carried out to investigate these effects of both BrA 
and oxLDL on U937 cells, human monocytes and HMDM cells. A concentration of 5 µM 
BrA and LC50 concentration of oxLDL which have been observed to cause approximately 50% 
of cell viability loss in earlier experiments were used in the experiments. 
Results showed that 5 µM BrA caused a large increase in intracellular Ca
2+
 compared to 
oxLDL in all cell types (Figure 5.55 A, 5.56 A and 5.57 A). The rise in intracellular Ca
2+
 has 
also resulted in an elevated intracellular ROS production by both BrA and oxLDL but the 
increase caused by BrA was greater compared to oxLDL (Figure 5.55 B, 5.56 B and 5.57 B). 
At the end of the experiments, cell viability data showed approximately similar percentage of 
cell viability loss (approximately 25 to 30% less than control – PI negative cells) incurred by 
both BrA and oxLDL in (Figure 5.55 C, 5.56 C and 5.57 C). These results may indicate that 
increased levels of intracellular Ca
2+
 and ROS induced by oxLDL were sufficient to cause 
around 40% cell death. Additional increased in intracellular Ca
2+
 and ROS levels seen by 
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Figure ‎5.55: Effect of BrA and oxLDL on intracellular calcium levels, intracellular ROS levels and cell viability in U937 cells 
U937 cells (0.5×10
6
 cells/ml) were treated with the LC50 concentration (0.4 mg/mL) of oxLDL and 5 µM BrA followed by incubation at 37
o
C in non-phenol 
red RPMI-1640. A) Intracellular Ca
2+
 was measured using Fluo 3AM-flow cytometry assay after 1 hour. B) Intracellular ROS production was measured using 
DHE-flow cytometry assay after 3 hours. C) Cell viability was measured using the PI-flow cytometry assay after 12 hours. Results are displayed as mean ± 
SEM of triplicates from a representative experiment. Significance (two-way ANOVA, Sidak’s multiple test) is indicated from: oxLDL vs BrA, ^^, p<0.01 (A 
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Figure ‎5.56: Effect of BrA and oxLDL on intracellular calcium levels, intracellular ROS levels and cell viability in human monocytes 
Human monocytes (1×10
6
 cells/ml) were treated with the LC50 concentration (0.8 mg/mL) of oxLDL and 5 µM BrA followed by incubation at 37
o
C in non-
phenol red RPMI-1640. A) Intracellular Ca
2+
 was measured using Fluo 3AM-flow cytometry assay after 1 hour. B) Intracellular ROS production was 
measured using DHE-flow cytometry assay after 6 hours. C) Cell viability was measured using the PI-flow cytometry assay after 12 hours. Results are 
displayed as mean ± SEM of triplicates from a representative experiment. Significance (two-way ANOVA, Sidak’s multiple test) is indicated from: oxLDL vs 
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Figure ‎5.57: Effect of BrA and oxLDL on intracellular calcium levels, intracellular ROS levels and cell viability in HMDM cells. 
HMDM cells (1×10
6
 cells/ml) were treated with the LC50 concentration (1.25 mg/mL) of oxLDL and 5 µM BrA followed by incubation at 37
o
C in non-phenol 
red RPMI-1640. A) Intracellular Ca
2+
 was measured using Fluo 3AM-flow cytometry assay after 1 hour. B) Intracellular ROS production was measured using 
DHE-flow cytometry assay after 6 hours. C) Cell viability was measured using the PI-flow cytometry assay after 12 hours. Results are displayed as mean ± 
SEM of triplicates from a representative experiment. Significance (two-way ANOVA, Sidak’s multiple test) is indicated from: oxLDL vs BrA, ^, p<0.05, ^^, 




Effects of BrA and EGTA on intracellular ROS production and cell 
viability 
Experiments were also carried out to assess the effect of BrA and EGTA on intracellular ROS 
generation and the subsequent effect on cell viability. In previous experiments, BrA has been 
shown to induce the increase in intracellular Ca
2+
. Elevated level of intracellular Ca
2+
 caused 
by BrA has resulted in the rise of intracellular ROS generation which eventually ended in cell 
viability loss. On the other hand, EGTA has been shown to stop the rise of intracellular Ca
2+
 
which in turn reduced intracellular ROS formation. Yet, oxLDL-induced cell viability loss 
was not recovered by EGTA despite its ability to stop intracellular Ca
2+
 rise and reduce 
intracellular ROS generation. 
Results from the experiments showed that BrA-induced intracellular ROS level was reduced 
by EGTA in U937, human monocytes and HMDM cells (Figure 5.58 A, 5.59 A and 5.60 A). 
In addition, BrA-induced cell viability loss was also recovered by EGTA. Cell viability loss 
(PI negative cells) in cells treated with BrA was between 25 to 45% compared to control 
cells. An average of 10 to 30% of cell viability loss was recovered by EGTA (cells treated 
with both BrA and EGTA) compared to cells treated with BrA only (Figure 5.58 B, 5.59 B 
and 5.60 B).   
DHE results in this section and in the previous experiments showed that EGTA was able to 
reduce intracellular ROS levels induced by BrA and oxLDL. However, BrA-induced cell 
viability loss and not oxLDL-induced cell death was recovered by EGTA. Taken together, 
this suggests that oxLDL may trigger a Ca
2+
-independent reaction/mechanism that eventually 
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Figure ‎5.58: Effect of BrA and EGTA on intracellular ROS levels and cell viability in U937 cells 
U937 cells (0.5×10
6
 cells/ml) were treated with 5 µM BrA, 1 mM EGTA or combination of both followed by incubation at 37
o
C in non-phenol red RPMI-
1640. Intracellular ROS production was measured using DHE-flow cytometry assay after 3 hours and cell viability was measured using the PI-flow cytometry 
assay after 12 hours. A cell only control was included. A) shows the mean fluorescence intensity (MFI) of DHE measured by flow cytometry after 3 hours 
incubation. B) shows the percentage of cell viability measured using the PI-flow cytometry assay after 12 hours incubation. Results are displayed as mean ± 
SEM of triplicates from a representative experiment. Significance (two-way ANOVA, Sidak’s multiple test) is indicated from: 5 µM BrA vs 5 µM BrA + 1 
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Figure ‎5.59: Effect of BrA and EGTA on intracellular ROS levels and cell viability in human monocytes 
Human monocytes (1×10
6
 cells/ml) were treated with 5 µM BrA, 1 mM EGTA or combination of both followed by incubation at 37
o
C in non-phenol red 
RPMI-1640. Intracellular ROS production was measured using DHE-flow cytometry assay after 6 hours and cell viability was measured using the PI-flow 
cytometry assay after 12 hours. A cell only control was included. A) shows the mean fluorescence intensity (MFI) of DHE measured by flow cytometry after 
6 hours incubation. B) shows the percentage of cell viability measured using the PI-flow cytometry assay after 12 hours incubation. Results are displayed as 
mean ± SEM of triplicates from a representative experiment. Significance (two-way ANOVA, Sidak’s multiple test) is indicated from: 5 µM BrA vs 5 µM 
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Figure ‎5.60: Effect of BrA and EGTA on intracellular ROS levels and cell viability in HMDM cells 
HMDM cells (1×10
6
 cells/ml) were treated with 5 µM BrA, 1 mM EGTA or combination of both followed by incubation at 37
o
C in non-phenol red RPMI-
1640. Intracellular ROS production was measured using DHE-flow cytometry assay after 6 hours and cell viability was measured using the PI-flow cytometry 
assay after 12 hours. A cell only control was included. A) shows the mean fluorescence intensity (MFI) of DHE measured by flow cytometry after 6 hours 
incubation. B) shows the percentage of cell viability measured using the PI-flow cytometry assay after 12 hours incubation. Results are displayed as mean ± 
SEM of triplicates from a representative experiment. Significance (two-way ANOVA, Sidak’s multiple test) is indicated from: 5 µM BrA vs 5 µM BrA + 1 
mM EGTA, *, p<0.05 (A); 5 µM BrA vs 5 µM BrA + 1 mM EGTA, **, p<0.01 (PI negative cells) (B). 
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Effects of BrA and 7,8-NP on intracellular ROS production and cell 
viability 
In Chapter Four, 7,8-NP has been shown to reduce DHE levels as well as intracellular Ca
2+
 
levels. Studies by previous researchers, particularly in this lab have revealed the ability of 
7,8-NP to scavenge free radicals (Gieseg et al., 1993) and protects cells from oxLDL-induced 
cell death (Baird, 2003). In this section, experiments were carried out to investigate and 
compare the effect of BrA and 7,8-NP on intracellular ROS generation and subsequent cell 
death.  
Results from this section showed that BrA caused a great elevation in DHE fluorescence in 
all types of cells. In the earlier experiments of this chapter, BrA has been shown to have 
caused an increase in intracellular Ca
2+
 by increasing Ca
2+
 influx, thus the rise in intracellular 
Ca
2+ 
could have contributed to the rise in intracellular ROS, reflected by the increase in DHE 
fluorescence levels. However, when the cells were incubated with a combination of BrA and 
7,8-NP, the DHE fluorescence dropped significantly. As 7,8-NP has been demonstrated to 
reduce oxLDL-induced DHE level (Chapter Four), it may also act by scavenging the BrA-
induced intracellular ROS caused by the increased in intracellular Ca
2+
 (Figure 5.61 A, 5.62 
A and 5.63 A). Consequently, cell viability (PI negative cells) has also increased in cells 
treated with BrA and 7,8-NP in combination compared to cells treated with BrA only (Figure 
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Figure ‎5.61: Effect of BrA and 7,8-NP on intracellular ROS levels and cell viability in U937 cells. 
U937 cells (0.5×10
6
 cells/mL) were treated with 5 µM BrA, 200 µM 7,8-NP or combination of both followed by incubation at 37
o
C in non-phenol red RPMI-
1640. Intracellular ROS production was measured using DHE-flow cytometry assay after 3 hours and cell viability was measured using the PI-flow cytometry 
assay after 12 hours. A cell only control was included. A) shows the mean fluorescence intensity (MFI) of DHE measured by flow cytometry after 3 hours 
incubation. B) shows the percentage of cell viability measured using the PI-flow cytometry assay after 12 hours incubation. Results are displayed as mean ± 
SEM of triplicates from a representative experiment. Significance (two-way ANOVA, Sidak’s multiple test) is indicated from: 5 µM BrA vs 5 µM BrA + 200 
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Figure ‎5.62: Effect of BrA and 7,8-NP on intracellular ROS levels and cell viability in human monocytes. 
Human monocytes (1×10
6
 cells/mL) were treated with 5 µM BrA, 200 µM 7,8-NP or combination of both followed by incubation at 37
o
C in non-phenol red 
RPMI-1640. Intracellular ROS production was measured using DHE-flow cytometry assay after 3 hours and cell viability was measured using the PI-flow 
cytometry assay after 12 hours. A cell only control was included. A) shows the mean fluorescence intensity (MFI) of DHE measured by flow cytometry after 
3 hours incubation. B) shows the percentage of cell viability measured using the PI-flow cytometry assay after 12 hours incubation. Results are displayed as 
mean ± SEM of triplicates from a representative experiment. Significance (two-way ANOVA, Sidak’s multiple test) is indicated from: 5 µM BrA vs 5 µM 





































































1 0 0 0 0
2 0 0 0 0
3 0 0 0 0
4 0 0 0 0 *
 






























































P I  N e g a t iv e P I  P o s it iv e
* * *
 
Figure ‎5.63: Effect of BrA and 7,8-NP on intracellular ROS levels and cell viability in HMDM cells. 
HMDM cells (1×10
6
 cells/mL) were treated with 5 µM BrA, 200 µM 7,8-NP or combination of both followed by incubation at 37
o
C in non-phenol red RPMI-
1640. Intracellular ROS production was measured using DHE-flow cytometry assay after 3 hours and cell viability was measured using the PI-flow cytometry 
assay after 12 hours. A cell only control was included. A) shows the mean fluorescence intensity (MFI) of DHE measured by flow cytometry after 3 hours 
incubation. B) shows the percentage of cell viability measured using the PI-flow cytometry assay after 12 hours incubation. Results are displayed as mean ± 
SEM of triplicates from a representative experiment. Significance (two-way ANOVA, Sidak’s multiple test) is indicated from: 5 µM BrA vs 5 µM BrA + 200 




Effect of oxLDL on intracellular Ca
2+
 increase 
The effect of oxLDL on cytosolic Ca
2+
 levels was studied using Fluo 3AM probe via flow 
cytometry. Results obtained showed a continuous rise in the intracellular Ca
2+
 levels within 
the 6 hours after oxLDL treatment (Figure 5.2, 5.3 and 5.4). It is clearly depicted by the 
results that intracellular Ca
2+
 level increase was the greatest within the first three hours of 
incubation with oxLDL whereby the major boost happened after 1 hour. Generally, the 
increase slowed down after the third hour but remained high. These results clearly illustrate 
that oxLDL induced a high and sustained rise in cytosolic Ca
2+
.  
This finding is supported by Maziere et al. (2005) who have demonstrated the increase in 
intracellular Ca
2+
 in Jurkat cells as early as 15 minutes after the addition of oxLDL. In 
addition, van Tits et al. (2000) have found that oxLDL evoked an early but sustained increase 
in intracellular Ca
2+ 
but a delayed generation of superoxide. Morever, Deng et al. (2005) have 
also showed that intracellular Ca
2+
 level was increased in U937-derived macrophages 
following 20 minutes incubation with oxLDL of 100 µg/mL. Meanwhile, Matsumura et al. 
(1997) and Weisser et al. (1992) have shown that oxLDL induces Ca
2+
 mobilization in mouse 
peritoneal macrophages and smooth muscle cells cultured from rat aortas respectively. In 
another study by Yun et al. (2004), lysophosphatidylcholine (lysoPC) which is a 
phospholipid component of oxLDL has been shown to mobilised Ca
2+
 in U937 cells and the 
Ca
2+
 influx was from extracellular media. Moreover, they have demonstrated that G protein-
coupled receptors in the plasma membrane (G2A and GPR4) were not present in U937 cells 
thus allowing influx of Ca
2+
 into the intracellular compartment of the cells.  
This study has also demonstrated that intracellular Ca
2+
 increase induced by oxLDL is 
concentration-dependent (Figure 5.5) which has also been observed by Maziere et al. (2005). 
Therefore, cytosolic (intracellular) Ca
2+
 increase could be regarded as a secondary initiator of 
the subsequent oxidative damage in response to oxLDL. However, how oxLDL triggers Ca
2+
 
influx is unclear and yet to be determined.  
Ca
2+
 ionophore A23187 (BrA) is highly selective and enhances the ability of Ca
2+
 to cross the 
cell membrane and increases cytoplasmic Ca
2+
. It was used in this study as a positive control 
to confirm that the increase in fluorescence resulted from Ca
2+ 
reacting with Fluo 3AM dye 
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and not oxLDL reacting with the dye. BrA had caused a concentration-dependent increase in 
cytosolic Ca
2+
 levels after 3 hours incubation with the cells (Figure 5.6). This indicates that 
the observed increase in the fluorescence intensity in oxLDL-treated cells was most possibly 
due to the cytosolic Ca
2+
 reacting with the Fluo 3AM dye and not oxLDL reacting with the 
dye. Incubation with BrA after a period of time resulted in cell viability loss in all three types 
of cells (Figure 5.7). The degree of cell death correlated with the concentration of BrA which 
indicates increased cell death is associated with increased cytosolic Ca
2+
 accumulation 
(Figure 5.8). Salvayre et al. (2002) has indicated that a sustained elevation in cytosolic Ca
2+
 
is important in oxLDL-induced cell death (apoptosis and necrosis). 




) still showed an increase in 





 and RMPI1640). This indicates that, while the extracellular 
Ca
2+
 is mandatory for the rise in intracellular Ca
2+
, the involvement of intracellular 
mechanisms that mediate the overall increase is still important. 
Effects of different media on oxLDL-induced intracellular Ca
2+ 
levels and 
subsequent removal of oxLDL on cell viability 











) have indicated the effect of extracellular Ca
2+
 influx on intracellular Ca
2+ 
levels. 
OxLDL has been showed to induce Ca
2+ 
flux not only from extracellular compartment but 
also from intracellular organelles as seen in Figure 5.9 A, 5.10 A and 5.11 A. Cell viability 





removal of oxLDL did not help in restoring cell viability (Figure 5.9 B, 5.10 B and 5.11 B). 
This phenomenon indicates that the increase in intracellular Ca
2+ 
might not be important in 
oxLDL-induced cell death. OxLDL might have triggered other cellular responses which 
could have initiated cell death mechanisms upstream to intracellular Ca
2+ 
increase. Previous 
study in our lab by Shchepetkina (2013) showed that HMDM cells incubated for 6 hours in 
oxLDL lost almost 50% of intracellular GSH. When oxLDL was removed after 6 hours 
incubation with the cells, intracellular GSH was recovered but no recovery of cell viability 
was observed. This indicates that the cells were losing metabolic activity after 6 hours 





channel blockers and Ca
2+ 
chelators on intracellular Ca
2+
, 
ROS production and cell viability 
The intracellular Ca
2+
 homeostasis maintained low levels of Ca
2+
 (~100 nM) in resting cells 
by concerted operation of enzymes that translocate Ca
2+
 ions across the plasma membrane 
and intracellular store system (Carafoli, 1987; Hanson et al., 2004). Therefore, disruption of 
this operation caused by agents like oxLDL could result in increased Ca
2+
 influx and release 
of Ca
2+
 from intracellular stores. This could lead to an uncontrolled and sustained elevation in 
intracellular Ca
2+
 level (Nicotera et al., 1988). The increase in cytosolic Ca
2+
 could be caused 
by Ca
2+
 influx from the extracellular media and Ca
2+
 release from ER, which is the major 
intracellular Ca
2+
 store. Extracellular Ca
2+
 influx could occur via L- or T-type Ca
2+
 channels 
on plasma membrane while Ca
2+
 release from ER is through ryanodine receptors (RyRs) as 
well as inositol triphosphate receptors (IP3Rs) on SR/ER membrane (Deng et al., 2005; 
Negre-Salvayre et al., 1992; Yang, 2009; Yang et al., 2012a).  
Nifedipine was found to offer a limited protection in all types of cells against oxLDL-induced 
intracellular Ca
2+
 influx especially at lower concentration (5 µM) (Figure 5.13). Likewise, 
flunarizine and verapamil were found to inhibit intracellular Ca
2+
 rise caused by oxLDL in 
U937 cells and human monocytes and U937 cells only, respectively (Figure 5.12 and 5.14). 
However, intracellular DHE data revealed that there was no protection against oxLDL-
induced intracellular ROS found with any of the Ca
2+
 channel blockers tested (Figure 5.15, 
5.16 and 5.17). This phenomenon may indicate that oxLDL could have caused a Ca
2+
-
independent increase intracellular ROS or oxLDL may also trigger other mechanism of 
releasing ROS such as NOX on the plasma membrane. Consequently, none of the L- or T-
type Ca
2+
 channel blockers was able to protect the cells against oxLDL-mediated cell 
viability loss (Figure 5.18, 5.19, 5.20, 5.21, 5.22, 5.23, 5.24, 5.25 and 5.26). Moreover, 
flunarizine alone at 50 µM was cytotoxic to U937 cells and it did not increase intracellular 
Ca
2+
 but caused a rise in intracellular ROS instead. 
Earlier, it was reported by Negre-Salvayre and Salvayre (1992) that nifedipine 
(dihydropyridine) but not verapamil (phenylalkylamine) was protective against oxLDL-
mediated cell death in cultured lymphoid cells. In our lab, Yang (2009) has demonstrated that 
flunarizine, nifedipine and verapamil were able to block intracellular Ca
2+
 rise in HMDM 
cells caused by HOCl insult, suggesting that extracellular Ca
2+
 entered HMDM cells upon 
HOCl treatment mainly through L- and T-type Ca
2+
 channels on HMDM plasma membrane. 
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However, the cytosolic Ca
2+
 increase was never completely prevented using those Ca
2+
 
channel blockers, indicating that cytosolic Ca
2+
 accumulation might also occur through other 
pathways. Likewise, HOCl-induced cell viability loss was also inhibited by the above Ca
2+ 
channel blockers but the inhibition was also not complete, suggesting that HOCl caused cell 
death by activating other pathways or Ca
2+
 released from intracellular stores could result in 
cell death.  
The opening of Ca
2+
 channels on the plasma membrane could occur via plasma membrane 
depolarization. Maack and O'Rourke (2007) have previously suggested that plasma 
membrane depolarization in cardiac myocytes caused by voltage-gated Na
+
-channel 
activation resulted in inward Na
+
- current, facilitating L-type Ca
2+
-channels on the plasma 
membrane. Since Ca
2+
 transport systems are susceptible to redox conditions (Camello-
Almaraz et al., 2006), it is highly possible that ROS produced by oxLDL regulates the plasma 
membrane Ca
2+
 channels through thiol modification within the protein complex (Inoue et al., 
2008). In addition, Campbell et al. (1996) have reported that the thiol oxidizing agent 5,5’-
dithiobis (2-nitrobenzoic acid) (DTNB) upregulated L-type Ca
2+
 channels at the extracellular 
face of the cell membrane. They have also hypothesized that an allosteric thiol-containing 
‘redox switch’ is present on the L-type Ca
2+
 channel subunit complex. Superoxide and other 
ROS could inhibit L-type Ca
2+
 channels by acting directly on voltage sensor domain of the 
channels (Kourie, 1998). 
NADPH oxidase (NOX) on the plasma membrane could also be a possible regulator in the 
opening of the L- or T-type Ca
2+
channels upon cells exposure to oxLDL. A study by Wang et 
al. (2010) have showed that inhibition of NOX by specific NOX inhibitors i.e. apocynin, DPI 
and gp91ds-tat suppressed the L-type Ca
2+
 channel expression and blocked the influx of 
extracellular Ca
2+
 . It has been shown in Chapter Four of this study that apocynin decreases 
intracellular Ca
2+
 levels in U937 cells but not in human monocytes and HMDM cells. 
In this study, dantrolene (RyR inhibitor) provided limited protection against oxLDL-induced 
cytosolic Ca
2+
 increase only human monocytes but not U937 or HMDM cells (Figure 5.27). 
However, in the presence of oxLDL, intracellular ROS level was raised in cells treated with 
dantrolene (Figure 5.29) and cell viability loss caused by oxLDL was also not prevented 
(Figure 5.31, 5.32 and 5.33). This suggests that Ca
2+
 might also be released from ER 
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possibly via another channel i.e. IP3R whilst Ca
2+
 influx from extracellular source could 
caused a rise in intracellular Ca
2+
. 
It has been suggested that Ca
2+
 release from ER/SR could be a result from the influx of 
extracellular Ca
2+
 which triggers the opening of the RyRs on the ER/SR membrane (a process 




 release) (Maack & O'Rourke, 2007). However, other studies 
have demonstrated that oxLDL induced a gradual rise in cytosolic Ca
2+
 with time in the 
absence of external Ca
2+
 source (Deng et al., 2009; Deng et al., 2005), implying that 
mobilization of Ca
2+
 from intracellular ER store occurred in the absence of external Ca
2+
 and 
the opening of RyR on the ER membrane did not have to be initiated by the extracellular Ca
2+
  
influx. Therefore, it is likely that the critical thiol groups within the RyR protein are targeted 
by ROS in responses to oxLDL, leading to ER-Ca
2+
 release. Previous finding of HOCl 
interacting with the essential thiols leading to RyR activity suggests that RyR receptors on 
ER membrane could be activated via thiol oxidation by oxidants (Anzai et al., 1998; Sun et 
al., 2001).  
It has also been implicated that ER is the major intracellular Ca
2+





 can be released by the ER via IP3R and RyR to generate the Ca
2+
 
signal during stimulation whereas Ca
2+
 accumulation can occur through sarco/endoplasmic 
reticulum Ca
2+
-ATPase (SERCA) to buffer Ca
2+
 after stimulation, allowing cytosolic Ca
2+
 
concentration to return to the resting state (Berridge et al., 2003). Treatment of cells with 
thapsigargin (Tg) depleted Ca
2+
 store in ER causing ER stress. Our results showed an 
increase in intracellular Ca
2+
 in cells treated with Tg only and was further increased in the 
presence of oxLDL (Figure 5.28). Since Ca
2+
 was already depleted from the ER by Tg and 
accumulated in the cytosol, oxLDL further raised the cytosolic Ca
2+
 levels by probably 
increasing Ca
2+
 influx from the extracellular media. Likewise, intracellular ROS level was 
further enhanced by the presence of oxLDL (Figure 5.30). Eventually, this resulted in cell 
death whereby Tg alone was found to cause a drop in cell viability loss and it was further 
increased by oxLDL (Figure 5.34, 5.35 and 5.36). Depleting Ca
2+
 from the ER by Tg has 
caused stress to the ER, thus oxidative injury induced by oxLDL may potentiate the existing 
stress on the ER leading to increase in cell death.  
Studies have also reported that oxidants could release Ca
2+
 from the ER (Ermak & Davies, 
2001), most probably by inhibiting SERCA. ROS may also trigger ER stress through 
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generation and accumulation of oxidized protein. Additionally, ROS could directly damage 
proteins of the ER folding machinery such as the ER chaperones. This will then mediate the 
buildup of misfolded protein resulting in UPR activation (Dejeans et al., 2010). Tg has been 
shown to induce an increase in intracellular Ca
2+
 and cell death in cultured porcine aortic 
SMC (Chin et al., 2007). However, cell death mediated by Tg was not related to the increase 
in intracellular Ca
2+
 but was induced by targeting of the activated pro-apoptotic factor, Bax to 
the mitochondria and opening of the mitochondrial permeability transition pore (MPTP).  The 
opening of MPTP then triggered several key events leading to cell death including ΔΨm loss, 
cytochrome c release and caspase-3 activation.  
Next, when cells were treated with oxLDL in the presence of with calcium chelators (BAPTA 
AM and EGTA), intracellular Ca
2+
 influx was significantly blocked (Figure 5.37 and 5.38). 
In addition, intracellular ROS level was also reduced compared to oxLDL treated cells 
(Figure 5.39). However, cell viability loss was not prevented (Figure 5.40, 5.41, 5.42, 5.43, 
5.44 and 5.45) which suggests that cytosolic Ca
2+
 increase was not important and was not the 
cause for cell viability loss mediated by oxLDL. Moreover, the rise in intracellular ROS level 
was not greatly reduced as compared to the blocking of intracellular Ca
2+
 level indicating that 
oxLDL might induce a Ca
2+
-independent intracellular ROS which could then trigger a Ca
2+
-
independent cell death pathway. This finding is different from that found with HOCl in this 
lab, where cytosolic Ca
2+




 increase could also occur via other non-specific pathway (Deng et 
al., 2005). This is supported by previous study by Yang (2009) in this laboratory that showed 
HOCl-induced intracellular Ca
2+
 increase was never completely prevented using any of the 
Ca
2+
 channel blockers or Ca
2+
 chelator. Much evidence have revealed that ROS can induce 
intracellular Ca
2+
 rise by releasing Ca
2+
 from internal stores as well as disturbing Ca
2+
 
clearance systems. Indeed, elevated intracellular Ca
2+
 level is a constant feature associated 
with oxidative stress in pathological conditions (Camello-Almaraz et al., 2006).  
Effect of oxLDL-induce intracellular Ca
2+
 increase on mitochondria 
Studies have suggested that the increase in cytosolic Ca
2+
 induced by oxLDL to be an 
important event triggering Ca
2+
-dependent necrosis or apoptosis (Gieseg et al., 2009b; 





 increase is mainly caused by either extracellular Ca
2+
 influx or 
exhaustion of ER Ca
2+
, not much information is available describing the exact mechanism 
whereby the increased intracellular Ca
2+
 are involved in the oxLDL-toxicity effect. One 
possibility is that cytosolic Ca
2+
 accumulation triggers mitochondrial dysfunction leading to 
cell death. A recent study by Deng et al. (2009) reported that a significant increase in 
mitochondrial Ca
2+
 correlated with the cytosolic Ca
2+
 influx mediated by oxLDL in PMA-
stimulated U937 cells. This suggests that oxLDL-induced cytosolic Ca
2+
 rise triggered the 
Ca
2+
 mobilization from the cytosol into the mitochondria via Ca
2+
 uniporter on inner 
mitochondrial membrane (IMM), resulting in the MPTP opening and ΔΨm loss. Similar 
findings by Yang et al. (2012a) in our laboratory were also described in HOCl-treated 
HMDM cells. 
Mitochondria have the ability to rapidly accumulate and to release large quantities of Ca
2+
 
(Mattson & Chan, 2003). Excessive mitochondrial Ca
2+ 
uptake makes up the essential steps in 
mitochondrial ROS production in Ca
2+
-induced cytotoxicity yet mitochondrial Ca
2+ 
overload 
is also vital in the mechanism of oxidative stress leading to oxidation injury (Peng & Jou, 
2010). Thus, oxLDL-induced cytosolic Ca
2+
 overload may contribute to mitochondrial 
destabilization by inducing mitochondrial ROS production as a result of Ca
2+
 influx into the 
mitochondria. Grijalba et al. (1999) have demonstrated that Ca
2+
 modifies IMM lipid 
organization by interacting with the anionic head of cardiolipin molecules which suggests 
that increased Ca
2+
 levels may affect the mitochondrial respiratory chain function and favour 
superoxide radical production at intermediate steps of the respiratory chain. Moreover, 
mitochondrial ROS generation could serve as the oxidizing agent for MPT pore activation 
(Inoue et al., 2008). The excess oxidants possibly involves in the oxidation of thiols on the 
MPTP complex in cooperation with Ca
2+
 (Petronilli et al., 1994). The sensitivity of MPTP 
could also be increased by oxidation or cross-linking of critical dithiols in membrane proteins, 
thus promoting the subsequent MPTP opening (Chernyak et al., 1995). Alternatively, Ca
2+
 
could bind to the matrix side of IMM membrane and promotes extensive conformational 
changes of membrane proteins which caused the thiol groups to be more susceptible to 
oxidation (Kowaltowski et al., 1997). 
Mitochondrial Ca
2+
 may also induce MPTP opening by activating Ca
2+
-dependent calpains 
(Gores et al., 1998). Active calpain 10 has been demonstrated in the outer membrane, 
intermembrane and mostly matrix fractions of isolated mitochondria. Early study showed 
237 
 
mitochondrial matrix calpain 10 triggered MPTP and caused damage to mitochondrial 
Complex I (Arrington et al., 2006). Therefore, it is likely that mitochondrial calpain activates 
MPTP opening by cleaving proteins to generate positively charged peptides which may 
allosterically alter pore opening by binding at a site that normally binds cations (Aguilar et al., 
1996). Mitochondrial Ca
2+
 released from MPTP could subsequently activate cytosolic calpain. 
The inhibition of mitochondrial calpain activation prevented cytosolic calpain activation in 
HOCl-treated HMDM cells which indicates that cytosolic calpain activation occurs after 
MPT pore opening (Yang, 2009). Activated calpains have been shown to cause bleb 
formation and necrotic cell death by proteolytically cleaving cytoskeletal proteins (Miyoshi et 
al., 1996; Weber et al., 2005). Calpain activation can also cause lysosomal destabilization 
and the release of cathepsin, a protease responsible for degradation of cellular components 
that leads to necrotic or apoptotic cell death (Yap et al., 2006). Furthermore, there are also 
other apoptotic factors released from mitochondria through the activated MPTP such as 
cytochrome c, leading to caspase activation and subsequent apoptotic cell death (Nicotera & 
Orrenius, 1998). 
In this study, ruthenium red has been found to protect cells from oxLDL-induced cell death 
(Figure 5.47, 5.48 and 5.49). Likewise, oxLDL-induced intracellular ROS levels were also 
suppressed by ruthenium red (Figure 5.50). This showed that, inhibiting Ca
2+
 uptake into the 
mitochondria by ruthenium red has resulted in a reduction in intracellular ROS (possibly 
including mitochondrial ROS) levels which in turn protected cells from oxLDL-induced cell 
death. Thus, it is likely that ruthenium red protected against MPT activation and prevented 
ΔΨm loss to a certain degree. However, cell viability loss was not completely prevented by 
ruthenium red, suggesting other mechanisms might be inducing MPT activation caused by 
oxLDL. An incomplete protection against HOCl-induced cell death was also observed by 
(Yang, 2009) in this laboratory although ΔΨm loss was protected by ruthenium red. Calpains 
are also found in the intermembrane space of the mitochondria (Tavares & Duque-
Magalhaes, 1991). Thus, it is possible that Ca
2+
 diffused to the intermembrane space through 
VDAC, initiated the calpains and MPT was somehow activated. Additionally, Ca
2+
 binding to 
an extramitochondrial site might also activate MPT. In studies done by Kowaltowski et al. 
(1997), phenylarsine oxide-induced MMP was inhibited by EGTA but not by ruthenium red. 
This suggests that phenylarsine oxide induces MPT activation via a mechanism independent 
of matrix Ca
2+
 but dependent on Ca
2+
 binding to an extramitochondrial site. Further study 
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could be carried out to confirm and determine the effect of ruthenium red on oxLDL-induced 
ΔΨm loss. 
The exact mechanism on how Ca
2+ 
stimulates mitochondrial ROS production remains elusive 
although possible mechanisms have been proposed (Brookes et al., 2004). Among others, the 
suggested mechanisms include Ca
2+ 
stimulated increase of metabolic rate, Ca
2+ 
induced nitric 
oxide and the effects exerted on respiratory complexes, Ca
2+ 
triggered cytochrome c 
dissociation, Ca
2+ 
induced cardiolipin peroxidation, Ca
2+
-calmodulin dependent protein 
kinases activation as well as Ca
2+ 
induced MPT pore opening that could results in the release 
of cytochrome c and GSH- and NADPH- dependent antioxidative enzymes (Peng & Jou, 
2010). Additionally, different experimental conditions such as different types of 
mitochondrial preparations (intact or isolated mitochondria), mitochondria from different 
cells/tissues/animals species and combination of different pharmacological inhibitors used 
may affect and initiate different mechanism of ROS production by Ca
2+
 (Peng & Jou, 2010). 
OxLDL-induced cellular oxidative stress involves in modulating the functions of a series of 
signalling pathways which include activating the cell death pathway, dysregulating 
mitochondria and ER as well as promoting inflammation (Chang et al., 2014) whereby most 
of these pathways are potentially cytotoxic (Irani, 2000; Salvayre et al., 2002; Steinberg, 
1997). 
Effects of oxLDL on MPT activation and mitochondrial membrane 
potential (ΔΨm) 
Mitochondrial membrane potential (ΔΨm) is critical for maintaining the physiological 
function of the respiratory chain to generate ATP. Since mitochondria are the major 
machinery for ATP generation in cells, a significant loss of ΔΨm causes cells to be depleted 
of energy with subsequent death. In this study, results from preliminary experiments using 
TMRM showed that oxLDL caused a time-dependent decrease in ΔΨm in U937, human 
monocytes and HMDM cells (Figure 5.46). However, the common excitation wavelength of 
488 nm measured using flow cytometry was not optimal compared to 548 nm (Plasek et al., 
2005; Russell et al., 2002; Wlodkowic et al., 2006). Thus, studies on oxLDL-induced ΔΨm 
loss are underway using JC-1 dye, which should be more specific for flow cytometry 
measurement. Nevertheless, preliminary results suggest that ΔΨm might contribute to the 
necrotic cell death in these cells. Moreover, previous studies by Katouah (2012) in this lab 
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have clearly showed that oxLDL has caused ATP depletion in U937 and HMDM cells. The 
decrease in ATP was significant as early as 3 hours after incubation with oxLDL and 
remained low until 12 hours. However, the exact timing of mitochondrial shutdown is not 
known because with increasing incubation time of oxLDL, the number of dead cells increases. 
Tetramethylrhodamine methyl ester (TMRM) was the fluorescent dye used in this study and 
it has no effect on mitochondrial respiration at low concentrations (Scaduto & Grotyohann, 
1999). In addition, TMRM does not accumulate in cell membrane or interact with membrane 
proteins. There are other fluorescence probes available for the determination of ΔΨm 
including rhodamine 123 and tetramethylrhodamine ethyl ester (TMRE) and these dyes were 
found to inhibit the respiratory processes in isolated mitochondria (Scaduto & Grotyohann, 
1999).  
Cyclosporin A (CsA) was demonstrated by this study to protect only HMDM cells against 
oxLDL-induced cell death but not U937 cells and human monocytes (Figure 5.51, 5.52 and 
5.53). It was found that CsA alone had caused an increased in intracellular ROS levels in both 
U937 cells and human monocytes and intracellular ROS production sustained the in presence 
of oxLDL (Figure 5.54 A and B). The rise in intracellular ROS thus resulted in increased cell 
viability loss in U937 cells and human monocytes pre-treated with CsA. This finding is 
supported by de Hornedo et al. (2007) and O'Connell et al. (2012), who reported that CsA 
induced oxidative stress and mitochondrial dysfunction in renal tubular cells and human renal 
mesangial cells, respectively. Likewise, Diederich et al. (1994) found that endothelial 
dysfunction was caused by an increased in superoxide production by CsA whilst Wolf et al. 
(1997) demonstrated that CsA induced oxidative stress in rat hepatocytes. 
Interestingly, CsA was not toxic to HMDM cells but offered protection against oxLDL-
induced cell viability loss (Figure 5.53) and intracellular ROS production (Figure 5.54 C). 
CsA is potent immunosuppressive drug widely used in treating autoimmune disorders and in 
organ transplantation (Kahan, 1992). CsA has been shown to inhibit both apoptosis and 
necrosis in rat hepatocytes induced by Ca
2+
 ionophore (A23187) (Qian et al., 1999). This 
drug is known to bind and block the peptidyl-prolyl cis-trans isomerase activity of matrix 
cyclophilin D (CyP-D) (Bernardi et al., 2006), which is required to form an ANT/CyP-D 
protein complex for MPT pore opening (McStay et al., 2002; Vieira et al., 2000; Woodfield 
et al., 1998). Previous work by Yang (2009) showed that MPT activation was involved in 
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MMP loss in HMDM cells. The protection against oxLDL-induced cell viability loss 
provided by CsA possibly suggests that oxLDL-mediated MPT activation triggered ΔΨm loss 
which then resulted in HMDM necrotic cell death. This is in agreement with Asmis and 
Begley (2003) who demonstrated that oxLDL-induced peroxyl radical production caused 
MMP loss and subsequent necrotic cell death in macrophages. 
Mitochondrial permeability transition pore (MPTP) opening has been associated mostly with 
necrotic cell death but various stimulants such as BrA (Qian et al., 1999) were also found to 
induce apoptosis through Ca
2+
-dependent MPT activation (Zhivotovsky & Orrenius, 2011). 
Additionally, MPT activation has also been proposed to be a common pathway leading to 
both necrosis and apoptosis (Kim et al., 2003a; Lemasters et al., 2009). MPT activation is 
triggered by a high level of Ca
2+
 in the matrix and could be further stimulated by oxidative 
stress, pyridine nucleotide and thiol oxidation, alkalinisation and low transmembrane 
potential (Zhivotovsky & Orrenius, 2011). MPTP is in contact sites between the IMM and 
OMM and act as voltage-operated channel (Zhivotovsky & Orrenius, 2011) whereby MPT 
activation increases of the IMM permeability to low molecular weight ions and solutes (up to 
1500 Da) (Bernardi, 1999; Crompton, 1999) to escape from the matrix into the cytosol. This 
will then leads to rapid depolarization and uncoupling of oxidative phosphorylation while 
influx of water and solutes from the cytosol causes mitochondrial swelling due to osmotic 
disequilibrium and eventually outer membrane rupture (Kim et al., 2003b; Lemasters et al., 
2009). Consequently, this could either lead to the release of cytochrome c, activation of 
caspase cascades and apoptosis or severe loss of ATP through the disruption of the IMM and 
necrotic cell death. In their studies, Qian et al. (1999) have showed that MPT mediates both 
necrosis and apoptosis in BrA-induced mitochondrial Ca
2+
 increase in rat hepatocytes 
whereby necrotic and apoptotic cell death occurred in the absence of ATP and in the presence 
of glycolytic ATP, respectively. However, it might not be possible to clearly distinguish 
between the two types of death pathways (Jaeschke & Lemasters, 2003; Lemasters, 1999) 
and studies have suggested cross-talks between the different cell death mechanisms 
(Zhivotovsky & Orrenius, 2010). In this study, morphological characteristics of the cells 
treated with oxLDL resembled necrotic cells such cell swelling and disruption of cell 
membrane. Previous findings such as rapid loss of GSH and caspase-3 inactivation by other 
researchers in this group (Baird et al., 2004; Chen, 2012; Katouah, 2012) on oxLDL-induced 
toxicity suggested that oxLDL-induced cell death was necrotic rather than apoptotic.  
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Results in Chapter Four showed that oxLDL caused a time-dependent increase in 
mitochondrial ROS (measured using MitoSOX) in HMDM cells (Figure 4.7) whereby 
studies have suggested that mitochondria-mediated ROS production, as a results of exposing 
cells to oxidative stress or apoptotic stimuli could initiate MPT activation (Kim et al., 2003b; 
Kowaltowski et al., 2001). Other studies however, indicated that the mitochondrial ETC 
components such as cytochrome c, could leaked out from the mitochondria through the 
activated MPTP. Subsequently, this lead to the escape of electrons from Complex III which 
could reduce oxygen molecules forming superoxide radicals (Luetjens et al., 2000). Ca
2+
, 
oxidative stress, reactive chemicals, Pi, NAD(P)
+
 and high pH are among the factors that 
keep the MPTP opens whereas low pH (less than 7), high membrane potential, Mg
2+
, ADP 
and NAD(P)H block the opening of MPTP (Hansson et al., 2003; Lemasters et al., 2009). 
Effects of BrA on intracellular ROS and cell viability – in comparison with 
oxLDL, EGTA and 7,8-NP 
Results from this study have showed that oxLDL triggered an increase in intracellular Ca
2+
 as 
well as intracellular ROS. However, the increase in both intracellular Ca
2+
 and ROS was not 
as great as that caused by Ca
2+
 ionophore, BrA although both agents caused death to the cells 
(Figure 5.55, 5.56 and 5.57). This suggests that oxLDL-induced intracellular Ca
2+
 alone is 
not sufficient to cause cell death. Jou et al. (2010) have found that BrA treatment resulted in 
mitochondrial ROS production which relates to Ca
2+
 overload caused by BrA while previous 
study by Yang (2009) in this lab showed BrA activated MPT, which could be the cause of 
cell death.  
Further studies using BrA and EGTA revealed that intracellular ROS caused by BrA was 
significantly reduced by EGTA. Subsequently, cell viability loss was also protected (Figure 
5.58, 5.59 and 5.60). This showed that Ca
2+
 chelation by EGTA has a positive effect in 
reducing intracellular ROS caused by BrA-induced Ca
2+
 influx which also protected the cells 
from death. However, earlier results showed that EGTA was not able to inhibit oxLDL-
induced ROS production despite its ability to block intracellular Ca
2+
 increase. Taken 
together, this showed that oxLDL might be causing a Ca
2+
-independent increased in 
intracellular ROS compared to BrA.  
Results also showed the ability of 7,8-NP to reduce BrA-induced intracellular ROS level and 
provide protection against cell viability loss (Figure 5.61, 5.62 and 5.63). This suggests that 
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the mechanism of action of 7,8-NP is scavenging ROS induced by BrA. Results in Chapter 
Four and from previous work done by other researchers in this lab have clearly revealed that 
7,8-NP works by scavenging oxidants induced by oxLDL, thus protecting cells from oxLDL 







Results from the experimental works done for this chapter clearly showed that oxLDL 
initiated a rapid Ca
2+
 influx and accumulation of Ca
2+
 in the cytosol. Most of the Ca
2+
 flux is 
from extracellular origin but Ca
2+
 mobilisation from intracellular stores does play a role.  
Intracellular Ca
2+
 increase triggered by oxLDL correlated with the increase in intracellular 
ROS. However, blocking oxLDL-induced intracellular Ca
2+
 rise by Ca
2+
 chelator did not 
inhibit the increase in intracellular ROS. In contrast, blocking Ca
2+
 uptake by mitochondria 
had reduced intracellular ROS production and improved cell viability. This suggests that 
intracellular Ca
2+
 increased mediated by oxLDL is important in inducing mitochondrial ROS 
production and oxLDL may also trigger a Ca
2+
-independent pathway of cell death. 
Excess cytosolic Ca
2+
 can be taken up into the mitochondria and could caused mitochondrial 
Ca
2+
 overload. This could increase mitochondrial ROS generation and also trigger the 
opening of MPT pores, thus caused the collapse of MMP as a result of mitochondrial outer 
membrane rupture. These events will subsequently result in cell death. Results from this 
chapter clearly showed that blocking Ca
2+
 uptake into the mitochondria protected cells from 
oxLDL-induced cell death possibly by reducing ROS production and preventing MPT 
activation. Indeed, oxLDL insult to the mitochondria might play a vital role in oxLDL-
mediated cell death and should be the future direction. 
A diagram showing the proposed involvement of Ca
2+ 
and ROS in oxLDL-mediated toxicity 






Figure 64: Proposed involvement of Ca
2+
 and ROS in oxLDL-mediated toxicity to U937 
cells, human monocytes and HMDM cells. 
OxLDL activates NADPH oxidase (NOX) on the plasma membrane. NOX-derived ROS triggers the 
voltage-dependent L- and T-type Ca
2+
 channels on cell membrane and ryanodine receptors (RyR) on 
endoplasmic reticulum (ER), resulting in the influx of extracellular Ca
2+
 and release of Ca
2+
 from ER 
stores to cytosol. Both events lead to cytosolic Ca
2+
 increase. Excess cytosolic Ca
2+ 
can be taken up 
into mitochondria via Ca
2+
 uniporter on the inner mitochondrial membrane (IMS). Ca
2+
 accumulation 
in mitochondrial matrix increases mitochondrial ROS production, causing mitochondrial permeability 
transition pore (MPTP) to open. MPTP activation leads to mitochondrial membrane potential loss and 
will subsequently results in cell death. Ca
2+
 channel blockers (flunarizine, nifedipine, verapamil, 
dantrolene, thapsigargin, ruthenium red), Ca
2+
 chelators (EGTA and BAPTA-AM), cyclosporin A and 






6.  Hydrogen sulfide (H2S) and 
oxLDL-mediated cell death 
 
Introduction 
This chapter aims to investigate the effects of different types of slow releasing H2S donors on 
oxLDL-mediated cell death. This will include studying their effects on cell viability, 
intracellular Ca
2+
 and ROS productions in U937 cells, human monocytes and HMDM cells. 
An increasing body of evidence has implicated the involvement of hydrogen sulfide (H2S) in 
biological systems through a variety of interrelated mechanisms (Szabo, 2007). In the past 
decade, H2S has emerged as an important mediator in various physiological and 
pathophysiological processes (Whiteman et al., 2011a). Studies have shown that H2S can 
either protect or damage cells and this depends on its concentration, type of cell and 
experimental conditions (Wagner et al., 2009). High levels of H2S are always accompanied 
by cytotoxic effects that could result from free radical generation and loss of GSH. Low 
levels of H2S have been shown to be either cytoprotective or proapoptotic (Adhikari & 
Bhatia, 2008; Baskar et al., 2007; Cao et al., 2006). H2S has been reported to cause apoptosis 
in aortic smooth muscle (Yang et al., 2004; Yang et al., 2006), lung fibroblasts (Baskar et al., 
2007) and pancreatic acinar cells (Adhikari & Bhatia, 2008) but it is protective in neural cells 
(Xiao et al., 2012).  
H2S as ROS scavenger and inhibitor  
H2S is capable of scavenging free radicals by single electron or hydrogen atom transfer 
(Carballal et al., 2011). H2S has been reported to scavenge reactive oxygen and nitrogen 
species such superoxide (Yan et al., 2006), hydrogen peroxide (Lu et al., 2008), peroxynitrate 
(Whiteman et al., 2004), hypochlorous acid (Whiteman et al., 2005) and lipid hydroperoxides 
(Carballal et al., 2011; Muellner et al., 2009).  
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In human endothelial cells (Muzaffar et al., 2008a) and vascular smooth muscle cells 
(Muzaffar et al., 2008b), H2S has been demonstrated to inhibit superoxide production by 
reducing NOX expression and activity. Samhan-Arias et al. (2009) have also showed that 
H2S protects synaptic plasma membranes from oxidative stress by the inhibition of ROS 
production via NOX. Moreover, H2S has been shown to increase GSH levels, thus protecting 
mitochondria from oxidative stress in neurons (Kimura et al., 2010). Figure 6.1 shows the 
suggested protective effects of H2S against ROS in the vasculature. 
 
Figure ‎6.1: Potential protective effects of H2S towards vascular ROS 
H2S has been shown to inhibit NADPH oxidase activity and expression (A); mitochondrial ROS 
production (B) and possibly xanthine oxidase activity (C). It has also been reported to scavenge ROS 
and promote the actions of SOD (D) and GSH (E) (Streeter et al., 2013). 
H2S roles in mitochondria 
Mitochondria play a vital role as the key source and target for detrimental intracellular 
oxidants generation (Murphy, 2009). Studies have implicated the importance of H2S in 
regulating mitochondrial function (Modis et al., 2013a) as well as reducing mitochondrial 
ROS generation (Sun et al., 2012). Recent studies by Modis et al. (2013a) demonstrated that 
low levels of H2S generated by mitochondrial enzyme, 3-MST, has donated electrons to the 
Krebs cycle, enhancing mitochondrial electron transport and bioenergetics (Figure 6.2). In 
hepatoma cells, this effect is suppressed during oxidative stress but reversed with 
administration of exogenous H2S (Modis et al., 2013b). 
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Translocation of CBS (cystathionine-β-synthase) (Fu et al., 2012) and CSE (cystathionine-γ-
lyase) (Modis et al., 2013b; Szabo et al., 2013) from the cytosol to the mitochondrial matrix 
in response to hypoxic and calcium stress have been observed. The resulting H2S generation 
within the mitochondria might act as an electron acceptor in the mitochondrial respiratory 
chain which then increases cellular ATP production, thus preserving cell viability (Fu et al., 
2012; Modis et al., 2013b; Szabo et al., 2013; Teng et al., 2013). 
 
Figure ‎6.2: Role of endogenous H2S in the mitochondrial electron transport  
H2S and Krebs-cycle-derived electron donors (NADH+H, FADH2) donate electrons to complexes I 
and II respectively. Mitochondrial enzyme, 3-MST, converts 3-MP to H2S, which then serve as an 
inorganic electron donor that stimulates mitochondrial electron transport. H2S donates electrons into 
the mitochondrial electron transport chain via an enzyme linked to complex II, SQR (sulfide:quino-
oxidoreductase) (Modis et al., 2013a). 
H2S and intracellular calcium regulation 
Calcium (Ca
2+
) plays an important role as key signalling molecule in regulating a various 
biological processes. Cytoplasmic concentration of Ca
2+
 is being tightly regulated within 
nanomolar range, which is approximately ten thousand fold difference across plasma 
membrane (1.5 mM at extracellular and 0.1 µM in cytosol) (Montell, 2005). The mechanisms 
responsible for regulating the influx of external calcium are well established (Berridge, 
1998). Extracellular Ca
2+
 can cross plasma membrane via two major pathways i.e. voltage-
operated Ca
2+
 channels (VOCCs) and receptor operated Ca
2+
 channels (ROCCs) (Pinilla et 





 entry and this depends on the molecular nature of the Ca
2+
 entry pathway 
[reviewed by Munaron et al. (2012)]. 
In exerting cardioprotective effect, it has been proposed that H2S causes indirect inhibitory 
action on L-type calcium channels (VOCCs) besides directly inhibiting the β-adrenergic 
receptors (Mancardi et al., 2009). Thus, Sun et al. (2008) have showed the ability of H2S to 
inhibit L-type calcium channels in NaHS treated rat cardiomyocytes while (Maeda et al., 
2009) has reported that H2S may facilitate membrane currents through T-type calcium 
channels. In studies done on endothelial cells, Bauer et al. (2010) concluded that H2S can 
directly regulate Ca
2+
 homeostasis and signalling via multiple mechanisms. 
H2S roles in atherosclerosis 
Atherosclerosis is characterised by multiple key events including endothelial dysfunction, 
infiltration of monocytes into the vascular wall and their differentiation into macrophages, 
uptake of oxLDL and conversion of lipid laden macrophages into foam cells and smooth 
muscle cell proliferation. Increasing evidence has implicated the significant involvement of 
H2S in these biological processes and disruption of H2S homeostasis may contribute to the 
pathogenesis of atherosclerosis (Lynn & Austin, 2011).  
Recent studies have suggested that macrophages can produce H2S endogenously (Zhu et al., 
2010). Zhu et al. (2010) has reported the presence of CSE as well as endogenous H2S 
production in peritoneal and RAW 264.7 macrophages treated with L-cysteine and PLP. They 
have also showed that lipopolysaccharide (LPS) stimulated CSE but not CBS expression and 
H2S generation in macrophages. Moreover, NaHS in a dose-dependent manner has been 
found to suppress oxLDL-induced foam cell formation in THP-1 derived macrophages 
(Wang et al., 2009).  
Laggner et al. (2007) demonstrated that H2S counteracts LDL oxidation by HOCl, whereby 
50 µM HOCl was completely scavenged in the presence of equimolar concentrations of 
NaHS for 30 min at 37
o
C. In addition to its HOCl scavenging potential, the authors also 
found that H2S inhibited myeloperoxidase (MPO) activity and scavenge H2O2. Studies done 
on HMDM cells by Zhao et al. (2011) revealed that NaHS treatment significantly suppressed 
macrophage derived foam cell formation by inhibiting oxLDL binding and uptake into 
macrophages. In addition, NaHS treatment significantly lowered the levels of CD36, 
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scavenger receptor A and acetyl co-enzyme A acyltransferase-1 (ACAT1) expressions which 
were up-regulated by oxLDL in HMDM cells via KATP/ERK1/2 pathway. Figure 6.3 
summarises the possible protective effects of H2S in impeding atherogenesis at all stages of 
atherosclerosis development. 
 
Figure ‎6.3: Potential protective effects of H2S in the vasculature 
H2S has been shown to decrease adhesion and migration of leukocytes and their differentiation to 
foam cells (A); inhibits as well as scavenges the production of ROS (B); prevents proliferation and 
promotes apoptosis of vascular smooth muscle cells (C); prevents collagen deposition and neo-intima 
formation (D) and inhibits platelet adhesion (E) (Streeter et al., 2013). 
H2S donors 
Recently, several H2S releasing molecules (termed as H2S donors) have been developed to 
deliver a controlled and stable delivery of H2S to cells and tissues. The development and 
characterisation of appropriate H2S donors are vital for pharmacological use. H2S donors 
should not be toxic, should be soluble in aqueous media, should not metabolise rapidly and 
should release H2S in vivo slowly (Whiteman et al., 2011a).  
Although sulfide salts such as NaSH or Na2S (Szabo, 2007) can be conveniently used to 
prepare standardised H2S solution, they are not useful to study in H2S physiology. This is 
because generation of both H2S and Na
+
 as an instantaneous release of bolus dissipates in a 
very short period of time (Li et al., 2008; Whiteman et al., 2010) rather than replicate the 
slow and sustained generation of H2S from CSE, CBS or 3-MST enzymes in the tissues. 
Additionally, a huge and quick release of H2S result in rapid fall of blood pressure which may 
have damaging effects in tissues or organs (Li et al., 2008). 
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Thus, organic H2S donors which generate H2S in a physiologically-like manner were 
developed and synthesised (Whiteman et al., 2011a) to avoid the use of sulfide salts. Existing 
non-steroidal anti-inflammatory drugs (NSAIDs) compounds such as indomethacin (ATB-
343), diclofenac (ACS-15), naproxen (ATB-345) and mesalamine (ATB-429) (Whiteman & 
Winyard, 2011b) have been modified by adding ADT-OH [5-(4-hydroxyphenyl-3H-1,2-
dithiole-3-thione] group. Studies have shown that these organic H2S donors actively alleviate 
and limit the adverse effects and toxicity of NSAIDs and demonstrate promising outcomes in 
treating inflammatory bowel disease, oedema, acute inflammation and endotoxic shock. Even 
though the precise mechanism of how ADT-OH releases H2S is unknown (Whiteman et al., 
2011a; Whiteman et al., 2010), the potential therapeutic effects of ADT-OH derivatives in 
treating inflammatory and vascular disease as well as cancer is at least partly due to the 
release of H2S (Whiteman et al., 2011a). 
The more recently synthesised and characterised H2S donors do not consist of structurally 
modified established drug molecules such as GYY4137 (Whiteman et al., 2011a). The novel 
H2S donors used in this study were a gift from Professor Matthew Whiteman (University of 
Exeter Medical School, St. Luke’s Campus, Exeter, England). These water-soluble novel H2S 
donors provide as pharmacological tools which generate H2S at different rates [AP67 (fastest) 
> AP72 > AP105 > AP106 >>> GYY4137 (slowest)]. Recently, AP39, which is a novel 
dithiolethione derivative containing a triphenylphosphonium moiety enabling specific 
delivery of sub-nanomolar concentrations of the compounds to mitochondria was also 
developed (Le Trionnaire et al., 2014). The chemical structures and characteristics of these 
H2S donors are shown in Figure 6.4 and Table 6.1. 
The aim of this chapter is to investigate the effects of individual H2S donors on U937 cells, 
human monocytes and HMDM cells. Effects of these H2S donors on cell viability, 
intracellular calcium level and ROS production were studied following incubation with these 
compounds and also with oxLDL. The results section will present the data obtained from the 
experiments according to the type of cells being studied i.e. U937 cells, human monocytes 












Figure ‎6.4: Chemical structures of H2S donors 
Table ‎6.1: Characteristics of H2S donors 








used in this study 
GYY4137 376.4 White powder Cytoplasm 200 µM 
 
AP39 721.7 Orange-brownish 
solid 
Mitochondria 100 nM 
 
AP67 273.3 Whitish powder Cytoplasm 200 µM 
AP72 287.3 Whitish powder Cytoplasm 200 µM 
AP105 372.5 Yellowish powder Cytoplasm 200 µM 





Effects of various H2S donors on U937 cells, human monocytes and HMDM 
cells in the absence or presence of oxLDL: cell viability 
This is the first time these H2S donors are being used to examine their effects on oxLDL-
mediated cell death. Initial experiments were carried out on U937 cells (Figure 6.5 and 6.6), 
human monocytes (Figure 6.7 and 6.8) and HMDM cells (Figure 6.9 and 6.10) to assess 
their effects on the cells, with and without the presence of oxLDL. Cell viability results 
illustrated that all H2S donors were not toxic to the three different types of cells. However, 
when oxLDL was added to the cells, these H2S donors reacted differently that only certain 
H2S donors were able to protect the cells from oxLDL-mediated cytotoxicity. 
All of the H2S donors were not toxic when incubated with U937 cells for 28 hours (Figure 
6.5). However, in the presence of oxLDL, only GYY4137, AP67, AP72 and AP105 were 
found to be statistically significant in protecting the cells from oxLDL cytotoxicity i.e 15 to 
20% of protection compared to oxLDL only treated cells (PI negative cells). Additionally, the 
percentage of PI positive cells was also significantly reduced in cells pre-treated with 
GYY4137, AP67 and AP72 compared to oxLDL only treated cells. Meanwhile, no protection 
from oxLDL-induced toxicity was observed in cells treated with AP106 and AP39 (Figure 
6.6). 
Incubation of H2S donors only with human monocytes did not cause cell viability loss 
(Figure 6.7). Human monocytes treated with oxLDL had cell viability loss of approximately 
40% (PI negative cells). Novel H2S donors, AP67 and AP72 were found to be protecting 
human monocytes from oxLDL-mediated cell death (statistically significant) with 
approximately 15% more viable cells compared to oxLDL-only treated cells (PI negative 
cells) (Figure 6.8). Surprisingly, GYY4137 did not convey any protection to human 
monocytes against oxLDL insult as observed in U937 cells. Likewise, no protection against 
oxLDL-induced cell viability loss was seen in cells treated with AP105, AP106 and AP39. In 
fact, in the presence of oxLDL, cell viability loss was greater in AP105 pre-treated cells 
(lower percentage of PI negative cells and higher percentage of PI positive cells) compared to 
oxLDL treated cells. 
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Similarly, all H2S donors used in this study were not toxic to HMDM cells (Figure 6.9). 
However, in the presence of oxLDL, only three of the H2S donors were found to be protective 
to HMDM cells against oxLDL-induced toxicity. Cells treated with oxLDL had a reduction in 
cell viability by 40% (PI negative cells) whilst AP67, AP72 and AP39 had significantly 
decreased oxLDL-induced cell viability loss by 15 to 20% (increased in PI negative cells). 
Moreover, the percentage of PI positive cells were also significantly decreased in HMDM 
cells pre-treated with AP39 compared to oxLDL treated cells. Likewise, no protection against 
oxLDL-mediated cell viability loss was found in HMDM cells pre-treated with GYY4137, 
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Figure ‎6.5: Effect of various H2S donors on cell viability of U937 cells. 
U937 cells (0.5×10
6
 cells/mL) were incubated at 37
o
C in non-phenol red RPMI-1640 with various 
types of H2S donors for 28 hours. A) Cells were viewed in situ in tissue culture wells using an 
inverted microscope (400x magnification) after 28 hour.  Images were taken using a Leica C-Mount 
camera and processed using Leica Application Suite software. B) Cell viability was determined using 
PI-flow cytometry. A cell only treatment was included as control and data are expressed as percentage 
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Figure ‎6.6: Effect of various H2S donors and oxLDL on cell viability of U937 cells. 
U937 cells (0.5×10
6
 cells/mL) were incubated at 37
o
C in non-phenol red RPMI-1640 with various 
types of H2S donors for 4 hours before the addition of the LC50 concentration (0.25 mg/mL) of oxLDL 
and incubated for another 24 hours. A) Cells were viewed in situ in tissue culture wells using an 
inverted microscope (400x magnification) after 24 hours incubation with oxLDL. Images were taken 
using a Leica C-Mount camera and processed using Leica Application Suite software. B) Cell 
viability was determined using PI- flow cytometry. A cell only treatment was included as control and 
data are expressed as percentage of the total number of cells in control samples. Results shown are 
mean ± SEM of triplicates from a representative experiment. Statistical significance (two-way 
ANOVA, Sidak’s multiple comparison test) is indicated from: PI negative cells - control vs oxLDL, 
###, p<0.001 and oxLDL vs H2S donors + oxLDL, ***, p<0.001; PI positive cells – control vs 
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Figure ‎6.7: Effect of various H2S donors on cell viability of human monocytes. 
Human monocytes (1×10
6
 cells/mL) were incubated at 37
o
C in non-phenol red RPMI-1640 with 
various types of H2S donors for 28 hours. A) Cells were viewed in situ in tissue culture wells using an 
inverted microscope (400x magnification) after 28 hour.  Images were taken using a Leica C-Mount 
camera and processed using Leica Application Suite software. B) Cell viability was determined using 
PI-flow cytometry. A cell only treatment was included as control and data are expressed as percentage 
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 cells/mL) were incubated at 37
o
C in non-phenol red RPMI-1640 with 
various types of H2S  donors for 4 hours before the addition of the LC50 concentration (0.75 mg/mL) 
of oxLDL and incubated for another 24 hours. A) Cells were viewed in situ in tissue culture plates 
using an inverted microscope (400x magnification) after 24 hours incubation with oxLDL. Images 
were taken using a Leica C-Mount camera and processed using Leica Application Suite software. B) 
Cell viability was determined using PI via flow cytometry. A cell only treatment was included as 
control and data are expressed as percentage of the total number of cells in control samples. Results 
shown are mean ± SEM of triplicates from a representative experiment. Statistical significance (two-
way ANOVA, Sidak’s multiple comparison test) is indicated from: PI negative cells - control vs 
oxLDL, ###, p<0.001 and oxLDL vs H2S donors + oxLDL, ***, p<0.001; PI positive cells – control 
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Figure ‎6.9: Effect of various H2S donors on cell viability of HMDM cells. 
HMDM cells (1×10
6
 cells/mL) were incubated at 37
o
C in non-phenol red RPMI-1640 with various 
types of H2S donors for 28 hours. A) Cells were viewed in situ in tissue culture wells using an 
inverted microscope (400x magnification) after 28 hour.  Images were taken using a Leica C-Mount 
camera and processed using Leica Application Suite software. B) Cell viability was determined using 
PI-flow cytometry. A cell only treatment was included as control and data are expressed as percentage 
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Figure ‎6.10: Effect of various H2S donors with oxLDL on cell viability of HMDM cells. 
HMDM cells (1×10
6
 cells/mL) were incubated at 37
o
C in non-phenol red RPMI-1640 with various 
types of H2S donors for 4 hours before the addition of the LC50 concentration of oxLDL (1.5 mg/mL) 
and incubated for another 24 hours. A) Cells were viewed in situ in tissue culture wells using an 
inverted microscope (400x magnification) after 24 hours incubation with oxLDL. Images were taken 
using a Leica C-Mount camera and processed using Leica Application Suite software. B) Cell 
viability was determined using PI via flow cytometry. A cell only treatment was included as control 
and data are expressed as percentage of the total number of cells in control samples. Results shown 
are mean ± SEM of triplicates from a representative experiment. Statistical significance (two-way 
ANOVA, Sidak’s multiple comparison test) is indicated from: PI negative cells - control vs oxLDL, 
###, p<0.001 and oxLDL vs H2S donors + oxLDL, ***, p<0.001; PI positive cells – control vs 
oxLDL, ^^^, p<0.001 and oxLDL vs H2S donors + oxLDL, @, p<0.05. 
259 
 
Effects of various H2S donors on U937 cells, human monocytes and HMDM 
cells in the absence or presence of oxLDL: intracellular calcium levels 
Results from the first part of this chapter showed that some of these novel H2S donors were 
able to protect U937 cells, human monocytes and HMDM cells from oxLDL-induced 
cytotoxicity. Therefore, the next part of this study will investigate the mechanism of action of 
these novel H2S donors in protecting those cells against oxLDL-mediated cell death.  
A number of studies have found a role of H2S in regulating ion channels in the cells including 
Ca
2+
 ion channels (Munaron et al., 2012; Yong et al., 2010). As being revealed in Chapter 
Five, oxLDL was able to cause a rapid increase in intracellular Ca
2+
 levels over time. The rise 
in intracellular Ca
2+
 was able to be blocked by certain Ca
2+
 channel blockers and Ca
2+
 
chelators. Thus, experiments were performed to examine whether these H2S donors can 
regulate intracellular Ca
2+
 caused by oxLDL in U937 cells, human monocytes and HMDM 
cells. Since oxLDL has been shown to cause a rapid rise in intracellular Ca
2+
, changes in Ca
2+
 
levels were measured after 1 hour of exposure to oxLDL. 
There was no significant difference in intracellular Ca
2+
 level in U937 cells treated with H2S 
donors compared to cell only control although GYY4137 and AP105 showed some increase 
(Figure 6.11 B). When oxLDL was added to the cells, significant decreased of intracellular 
Ca
2+
 level was observed in cells treated with AP67, AP72 and AP105 compared to oxLDL 
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Figure ‎6.11: Effect of various H2S donors with or without oxLDL on intracellular 
calcium levels of U937 cells. 
U937 cells (0.5×10
6
 cells/mL) were pre-incubated with 1.5 µM Fluo-3AM for 30 minutes at 37
o
C in 
non-phenol red RPMI-1640 followed by incubation with various types of H2S donors for 4 hours 
before the addition of the LC50 concentration (0.25 mg/mL) of oxLDL and incubated for another hour 
before analysis by flow cytometry A) shows the representative flow cytometry histogram plot of cell 
counts against Fluo-3AM fluorescence. B) & C) shows mean fluorescence intensities measured by 
flow cytometry with and without oxLDL, respectively. Results shown are mean ± SEM of triplicates 
from a representative experiment. Statistical significance (two-way ANOVA, Sidak’s multiple 




In human monocytes, AP67 and AP72 were found to be statistically significant in blocking 
oxLDL-induced intracellular Ca
2+
 increase compared to oxLDL treated cells  while the effect 
of GYY4137 and AP105 were found to be of the opposite (Figure 6.12 C). There was no 
significant difference in intracellular Ca
2+
 levels in cells treated with H2S donors only 
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Figure ‎6.12: Effect of various H2S donors with or without oxLDL on intracellular 
calcium levels of human monocytes. 
Human monocytes (1×10
6
 cells/mL) were pre-incubated with 1.5 µM Fluo-3AM for 30 minutes at 
37
o
C in non-phenol red RPMI-1640 followed by incubation with various types of H2S donors for 4 
hours before the addition of the LC50 concentration (0.75 mg/mL) of oxLDL and incubated for another 
hour before analysis by flow cytometry A) shows the representative flow cytometry histogram plot of 
cell counts against Fluo-3AM fluorescence. B) & C) shows mean fluorescence intensities measured 
by flow cytometry with and without oxLDL, respectively. Results shown are mean ± SEM of 
triplicates from a representative experiment. Statistical significance (two-way ANOVA, Sidak’s 
multiple comparison) is indicated from: control vs oxLDL, #, p<0.05; oxLDL vs H2S donors + 
oxLDL, *, p<0.05; **, p<0.01 (AP67, AP72), ^^, p<0.01 (GYY4137, AP105). 
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As for HMDM cells, the was no significant difference in intracellular Ca
2+
 levels in cells 
treated with various H2S donors compared to cell only control even though some increase 
was observed with GYY4137, AP67 and AP105 (Figure 6.13 B). With the presence of 
oxLDL, AP67, AP72 and AP39 were able to block the rise of intracellular Ca
2+
 (statistically 
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Figure ‎6.13: Effect of various H2S donors with or without oxLDL on intracellular 
calcium levels of HMDM cells. 
HMDM cells (1×10
6
 cells/mL) were pre-incubated with 1.5 µM Fluo-3AM for 30 minutes at 37
o
C in 
non-phenol red RPMI-1640 followed by incubation with various types of H2S donors for 4 hours 
before the addition of the LC50 concentration (1.5 mg/mL) of oxLDL and incubated for another hour 
before analysis by flow cytometry A) shows the representative flow cytometry histogram plot of cell 
counts against Fluo-3AM fluorescence. B) & C) shows mean fluorescence intensities measured by 
flow cytometry with and without oxLDL, respectively. Results shown are mean ± SEM of triplicates 
from a representative experiment. Statistical significance (two-way ANOVA, Sidak’s multiple 
comparison) is indicated from: control vs oxLDL, ###, p<0.001; oxLDL vs H2S donors + oxLDL, *, 
p<0.05; **, p<0.01. 
266 
 
Effects of various H2S donors on U937 cells, human monocytes and HMDM 
cells in the absence or presence of oxLDL: intracellular ROS levels 
It has been well known that oxidative stress and the increase of ROS play vital role in cell 
death mechanisms. Chapter Four of this thesis has clearly showed that oxLDL triggers an 
increased in intracellular ROS (superoxide) in a time dependent manner. Studies also showed 
the ability of H2S to scavenge and inhibit ROS [reviewed in Streeter et al. (2013)]. Therefore, 
experiments were performed to examine the ability of these novel H2S donors in inhibiting 
ROS formation or scavenging ROS. Cells were incubated with H2S donors for 4 hours prior 
to addition of oxLDL. U937 cells were further incubated for 3 hours while human monocytes 
and HMDM cells were incubated for 6 hours before superoxide levels were measured via 
flow cytometry using DHE fluorescent probe to measure intracellular ROS (superoxide). 
No significant difference in intracellular ROS level (DHE) was found in U937 cells treated 
with different H2S donors compared to cell only control. Although AP105, AP106 and AP39 
treated cells showed some increase in DHE levels, the increase was not significant (Figure 
6.14 B). Only AP67 was found to be statistically significant in protecting U937 cells against 
oxLDL-induced superoxide increase compared to oxLDL treated cells. Higher DHE 
fluorescence levels were observed in cells treated with GYY4137 and AP 105 in the presence 
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Figure ‎6.14: Effect of various H2S donors with or without oxLDL on intracellular ROS 
levels of U937 cells. 
U937 cells (0.5×10
6
 cells/mL) were incubated with various types of H2S donors for 4 hours at 37
o
C in 
non-phenol red RPMI-1640 followed by addition of the LC50 concentration (0.25 mg/mL) of oxLDL 
and incubated for another 3 hours. At the end of the treatment, cells were washed and probed with 10 
µM DHE for 20 minutes in the dark before analysis by flow cytometry A) shows the representative 
flow cytometry histogram plot of cell counts against DHE fluorescence. B) B) & C) shows mean 
fluorescence intensities measured by flow cytometry with and without oxLDL, respectively. Results 
shown are mean ± SEM of triplicates from a representative experiment. Statistical significance (two-
way ANOVA, Sidak’s multiple comparison) is indicated from: control vs oxLDL, #, p<0.05; oxLDL 
vs H2S donors + oxLDL, *, p<0.05. 
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In human monocytes, there was no significant difference observed for DHE levels between 
cells treated with H2S donors and cell only control (Figure 6.15 B) indicating that H2S 
donors did not trigger significant increase in intracellular ROS. However, when oxLDL was 
added, significant decrease in DHE levels were observed in cells treated with AP67 and 
AP72 compared to oxLDL treated cells (Figure 6.15 C). In addition, oxLDL had caused an 
increase of DHE fluorescence levels in cells treated with GYY4137 and AP105 indicating 
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Figure ‎6.15: Effect of various H2S donors with or without oxLDL on intracellular ROS 
levels of human monocytes. 
Human monocytes (1×10
6
 cells/mL) were incubated with various types of H2S donors for 4 hours at 
37
o
C in non-phenol red RPMI-1640 followed by addition of the LC50 concentration (0.75 mg/mL) of 
oxLDL and incubated for another 3 hours. At the end of the treatment, cells were washed and probed 
with 10 µM DHE for 20 minutes in the dark before analysis by flow cytometry A) shows the 
representative flow cytometry histogram plot of cell counts against DHE fluorescence. B) & C) shows 
mean fluorescence intensities measured by flow cytometry with and without oxLDL, respectively. 
Results shown are mean ± SEM of triplicates from a representative experiment. Statistical 
significance (two-way ANOVA, Sidak’s multiple comparison) is indicated from: control vs oxLDL, 




There was no difference in DHE levels in HMDM cells treated with H2S donors compared to 
cell only control (Figure 6.16 B). In the presence of oxLDL, only cells treated with AP67, 
AP72 and AP39 have shown a decrease in DHE levels compared to oxLDL treated cells 
(Figure 6.16).  In contrast, GYY4137, AP105 and AP106 were unable to inhibit or scavenge 
oxLDL-induced ROS that led to an increase in DHE levels.  
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 cells/mL) were incubated with various types of H2S donors for 4 hours at 37
o
C 
in non-phenol red RPMI-1640 followed by addition of the LC50 concentration (1.5 mg/mL) of oxLDL 
and incubated for another 3 hours. At the end of the treatment, cells were washed and probed with 10 
µM DHE for 20 minutes in the dark before analysis by flow cytometry A) shows the representative 
flow cytometry histogram plot of cell counts against DHE fluorescence. B) & C) shows mean 
fluorescence intensities measured by flow cytometry with and without oxLDL, respectively. Results 
shown are mean ± SEM of triplicates from a representative experiment. Statistical significance (two-
way ANOVA, Sidak’s multiple comparison) is indicated from: control vs oxLDL, #, p<0.05; oxLDL 





Results achieved in this chapter clearly demonstrate varied responses of the different types of 
cell towards the novel H2S donors (summarised in Table 6.2). It is likely that the cellular 
responsiveness to H2S may be dependent upon the way in which cells are being exposed to 
these compounds (Li et al., 2008). In general, these H2S donors were not toxic to U937 cells, 
human monocytes and HMDM cells as there was no significant cell death observed in cells 
treated with H2S donors only compared to cell only control. However, when oxLDL was 
added, the outcome of cell viability varied with each individual H2S donor compounds.  
In the current study, GYY4137, AP67, AP72 and AP105 were found to be significantly 
protective against oxLDL-induced cytotoxicity in U937 cells. As for human monocytes, 
significant protection from oxLDL-induced cell death was demonstrated only by AP67 and 
AP72. Three of the novel H2S donors namely AP67, AP72 and AP39 were found to provide 
significant protection against oxLDL-induced cell death in HMDM cells. Among the factors 
that could have contributed to the findings are the rate of H2S release from the donors as each 
of the donors has a different releasing rate and also different reactions by different types of 
cells (Wagner et al., 2009) being used in this study. In addition, the protection from cell 
viability loss offered by these H2S donors were around 15 to 20% from the percentage of cell 
death caused by oxLDL (PI negative cells). 
GYY4137 which is the slowest releasing H2S donor was only protective to U937 cells 
(Figure 6.6) but surprisingly not for human monocytes and HMDM cells. In this study, the 
mechanism of action by which GYY4137 protects U937 cells could not be explained since it 
neither block the rise of intracellular Ca
2+
 nor ROS formation at the time of measurement. In 
other studies, GYY4137 has been shown to inhibit inflammatory signalling in in vivo model 
of atherosclerosis (Liu et al., 2013) as well as oxidative stress-mediated cytotoxicity and loss 
of mitochondrial function induced by oxidants such as H2O2 (Fox et al., 2012a). However, 
since GYY4137 is highly water soluble (Li et al., 2008), this will then limits its cellular 
permeability. Additionally, studies have shown that high concentrations (100 µM and above) 
of GYY4137 are needed to achieve anti-inflammatory, cytoprotective and mitochondrial 
protective effects which will then limits the therapeutic potential of this compound (Le 
Trionnaire et al., 2014). GYY4137 has also been reported to have anti-hypertensive and anti-
inflammatory action (Li et al., 2009; Li et al., 2008). 
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Among all of the H2S donors, AP67 was the most potent in preventing cell death from 
oxLDL followed by AP72 and this finding is in line with the studies in endothelial cells done 
by Jeney et al. (2013). In this study, AP67 and AP72 were found to be protecting against 
oxLDL-induced cell viability loss in human monocytes and HMDM cells. Approximately, 
20% recovery of cell loss has been observed with the two H2S donors in human monocytes 
and HMDM cells (Figure 6.7 and 6.9). Experimental results showed that AP67 and AP72 
were able to block intracellular Ca
2+
 rise (Figure 6.11 B and 6.12 B) as well as scavenging 
ROS triggered by oxLDL (Figure 6.14 B and 6.15 B). Therefore, this may suggest the mode 
of action by these H2S donors. 
This finding is in agreement with Le Trionnaire et al. (2012) whom showed that slow 
releasing H2S donors, AP67 and AP72 significantly inhibited oxidative stress induced cell 
viability loss, ROS generation and ΔΨm loss in human microvascular endothelial cells 
(HMEC). Studies by Jeney et al. (2013) have showed the protective effects of H2S donors 
including AP67 and AP72 against heme-mediated LDL oxidation and H2O2 oxidation. They 
have also found that these H2S donors prevented lipid peroxidation of lipids taken from 
human soft plaques, this in turn reduced endothelial cytotoxicity by diminishing the 
accumulation of those peroxides. Moreover, AP67 was found to be the most potent in 
preventing haemoglobin oxidation (Jeney et al., 2013). 
In another study, Le Trionnaire et al. (2013) found that AP72 (100-500 µM) was able to 
inhibit the activation of caspase 3 and caspase 3/7 activity after treatment with 
staurosporine/etoposide in HMECs. Study in bovine retinal endothelial cells by Whatmore et 
al. (2013) has highlighted the therapeutic potential of AP67 in hyperglycaemic conditions. 
Other studies have showed that H2S effects on oxidative stress may be by scavenging ROS 
and also up-regulating antioxidant defences (Lynn & Austin, 2011).  
AP39 is the other H2S donor found to offer protection against oxLDL-induced cytotoxicity in 
HMDM cells (Figure 6.7). AP39 has been shown to reduce oxLDL-induced intracellular 
Ca
2+
 level (Figure 6.12 B) and intracellular ROS generation (Figure 6.15 B). This relates to 
the experimental results in Chapter Five whereby blocking Ca
2+
 uptake into the 
mitochondria by ruthenium red decreases ROS production and improves cell vialbility. AP39 
is the type of H2S releasing molecule which targeted the mitochondria (Le Trionnaire et al., 
2014). In their studies, AP39 has been shown to preserve the mitochondria and inhibit 
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oxidative stress-induced cytotoxicity in HMECs although it was not possible to conclude 
whether the mitochondrial protection was the cause or consequence of cellular protection. 
Moreover, AP39 (<100 nM) has also been found to inhibit caspase 3/7 activity in HMEC (Le 
Trionnaire et al., 2013). Le Trionnaire et al. (2014) have observed co-localisation of H2S 
generation with mitochondria, preservation of ATP levels and ΔΨm as well as decreased 
mitochondrial oxidant production. This finding suggests that the endogenous enzymes 
responsible for H2S production are either located within or being translocate to the 
mitochondria in response to cellular stress (Le Trionnaire et al., 2014). 
In the previous chapters in this thesis, oxLDL has been demonstrated to have caused a time-
dependent intracellular Ca
2+
 increase which in turn caused an increase in intracellular ROS 
production. Taken together, such effects then initiated various intracellular events and 
pathways leading to the death of the cells.  
Results in this chapter showed for the first time the effects of various slow release hydrogen 
sulfide donors on oxLDL-induced intracellular Ca
2+
 levels in U937 monocyte-like cells, 
human monocytes and HMDM cells. AP67, AP72 and AP39 (Figure 6.11 B & 6.12 B) had 
shown promising effects in blocking cytoplasmic Ca
2+
 rise caused by oxLDL in human 
monocytes and HMDM cells although the exact mode of action of these donors could not be 
ascertain at this stage. Previous studies revealed that H2S causes indirect inhibitory action on 
L-type calcium channels (Mancardi et al., 2009; Sun et al., 2008). Moccia et al. (2011) and 
Bauer et al. (2010) have showed that H2S regulate store-operated calcium entry (SOCE) in rat 
aortic endothelium and human endothelial cells respectively. Moreover, H2S may affect 
intracellular Ca
2+
 mobilisation by either inhibiting inositol triphosphate receptors (IP3Rs) or 
exciting ryanodine receptors (RyRs) (Hennig & Diener, 2009; Moccia et al., 2011) 
considering that ORAI1, the crucial protein of SOCE, IP3Rs and RyRs are all prone to 
covalent modifications such as phosphorylation and nitrosilation. Munaron et al. (2012) 
recommended that future studies is needed to reveal the possible co-regulations of ion 
channels by H2S and NO as some Ca
2+
 channels contain cysteine residues which may be the 
potential target through sulfhydration and nitrosilation. 
On the other hand, Maeda et al. (2009) have reported that H2S may facilitate membrane 
currents through T-type Ca
2+
 channels. Studies in neurons, astrocytes and microglia showed 







 channels (Garcia-Bereguiain et al., 2008; Lee et al., 2006; Nagai et al., 
2004). It is noted that sulfide salt such as NaHS is normally used to examine H2S roles in 
calcium signalling in variety of cell types. Thus, the effects of hydrogen sulfide from this 
type of donor might not be the same as the novel H2S donors used in the current study due to 
different characteristics and nature of the molecules. The differences observed may be due to 
the rate of release, site of release and the generated local concentrations. 
Other studies by Kimura and Kimura (2004) have showed that H2S may protect neurons from 
oxidative stress by increasing GSH levels. H2S has also been demonstrated to inhibited 
peroxynitrite (ONOO
-
)-mediated cytotoxicity to a similar extent as GSH (Whiteman et al., 
2004). The potential antioxidant action of H2S was attributed to the functional thiol group 
which can scavenge ONOO
-
 (Halliwell et al., 1999). It has also been demonstrated that H2S 
possesses anti-neuroinflammatory, anti-oxidant and anti-apoptotic effects in neuron and glial 























































































































This chapter presented for the first time the results of the study done using six different types 
of slow releasing H2S donors i.e. GYY4137, AP39, AP67, AP72, AP105 and AP106 on 
U937 cells, human monocytes and HMDM cells. These H2S donors have diverse outcomes in 
different types of cell with results indicating that few of these donors might have some 
promising effects against oxLDL-mediated cell death particularly AP72, AP67 and AP39. 
Thus, the data highlight the potential therapeutic application of these compounds in the 
prevention and/or treatment of atherosclerosis and endothelial dysfunction. 
Possible mechanisms of this protection are by inhibiting the increase in intracellular Ca
2+
 
therefore preventing excessive ROS formation resulting in protection against oxLDL-
mediated cytotoxicity as demonstrated by AP67, AP72 and AP39. Hence, the exact 
mechanisms of action by which these H2S donors provide protection to the cells against 
oxLDL attack need to be explored further including their pharmacological properties to 





7.  General discussion, future work and 
conclusion 
 
OxLDL toxicity and cell death mechanisms 
This study began with investigating the effect of oxLDL on the monocytic lineage cells i.e. 
U937 cells, human monocytes and HMDM cells in order to confirm the previous findings by 
researchers from this lab (Chapter Three). OxLDL was found to be toxic and caused cell 
viability loss to all types of cells used in this study. The degree of toxicity was concentration- 
and time-dependent and in agreement with previous studies (Baird, 2003; Chen, 2012; 
Katouah, 2012; Shchepetkina, 2013). OxLDL caused rapid cell viability loss whereby 
approximately 40-50% cell death occurred within 12 hours of incubation with oxLDL. There 
was a lag time before cell viability loss could occur (after 3 hours) suggesting that oxLDL-
induced cell death was not immediate. During this time of delay, oxLDL might trigger 
cellular events such as loss of glutathione (GSH), metabolic dysfunctions and oxidative stress 
that could lead to cell death. 
Morphological examinations on the cells during incubation with oxLDL illustrated that 
oxLDL induced necrotic cell death. However, oxLDL has been shown to induce necrotic or 
apoptotic cell death depending on types of cells (Baird et al., 2004; Gieseg et al., 2009b). It 
has been shown by Baird et al. (2004) that oxLDL-induced oxidative stress was adequate to 
inhibit caspase-3 which blocks the apoptotic process, thus activates necrosis in U937 cells. In 
THP-1 cells, oxLDL caused apoptosis with characteristics of caspase-3 activation, cell 
shrinkage and a small reduction in cellular GSH level (Baird et al., 2004). Furthermore, 
examination of atherosclerotic plaque also showed a significant amount of extracellular 
debris (Stocker & Keaney, 2004) suggesting that necrosis is major process occurring within 
the plaque. 
In addition, studies have implicated the importance of endoplasmic reticulum (ER) stress in 
atherosclerosis and plaque rupture due to the presence of oxidised lipids, inflammation and 
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metabolic stress (Muller et al., 2011a). Recently, Yao et al. (2013) have demonstrated that 
oxLDL was capable to induce ER stress. Since ER is the major site for intracellular Ca
2+
 
storage and protein folding, ER stress could result in protein misfolding and activates 
unfolded protein response (UPR). If ER stress is sustained and unresolved, apoptosis could 
occur via the induction of the proapoptotic transcriptional factor C/EBP homologous protein 
(CHOP), activation of c-jun amino-terminal kinase (JNK) and Bcl-2 proteins (Muller et al., 
2011a). Moreover, studies have also shown that NOX is activated by ER stress and is 
involved in modulating ER stress signaling (Jiang et al., 2011). Therefore, future studies 
could further investigate the role of oxLDL in ER stress that leads to the activation of cell 
death pathway. 
This research has examined three types of cells of similar lineage, namely monocyte-like 
U937 cells, primary human monocytes and primary HMDM cells. U937 cell line has been an 
excellent cell model in various health and disease related studies. Primary human monocytes 
and primary HMDM cells are the best type of cells for in vitro study of atherosclerosis since 
both are involved in atherosclerotic plaque progression in vivo. Studying the three types of 
cells adds validity to the research data obtained whereby similar results or trends were found 
for most of the investigations done. This leads to a valid interpretation of the effect of oxLDL 
on these cell types in atherosclerosis development. However, there were cases where these 
cells responded differently to various types of treatments. It has been shown by numerous 
studies that different types of cells acted differently when treated with the same treatment or 
compound/molecule. In my opinion, this phenomenon could happen due to various factors 
such as differences in cell metabolism, cell size and uptake of compounds/molecules into the 
cell. As an example in this study, human monocytes might act differently compared to 
HMDM cells because HMDM cells have been stimulated using GM-CSF while in culture. 
This could introduce changes to the cells (e.g. number of receptors) that might influence these 
cells to react differently to the same treatment. 
NADPH oxidase (NOX) as oxidants generator 
In Chapter Four, it was shown that oxLDL induced rapid intracellular ROS generation 
(measured by DHE fluorescent probe). Additionally, it has also been demonstrated that 
oxLDL caused an increase in mitochondrial ROS (measured by MitoSOX). Furthermore, 
Western blot results demonstrated that oxLDL activated NOX. Thus, it is of high possibility 
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that NOX might be the key generator of intracellular ROS mediated by oxLDL. However, 
only limited protection was conveyed by apocynin against oxLDL-induced cell death on 
U937 cells and no cellular viability protection was seen in human monocytes and HMDM 
cells. Lack of protection suggests unspecific action of apocynin or the potential involvement 
of other sources of intracellular ROS that causes oxidative damage such as from the 
mitochondria. NOX activation by oxLDL indicates the involvement of NOX2 in oxLDL-
induced ROS generation since NOX2 is dependent on p47
phox
 activation. Therefore, a specific 
NOX2 inhibitor, gp91-ds-tat (NOX2-ds-tat) would be a potential candidate to further 
investigate the involvement of NOX2 in oxLDL-mediated ROS production. 
gp91-ds-tat (gp91/NOX2 docking sequence-tat) (Rey et al., 2001) is regarded as the most 
specific and efficacious NOX inhibitor available (Cifuentes-Pagano et al., 2012). gp91ds-tat 
is a chimeric 18-amino acid peptide ([H]-R-K-K-R-R-Q-R-R-R-C-S-T-R-I-R-R-Q-L- [NH2]) 
that has been shown to inhibit in vivo and in vitro NOX activity (Rey et al., 2001; Touyz, 
2002). The gp91-ds portion of the peptide is a 9 amino acid sequence from the cytosolic B-
loop of NOX2 (amino acids 86–94) designed to selectively inhibit the interaction between 
NOX2 and p47
phox
 (Rey et al., 2001), thus prevents the assembly of NOX. The tat portion of 
the peptide corresponds to a 9 amino acid sequence of the HIV-tat transport region that 
facilitates internalization by the cells (Fawell et al., 1994). The viability of gp91-ds as an 
inhibitor was predicted by random-sequence peptide phage display library analysis of the 
human NOX2 and was shown to inhibit NOX activity in a neutrophil cell-free system (DeLeo 
et al., 1995). Since HMDM cells are expressing mainly NOX2 isoform of NOX, therefore it 
could be beneficial to incorporate this compound into oxLDL-induced intracellular oxidants 
generation studies. This investigation is currently underway. 
Lee et al. (2010) have demonstrated the existence of oxLDL-inducible NOX4 in human 
monocytes and macrophages.  NOX4 have been shown to localise in intracellular organelles 
and colocalises with p22
phox
 that formed a functional ROS-generating enzyme complex 
(Bedard & Krause, 2007). It has been suggested that NOX4 is present as NOX4/p22
phox
 
dimers and constitutively active in HMDM cells (Lee et al., 2010).  GKT137831 is another 
compound that has been investigated as a possible NOX inhibitor, particularly for NOX1 and 
NOX4. In their recent review, Altenhofer et al. (2014) have indicated GKT137831 as the first 
NOX inhibitor in clinical development that will soon provide information for the clinical 
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potential of NOX inhibition. Thus, GKT137831 would be another NOX inhibitor candidate 
worth pursuing. 
Mitochondrial ROS generation could be the most possible source of intracellular ROS in 
HMDM cells. It has been shown in this study that oxLDL induced an increase in 
mitochondrial ROS level in HMDM and Complex III of the mitochondrial electron transport 
chain (mETC) was recognised as the source of superoxide in damaged cells (Turrens, 2003). 
Therefore, it would be beneficial to investigate the involvement of oxLDL-induced 
mitochondrial ROS by investigating the effect of mitochondrial inhibitors such as antimycin 
A (Complex III) and rotenone (Complex I). 
OxLDL-induced Ca
2+
 increase and its effect on 
mitochondria 
OxLDL induced a rapid and sustained cytosolic Ca
2+
 increase with extracellular Ca
2+
 as the 
main contributor. Excess accumulation of cytosolic Ca
2+
 could be taken up into the 
mitochondria and resulted in mitochondrial Ca
2+
 overload. This could then increase 
mitochondrial ROS production, triggers MPTP opening and subsequently ruptures the OMM 
which caused the collapse of mitochondrial membrane potential (ΔΨm) whereby preliminary 
results from this study have showed that oxLDL caused ΔΨm loss. In Chapter 5, it has been 
shown that blocking Ca
2+
 uptake by ruthenium red (mitochondrial Ca
2+
 uniporter inhibitor) 
protected cells from oxLDL-induced cell death, possibly by reducing ROS generation and 
preventing MPT activation. Additionally, cyclosporin A (CsA) also prevented oxLDL-
mediated cell viability loss in HMDM cells, possibly by preventing ΔΨm loss triggered by 
MPT activation. Thus, it will be worth investigating whether these agents protect cell 
viability loss by inhibiting MPT activation which in turn protects from oxLDL-induced ΔΨm 
loss. 
Protective effect of H2S donors on oxLDL-mediated cell 
death 
Preliminary results from this study (Chapter 6) have showed the promising effect of 
selective, slow releasing, H2S donors in protecting monocytic lineage cells from oxLDL 
toxicity. H2S have been proposed to have multiple protective effects in the vasculature which 
include scavenging intracellular ROS production (reviewed in Streeter et al. (2013)). In this 
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study, the H2S donors were able to reduce intracellular Ca
2+
 level as well as intracellular ROS 
generation induced by oxLDL, thus protects cells from death. Therefore, further 
investigations in the determining the specific mechanism of action of these H2S donors will 
be worth pursuing. Moreover, one of the H2S donors, AP39, is specific in targeting 
mitochondria and has been shown to protect HMDM cells against oxLDL insult. It would be 
beneficial to further investigate its effect such as on MPT activation and mitochondrial ROS 
generation. 
Conclusion 
This study has further characterised the cytotoxicity of oxLDL to various types of cells. 
Toxic concentration of oxLDL caused a rapid loss in cell viability which is time- and 
concentration-dependent, whereby almost half of the cell viability loss occurred during the 
first 12 hours of incubation with oxLDL. Morphological changes of the cells revealed that 
oxLDL caused necrotic cell death with the characteristics of cell swelling, disrupted cell 
membrane and loss of cellular contents. This research also detailed the procedures and served 
as a bench-mark study for flow cytometric approach in assessing cell viability using 
propidium iodide (PI) fluorescent probe. 
OxLDL has been shown to induce intracellular oxidative stress including in the mitochondria 
whereby the increased in ROS production showed a time-dependent trend. NOX could be the 
key generator of intracellular ROS in oxLDL-induced cells. Immunoblotting results 
demonstrated that oxLDL activated NOX and increased the expression of p47
phox
 of NOX 
protein subunit. The progression of NOX activation was strongly associated with oxLDL-
induced ROS generation which suggests that NOX produces a burst of ROS in response to 
oxLDL, thus resulting in the increase of oxidative stress and cell viability loss. Since 
apocynin and VAS2870 were unable to inhibit NOX, this suggests that either these NOX 
inhibitors are unspecific for the targeted NOX or other sources of ROS might also exist and 
caused the increase in oxidative flux. Additionally, 7,8-NP has been shown to reduce 
oxidative stress and protected cells from oxLDL insult by scavenging intracellular ROS. 





 does play a role in Ca
2+
 flux but extracellular Ca
2+
 involvement is crucial. 
OxLDL-induced intracellular Ca
2+





 rise did not inhibit the increase in intracellular ROS suggests that 
oxLDL may trigger a Ca
2+
-independent cell death pathway and increase in Ca
2+
 level is not 
the cause of oxLDL-mediated cell death. Blocking mitochondria from Ca
2+
 overload 
protected cells from oxLDL-induced cell death possibly by reducing ROS generation and 
preventing ΔΨm loss. 
Selective slow releasing H2S donors are shown in this study to offer protection against 
oxLDL-induced cell death. Although the exact mechanism of action of the H2S donors has 
yet to be determined, a select few of these H2S donors (AP39, AP67 and AP72) have been 
shown to reduce the rise of oxLDL-induced intracellular ROS and Ca
2+
 levels, which in turn, 
reduced cell viability loss. 
An overall diagram showing the pathways involved for oxLDL to exert its toxicity in the 






Figure 17 Overall diagram of proposed pathways for oxLDL toxicity and agents used to 
lessen oxLDL-mediated cell death 
OxLDL activates NADPH oxidase (NOX) on the cell membrane to produce ROS. NOX-derived ROS 
stimulates L- and T-type Ca
2+
 channels on cell membrane and ryanodine receptors (RyR) on 
endoplasmic reticulum (ER), causing the influx of extracellular Ca
2+
 and the release of Ca
2+
 from ER 
stores into the cytosol which lead to cytosolic Ca
2+
 increase. Excess cytosolic Ca
2+
 can be taken up 
into the mitochondria via Ca
2+
 uniporter on the inner mitochondrial membrane (IMS). Ca
2+
 
accumulation in mitochondrial matrix could possibly activates mitochondrial calpain (light blue), 
triggering the opening of mitochondrial permeability transition pore (MPTP). Ca
2+
 also causes the 
increase in mitochondrial ROS production, which also contributes to MPTP opening. MPTP 
activation leads to mitochondrial membrane potential (MMP) loss, along with the release of activated 
mitochondrial matrix calpain (light blue), Ca
2+
 and other factors, such as cytochrome c. The released 
Ca
2+ 
also activates cytosolic calpain (dark blue). Together with the mitochondrial calpain, they may 
lead to necrotic cell death by degrading cytoskeletal proteins, leading to cell membrane blebbing and 
rupture. They can also destabilise lysosomes, resulting in the release of cathepsin protease that may 
degrade cellular components, causing cell death. Apocynin and VAS2870 were the two NOX 
inhibitors used in this research. Apocynin reduces ROS generation and provides partial protection 
against oxLDL-mediated cell death in U937 cells only. VAS2870 was not protecting against oxLDL-
mediated ROS generation and cell death in all types of cells. Ruthenium red reduces ROS generation 
by blocking Ca
2+ 
uptake into the mitochondria, thus protects against oxLDL-induced cell death in all 
types of cells. Cyclosporin A reduces oxLDL-induced ROS generation and cell death only in HMDM 
cells only, possibly by inhibiting MPTP activation. EGTA decreases intracellular Ca
2+ 
level but not 
ROS in oxLDL-mediated cells. 7,8-NP was able to reduce intracellular Ca
2+ 
and ROS levels as well as 
protecting cells against oxLDL-induced toxicity. The arrows with “?” indicate that the pathways are a 
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